| Package | Version | Identity | Name/Title | Status | Date | Auth |
|---|
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5020  | Acknowledgment Code (HL7) (PHLIP) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5021 | Original Specimen Source Site PHLIP (PLT212) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5022 | Original Specimen Source Site Modifier PHLIP | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5023 | Original Specimen Collection Method PHLIP | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5024 | Original Specimen Type PHLIP | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5026 | Lab Test Result PHLIP Salmonella | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5027 | Identifier Type (HL7) (PHLIP for PID3.5) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.5028 | Method Detail (PHLIP) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6000 | Problem Goal Action Code (HL7) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6001 | Certifier Types (NCHS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6002 | Manner of Death (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6003 | Pregnancy Status (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6004 | Contributory Tobacco Use (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6005 | Transportation Relationships (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6006 | Legacy Reporting Jurisdiction (CDS) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6013 | Lab Test Type (Hepatitis) | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6014 | Lab Test Type Enzymes (Hepatitis) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6027 | Smoking Status (PI) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6036 | Occupation (Census) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6037 | Industry (Census) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6038 | Morphology of Neoplasms ICD-9-CM | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6039 | Funding Eligibility Observation Method (IIS) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6040 | VIS Vaccines (IIS) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6041 | VIS Bar Codes (IIS) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6046 | Specimen Type (HL7) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6047 | Message Structure (Syndromic Surveillance) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6048 | Event Type (Syndromic Surveillance) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6049 | Message Type (Syndromic Surveillance) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6050 | Universal ID Type (Syndromic Surveillance) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6053 | Lab Test Name (Reportable Conditions) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6054 | Lab Test Result (Reportable Conditions) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6055 | Lab Test Name (HEDIS) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6056 | Name Type (Syndromic Surveillance) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6057 | Value Type (Syndromic Surveillance) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6062 | Observation Result Status Interpretation Codes | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6063 | Universal ID Type (IIS) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6064 | Value Type (ELR) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6065 | Race (HL7) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6066 | Ethnic Group (HL7) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6067 | Universal ID Type (ELR) | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6069 | NAACCR ICD-10-CM Cancer Reportability List | active | 2012-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6070 | Infections During Pregnancy - Live Birth (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6071 | Gonorrhea (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.6072 | Trachoma (NCHS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7055 | Antituberculosis Drugs (TB) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7102 | VPD Lab Test Identifiers | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7103 | VPD Laboratory Coded Observation | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7104 | VPD Specimen Type | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7105 | VPD Specimen Collection Method | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7106 | VPD Specimen Source Body Site | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7107 | VPD Specimen Role | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7108 | VPD Specimen Condition | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7109 | VPD Lab Order Identifier | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7110 | VPD Specimen Reject Reason | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7111 | Birth Attendant Titles (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7112 | Fetal Death Time Points (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7113 | Fetal Presentations (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7115 | Karyotype Suspected Chromosomal Disorder (NCHS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7116 | Karyotype Down Syndrome (NCHS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7117 | Labor and Delivery Characteristics (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7118 | Delivery Routes (NCHS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7119 | Maternal Morbidities (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7121 | Newborn Abnormal Conditions (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7122 | Newborn Congenital Anomalies (NCHS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7123 | Onset Labor (NCHS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7124 | Birth or Delivery Occurred (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7126 | Pregnancy Risk Factors (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7129 | Employment Status (ODH) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7130 | Work Schedule (ODH) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7135 | Infections During Pregnancy Fetal Death (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7136 | Obstetric Procedures (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7137 | Autopsy Examination (NCHS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7138 | Histological Placental Examination (NCHS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7140 | Autopsy Planned (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7142 | Non-Vertex Presentation (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7143 | Steroids For Fetal Lung Maturation (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7144 | Assisted Ventilation Minutes After Birth (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7145 | Assisted Ventilation More Than Six Hours (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7153 | Estimated Time of Death No Labor Ongoing (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7154 | Fetal Presentation at Birth- Unknown (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7155 | Height (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7156 | Assisted Ventilation (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7157 | Binational Reporting Criteria | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7158 | State or Province of Exposure | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7159 | Mexican Health Jurisdictions (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7162 | Country (GEC) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7163 | Birth and Fetal Death Financial Class (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7164 | Birth and Fetal Death Report Event Reason (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7165 | Previous Cesarean (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7166 | Binational Reporting Criteria (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7167 | Case Transmission Mode (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7168 | Notifiable Event Disease Condition (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7169 | US Mexico States (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7170 | Specimen Site (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7171 | Salmonella Serogroup (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7172 | Shigella Serogroup (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7173 | Campylobacter Species (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7174 | Campylobacter Nonculture Test Type (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7175 | E. coli Culture Isolate Id Serotype (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7176 | STEC Nonculture Test Type (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7177 | E. coli Shiga Toxin Test Type (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7178 | E. coli Shiga Toxin (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7179 | Vibrio Culture Species (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7180 | Vibrio Serotype (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7181 | Vibrio Biotype (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7182 | Vibrio Cholera Toxin Test Type (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7183 | Listeria Culture Species (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7184 | Occupation CDC Census 2002 | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7185 | Industry CDC Census 2002 | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7186 | Occupation CDC Census 2010 | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7187 | Industry CDC Census 2010 | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7188 | Travel Reason (Hepatitis A) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7189 | Specimen Source (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7190 | Current Sex (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7191 | Syphilis Neurologic Involvement (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7192 | HIV Status (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7193 | YNRD (CDC) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7194 | Drugs Used (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7195 | Clinician Observed Lesions (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7196 | Non Treponemal Serologic Test (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7197 | Treponemal Serologic Test (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7198 | Transmission Category (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7199 | Detection Method (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7200 | Lab Results (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7201 | Lab Tests (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7202 | Country Imported From (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7203 | Quantitative Syphilis Test Result (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7204 | Race Category including Refused | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7205 | Race Category including Null Flavor | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7206 | Lab Test Result Qualitative (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7208 | Newborn Vital Signs (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7209 | Maternal Vital Signs (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7210 | Apgar Assessments (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7211 | Influenza Transmission Zones (PHLIP) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7212 | Certifier Titles (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7213 | PHIN Questions (BIDS) | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7216 | Place of Death (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7217 | Lab Test Reactivity (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7218 | Syphilis Clinical Stage (CS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7219 | Syphilis Surveillance Stage (CS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7220 | Pregnancy Treatment Stage (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7221 | Syphilis Treatment Mother (CS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7222 | Serologic Response (CS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7223 | Birth Status (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7224 | Darkfield DFA Result (CS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7225 | Signs Symptoms (CS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7226 | X-Ray Result (CS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7227 | VDRL Test Result (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7228 | CSF WBC Protein Result (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7229 | Syphilis Treatment Infant (CS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7231 | Result Status (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7234 | Qual Lab Result Positive (Reportable Conditions) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7235 | Qual Lab Result Negative (Reportable Conditions) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7236 | Qual Lab Result Inconc (Reportable Conditions) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7243 | Lab Test Name (Ebolavirus) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7244 | History of Disease as Evidence Of Immunity (IIS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7245 | Serological Evidence Of Immunity (IIS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7246 | Vital Signs (Syndromic Surveillance) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7247 | Symptoms (EVD Triage) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7248 | Countries Widespread Transmission (EVD) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7249 | Exposure Risk (EVD) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7250 | Observation Identifiers (EVD Triage) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7256 | Morphologic Abnormalities of Neoplasms | draft | | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7257 | Abdominal Pain (CDS - EHR) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7258 | Weakness (CDS - EHR) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7259 | Fever (CDS - EHR) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7260 | Headache (CDS - EHR) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7261 | Hemorrhage (CDS - EHR) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7262 | Muscle Pain (CDS - EHR) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7263 | Vomiting (CDS - EHR) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7264 | Diarrhea (CDS - EHR) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7265 | Duration Unit | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7267 | Death Report Observation Identifier (NCHS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7268 | Data Elements (NND Gen V2) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7269 | Reason for Missing Test (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7270 | Lab Test Result Interpretation (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7271 | Case Notification Specification Version (NND) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7272 | Case Notification MMG Version (NND) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7273 | Death Pronouncement Finding (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7274 | Death Pronouncement Procedure (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7275 | Nationally Notifiable Event Code (Hepatitis) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7276 | Nationally Notifiable Event Code (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7277 | Transport Mode to Hospital (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7278 | Lab Test Performed Modifier (CS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7279 | Non-Treponemal Test Result (STD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7282 | Complications (Mumps) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7283 | Signs and Symptoms (Mumps) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7284 | Signs and Symptoms (Pertussis) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7285 | Complications (Pertussis) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7328 | 1 Min Apgar Score (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7329 | Type of Testing at CDC (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7330 | Performing Laboratory Type (VPD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7331 | Vaccine Administered (MMR) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7332 | Setting of Further Spread | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7333 | Timing of Maternal Treatment (NND) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7334 | Lab Test Interpretation (Pertussis) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7335 | Vaccine Administered (Pertussis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7336 | Lab Test Type (Mumps) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7337 | Lab Test Type (Pertussis) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7339 | Lab Test Name (Chikungunya virus) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7340 | Lab Test Name (Junin Hemorrhagic fever) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7341 | Lab Test Name (Lassa fever) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7342 | Lab Test Name (Marburgvirus) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7343 | Lab Result (Chikungunya virus) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7344 | Lab Result (Crimean-Congo hemorrhagic fever) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7345 | Lab Result (Guanarito hemorrhagic fever) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7346 | Lab Result (Junin hemorrhagic fever) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7347 | Lab Result (Lassa fever) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7348 | Lab Result (Lujo virus) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7349 | Lab Result (Machupo hemorrhagic fever) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7350 | Lab Result (Sabia virus hemorrhagic fever) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7351 | Lab Test Performed Modifier (NND) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7352 | No Prenatal Care Visit (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7354 | Part/line Number | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7356 | Diagnosis (ICD-10 CM) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7357 | Hysterectomy (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7358 | Hysterotomy (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7359 | Point of Origin (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7360 | Discharge Disposition IP (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7361 | Disposition OPD (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7362 | Follow-up Attempt Outcome (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7363 | Specialty Unit Type (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7364 | Type of clinic/location (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7365 | Priority (Type) of Admission or Visit (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7366 | Relationship (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7367 | Exposure Time Frame (NND) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7369 | Present on Admission (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7370 | Activity Type (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7371 | Procedure (ICD-10 PCS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7372 | Time Units (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7373 | Race (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7374 | Place of Injury (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7375 | Ethnicity Group (NCHS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7376 | Ethnicity Detail (NCHS) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7377 | Bridged Race (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7378 | Death Reporting Name Type Code (NCHS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7379 | Methods of Disposition (NCHS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7380 | Marital Status (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7382 | Death Reporting Identifier Type (HL70203) (NCHS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7383 | Death Reporting Event Reason (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7385 | Decedent Education Level (NCHS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7386 | Death Reporting Profiles (NCHS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7387 | Edit Flags (NCHS) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7388 | Education Level Edit Flags (NCHS) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7389 | Intentional Reject Edit Flags (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7390 | Marital Status Edit Flags (NCHS) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7391 | Pregnancy Edit Flags (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7392 | Race Coding Flag (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7393 | Source Flags (NCHS) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7395 | System Reject Codes (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7396 | Transax Conversion Flag (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7397 | Void Flags (NCHS) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7398 | Nationally Notifiable Event Code (Syphilis) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7401 | Triage System (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7402 | Patient Residence (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7403 | Injury or Poisoning (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7404 | Major reason for visit (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7405 | Co-morbid Conditions (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7419 | Provider ED (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7421 | Body Weight (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7422 | Fetal Death Cause or Condition (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7423 | Pregnancy Resulting From Fertility Enhancing Drugs | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7426 | Estimated Time Of Fetal Death (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7430 | Histological Placental Exam Performed (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7431 | Surfactant Replacement Therapy (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7432 | Asthma (NCHS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7433 | Condition Control (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7436 | Disposition (NCHS) | active | 2014-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7437 | Disposition ED (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7438 | Application Error Code (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7439 | Episode of Care (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7440 | Hospital Discharge Status (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7441 | Neurological Manifestation (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7442 | Death Reporting Event Type (NCHS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7443 | Death Reporting Message Structure (NCHS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7444 | Death Reporting Message Type (NCHS) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7446 | States Territories Provinces (NCHS) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7447 | Nationally Notifiable Event Code (Generic) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7448 | Vaccine Type (NND) | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7449 | Qualitative Lab Result (RCMT) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7450 | Vaccine Event Information Source (NND) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7451 | Type of Testing at CDC (VZ) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7452 | Age Unit (NND) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7453 | Body Region(s) of Rash | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7454 | Character of Lesions | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7456 | Lab Test Type (Varicella) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7457 | Zika-affected areas | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7458 | Transmission Mode (Zika) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7459 | Signs Symptoms (Zika) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7460 | Signs Symptoms (Arbovirus) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7462 | Prenatal Diagnostic Procedures | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7463 | Specimen Type (Zika) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7464 | Insect Repellant | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7465 | Vector (Zika) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7466 | Complications (Zika) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7467 | Drug Disease Interaction (Dengue) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7468 | Length of Gestation in Weeks | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7469 | Microcephaly Causes | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7470 | Head Circumference Findings | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7472 | Lab Test Type (Arbovirus) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7473 | Diagnostic Lab Test Findings (NND) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7474 | Type of Complication (VZ) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7475 | Epidural/Spinal Anesthesia - Medication (NCHS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7476 | Positive Negative Equivocal Not Done | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7477 | Positive Negative 4 Fold Rise Not Done | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7478 | Serotype (Dengue) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7479 | Lab Result (Zika virus) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7480 | Lab Test Name (Zika virus) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7481 | Signs Symptoms (Dengue) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7482 | Signs Symptoms (Chikungunya) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7483 | Signs Symptoms Dengue ICD-10 CM | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7484 | Signs Symptoms Chikungunya ICD-10 CM | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7485 | Signs Symptoms Zika ICD-10 CM | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7486 | Yes No Not Applicable (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7487 | Reason for Hospitalization (VZ) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7488 | Specimen Type (Arbovirus) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7489 | Transmission Mode (Arbovirus) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7490 | Clinical Syndrome - Secondary (Arbovirus) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7491 | Pregnancy Complications (Arbovirus) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7492 | Newborn Complications (Arbovirus) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7493 | Performing Lab Type (Arbovirus) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7494 | Pregnancy Outcome | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7495 | Serotype (Arbovirus) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7496 | Death Reporting Observation Result Status (NCHS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7497 | Death Reporting Value Type (NCHS) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7512 | City Places (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7513 | Message Error Condition Codes (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7515 | Data Elements (NND Hep Core) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7516 | Data Elements (NND Hep A Acute) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7517 | Data Elements (NND Hep B Acute) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7518 | Data Elements (NND Hep B Perinatal) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7519 | Data Elements (NND Hep B Chronic) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7520 | Data Elements (NND Hep C Acute) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7521 | Data Elements (NND Hep C Chronic) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7522 | Data Elements (NND Mumps) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7523 | Data Elements (NND Pertussis) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7524 | Data Elements (NND STD) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7525 | Data Elements (NND CS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7526 | Method of Delivery VaginalSpon Finding (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7527 | Method of Delivery Cesarean Finding (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7528 | Method of Delivery Vaginal Forceps Finding (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7529 | Method of Delivery Vaginal Vacuum Finding (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7530 | Scheduled Cesarean Finding (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7531 | Induction of Labor Finding (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7532 | Augmentation of Labor Finding (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7536 | Height Unit (CDC) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7537 | Duration Unit (1) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7538 | Type of Complication (Babesiosis) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7539 | Medication Treatment (Babesiosis) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7540 | Blood Product | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7541 | Clinical Manifestations (Babesiosis) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7542 | Lab Test Name (Hantavirus Infection) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7543 | Lab Result (Hantavirus Infection) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7544 | Outdoor Activities | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7545 | Lab Test Type (Babesiosis) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7546 | NAT Tests (Zika) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7547 | IgM Ab Tests (Zika) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7548 | Neutralizing Ab Tests (Zika) | active | 2016-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7549 | Test Type (Syphilis) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7550 | Lab Test Type (STD) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7551 | Test Result Coded Qualitative | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7552 | Organism Identified AST (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7553 | Specimen Type AST (STD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7554 | Specimen Collection Site AST (STD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7555 | Susceptibility Test Type (STD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7556 | Susceptibility Test Method (STD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7557 | Susceptibility Test Interpretation (STD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7558 | Susceptibility Test Result Units (STD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7559 | Susceptibility Test Result Quantitative (STD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.756 | Gender Identity | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7563 | Sexual Orientation | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7564 | Birth Reporting Address Type (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7565 | Birthdate Edit Flags (NCHS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7566 | Pregnancy Report Edit Flags (NCHS) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7567 | Estimate Of Gestation Edit Flags (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7568 | Number Of Previous Cesareans Edit Flags (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7569 | Birth Reporting Associated Party Relation (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7570 | Birth Reporting Event Reason (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7571 | Birth Reporting Event Type (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7572 | Birth Reporting Message Structure (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7573 | Birth Reporting Message Type (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7574 | Birth Reporting Value Type (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7575 | Birth Reporting Observation Result Status (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7576 | Birth Weight Edit Flags (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7577 | Plurality Edit Flags (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7578 | Consolidated Ethinicity (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7579 | Weight Of Fetus Edit Flag (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7580 | Informant Relationship to Mother (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7581 | Birth Reporting Associated Party ID Type (NCHS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7582 | Vital Records Education Level (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7583 | Birth Reporting Observation Type (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7584 | CCOFDI Observation Type (NCHS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7585 | Fetal Remains Disposition Method (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7586 | JFDI Observation Type (NCHS) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7587 | JLBI Observation Type (NCHS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7588 | PSFDI Observation Type (NCHS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7589 | PSFFDI Observation Type (NCHS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7590 | PSFLBI Observation Type (NCHS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7591 | PSLBI Observation Type (NCHS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7592 | PSMFDI Observation Type (NCHS) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7593 | Consolidated Race (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7594 | PSMLBI Observation Type (NCHS) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7596 | Adverse Event Severity (Malaria) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7597 | Work Classification (ODH) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7598 | Baby Or Fetus Weight Unit Of Measure (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7599 | Birth Reporting Mother's NameType (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7600 | Birth Reporting Related Party Address Type (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7601 | Jurisdiction Certificate ID Type (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7603 | Fetal Death Reporting Associated Party Relation (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7604 | Route Method of Delivery SpontaneousProcedure (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7605 | Tobacco Use Unit Of Measure (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7606 | Live Birth Reporting Associated Party Relation (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7607 | Type of Testing at CDC | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7608 | Type Of Complication (CRS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7609 | Sexual Orientation (STD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7610 | Gender Identity (STD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7611 | Clinical Manifestations (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7612 | Late Clinical Manifestation (STD) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7613 | Job Supervisory Level or Pay Grade (ODH) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7614 | Case Appraisal (CRS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7615 | Pre-Pregnancy SerologicalTestInterp (CRS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7616 | Specimen From Mother Or Infant (CRS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7617 | Organism (FDD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7618 | Yes No Unknown Refused (NND) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7619 | Antibiotics (FDD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7620 | Antacids (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7621 | Signs and Symptoms (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7622 | Positive Negative Not Done | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7623 | Test Method (FDD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7624 | Performing Lab Type (FDD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7625 | Test Type (FDD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7626 | Test Result (FDD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7627 | Specimen Collection Source (FDD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7628 | Yes No Unknown Maybe (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7629 | Yes No Don't Know Maybe (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7630 | Drinking Water (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7631 | Recreational H2O Treatment (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7632 | Raw Unpasteurized Products (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7633 | Day Care Setting (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7634 | Sexual Contact (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7635 | Medication Administered (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7636 | Medical History (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7637 | Seafood Preparation (FDD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7638 | Seafood Source (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7639 | Shellfish Distributed (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7640 | Improper Handling Storage (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7641 | Harvest Region (FDD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7642 | Harvest Classification (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7643 | Vibrio Species (FDD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7644 | Vibrio Cholera Serotype (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7645 | Vibrio Cholera Biotype (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7646 | Vaccine Received (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7647 | Typhoid Paratyphoid Serotype (FDD) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7648 | Yes No Not Tested (NND) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7649 | Signs and Symptoms (Rubella) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7650 | Type Of Complication (Rubella) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7651 | Previous Case Diagnosed By (Rubella) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7652 | Mailing Address Indicator (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7653 | Specimen Type (CRS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7655 | PCR Specimen Source (CRS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7656 | Specimen Source (Rubella) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7657 | Specimen Type (Rubella) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7658 | CREI Observation Type (NCHS) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7659 | Type of Testing at CDC(Rubella) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7660 | Type of Complication (Measles) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7661 | Lab Test Type (Measles) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7662 | Signs and Symptoms (Measles) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7663 | Data Elements (NND Malaria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7664 | Data Elements (NND Babesiosis) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7665 | Data Elements (NND Varicella) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7666 | Signs and Symptoms (Trich) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7667 | Eosinophil Units | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7668 | Meat Consumed Type (Trich) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7669 | Food Processing Method (Trich) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7670 | Meat Purchase Info (Trich) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7671 | Food Cooking Method (Trich) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7672 | Performing Lab Type (Trich) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7673 | Lab Test Type (Trich) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7674 | Lab Test Interpretation (Trich) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7675 | Specimen type (Trich) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7676 | Strain Type (Trich) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7677 | Form Status (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7678 | Discharge Location (RIBD) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7679 | Pregnancy Status (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7680 | Fetal Outcome (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7681 | Underlying Condition (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7682 | Smoking Status (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7683 | Substance Abuse (RIBD) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7684 | Mode of Delivery (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7685 | GBS Time Period (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7686 | Microorganism (RIBD) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7687 | Performing Lab Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7688 | Vaccine Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7689 | Vaccination Information Source (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7690 | GAS Risk Factor (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7691 | GAS Risk Factor Interval (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7692 | Rehab Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7693 | Antibiotic Received (RIBD) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7694 | Administration Route (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7695 | Antibiotic Reason (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7696 | Detection Method (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7697 | Birth Location (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7698 | Gestational Age Determination (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7699 | Susceptibility Data NA (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7700 | AR Agent (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7701 | AR Test Method (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7702 | ATI Method (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7703 | MIC Operator (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7704 | Susceptibility Interpretation (RIBD) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7705 | ICD Codes (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7706 | Sequelae (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7707 | Blood Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7708 | Rupture Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7709 | Delivery Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7710 | Medication Pre-Treatment (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7711 | Contact Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7712 | School Year (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7713 | College Living Situation (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7714 | Legionella Diagnosis (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7715 | Legionella Exposure (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7716 | Definitely Possibly No (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7717 | Legionella Exposure Setting (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7718 | Healthcare Exposure Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7719 | Facility Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7720 | Water Source (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7721 | Cruise Line (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7722 | Titer Test Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7723 | Signs and Symptoms (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7724 | Personal Protective Equipment (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7725 | Respiratory Protective Equipment (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7726 | Glove Material (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7727 | Titer Test Method (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7728 | Bird Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7729 | Establishment Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7730 | Residence Location (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7731 | Insurance Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7732 | Infection Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7733 | Lab Test Method (RIBD) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7734 | Lab Test Interpretation (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7735 | SPN/IPD Serotype (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7736 | Serotype Method (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7737 | Legionellosis Serogroup (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7738 | Isolate Not Available (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7739 | GAS Lab Test Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7740 | Colony Count Magnitude | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7741 | H Antigens (FDD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7743 | Lab Test Type (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7744 | Lab Test Interpretation (TB) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7745 | Type of Radiology Study | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7746 | Result of Radiology Study (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7747 | Diabetes Status | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7748 | Epidemiological Risk Factors (TB) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7749 | Smoking Status | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7750 | Diagnosis Type (TB) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7751 | Type of Link (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7752 | Strength of Link (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7753 | Directionality of Link (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7754 | Treatment Administration Type (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7755 | LTBI Drug Regimen (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7756 | Reason LTBI Not Started (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7757 | Reason LTBI Treatment Stopped (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7758 | Adverse Event Severity (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7759 | Medication (TB) | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7760 | Susceptibility Test Type (TB) | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7761 | Susceptibility Test Interpretation (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7762 | Susceptibility Test Method (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7763 | Gene Name (TB) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7764 | Molecular Test Results (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7765 | Molecular Indel (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7766 | Molecular Test Methods (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7767 | Reason Not Treated with RIPE (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7768 | Moved Where During Therapy (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7769 | Final Treatment Outcome (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7770 | Length of Time Drug Taken (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7771 | Side Effect Time to Onset (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7772 | Side Effect of Treatment (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7773 | Serogroup Method (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7774 | Specimen Type (RIBD) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7775 | Lab Test Type (RIBD) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7776 | Emergency Severity Index - Acuity | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7777 | Healthcare Service Location (Syndromic) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7778 | Specimen Site (FDD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7779 | Condition Status (FDD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7780 | Lab Test Name (Crimean-Congo hemorrhagic fever) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7781 | Animal Contact Type (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7782 | Deli Meats (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7783 | Deli Salads (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7784 | Diet Type (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7785 | Extended Race Group (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7786 | Food (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7787 | Food Allergy (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7788 | Food Freshness (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7789 | Fruit (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7790 | Heated Food (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7791 | Hispanic Ethnic Group (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7792 | Illness (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7793 | Likely Contact (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7794 | LikelyAte (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7795 | Medical History (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7796 | Patient Type (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7797 | Birth Location (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7798 | Pregnancy Outcome (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7799 | Reason Not Interviewed (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7800 | Respondent (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7801 | Signs and Symptoms (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7802 | Specimen Type (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7803 | Yes No Unknown Refused (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7804 | Patient Outcome (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7805 | Yes No None (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7806 | Assisted Living Exposure Type (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7807 | Bird Exposure Setting (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7808 | N. meningitidis Serogroup (RIBD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7809 | H. influenzae Serotype (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7810 | Provider Information Source (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7811 | Data Elements (CRS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7812 | Case Type (CP-CRE) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7813 | Specimen Source (CP-CRE) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7814 | Genotypic Test Result (CP-CRE) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7815 | Death Reporting Provider Identifier Type (HL70203) (NCHS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7816 | Data Elements (Rubella) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7817 | Type of Dairy Product (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7818 | General Condition Status (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7819 | Unit of Measure (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7820 | Born in the United States (Listeria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7821 | Lab Test Type (Psittacosis) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7822 | Lab Test Type (Legionellosis) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7823 | Lab Test Interpretation (Legionellosis) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7824 | Death Reporting Certificate Identifier Type (HL70203) (NCHS) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7825 | Gene Name (CP-CRE) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7826 | Specimen Source Site (VPD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7827 | Segment Action Code (HL7_2x) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7828 | Immunization Profile ID (IIS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7829 | Series Status (IIS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7830 | Observation Identifier V2 (IIS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7831 | Evaluation Status Reason (IIS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7832 | Clinical Manifestation (TBRD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7833 | Complications (TBRD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7834 | Medication Received (TBRD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7835 | Lab Test Type (TBRD) | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7836 | Organism (TBRD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7837 | Coinfection Type (TBRD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7838 | Specimen Type (TBRD) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7839 | Medication Received (Lyme) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7840 | Clinical Manifestations (Lyme) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7841 | Specimen Type (Lyme) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7843 | Organism (Lyme) | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7844 | Lab Test Type (Lyme) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7845 | Serotype Master (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7846 | Lab Test Interpretation Master (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7847 | Lab Test Type Master (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7848 | Exposure Setting Master (RIBD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7849 | Usual Occupation and Industry (TB) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7850 | Organism (CP-CRE) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7851 | Contact Type (FDD) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7852 | Geographic Location | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7853 | MCDI Observation Identifier (NCHS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7854 | FDDI Observation Identifier (NCHS) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7855 | DR Observation Identifier (NCHS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7856 | JDI Death Report Observation Identifier (NCHS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7857 | CREI Observation Identifier (NCHS) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7858 | CCOD Observation Identifier (NCHS) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7859 | Death Reporting Decedent Identifier Type (HL70203) (NCHS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7860 | Medication Administered Relative to Treatment (Malaria) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7861 | Death Reporting Decedent and Certificate Identifier Type (HL70203) (NCHS) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7862 | Test Result (CP-CRE) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7863 | Lab Test Type (C. auris) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7864 | Specimen Source (C. auris) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7866 | Lab Test Method (MDRO) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7867 | Test Result (C. auris) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7868 | Type of Long Term Care Facility (C. auris) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7869 | Specimen Collection Setting Type (C. auris) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7870 | Type of Co-infection (C. auris) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7871 | Case Type (RIBD) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7874 | Poison Control Center Record (CO) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7875 | Workers Compensation Record (CO) | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7876 | Intent of Exposure (CO) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7877 | Extreme Weather Type (CO) | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7878 | Exposure Source (CO) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7879 | Treatment Type (CO) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7880 | Education (CO) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7881 | Generator Location (CO) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7882 | Generator Distance (CO) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7883 | Person/Organization Taking CO Reading (CO) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7884 | Exposure Site Category (CO) | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7885 | Public Site of Exposure (CO) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7886 | Treatment Location (CO) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7887 | Underlying Conditions (CO) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7888 | Signs and Symptoms (CO) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7889 | ICD Codes List (CO) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7890 | Treatment Site (CO) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7891 | Data Reporting Source (CO) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7892 | Lab Result (Candida auris) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7893 | Lab Test Name Carbapenem Resistant Enterobacteria | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7894 | Lab Test Name (Candida Auris) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7895 | Lab Result Carbapenem Resistant Enterobacteriace | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7896 | Residential Site of Exposure (CO) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7897 | Lab Test Measurement (CO) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7899 | Household Member Roletype (ODH) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7900 | Industry NAICS Detail (ODH) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7901 | Occupation ONETSOC Detail (ODH) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7902 | GC specimen quality (ARLN) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7903 | GC beta-lactamase result (ARLN) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7904 | Program study or event (ARLN) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7905 | Age units (ARLN) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7906 | Test result units (ARLN) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7907 | Ethnicity (ARLN) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7908 | Gender (ARLN) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7909 | Identifier type (ARLN) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7910 | Regional Labs (ARLN) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7911 | Clinical sample or isolate (ARLN) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7912 | Candida auris culture result (ARLN) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7913 | Candida auris PCR result (ARLN) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7914 | Acinetobacter culture result (ARLN) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7915 | Carbapenemase phenotypic result (ARLN) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7916 | CPO phenotypic method (ARLN) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7917 | CPO PCR method (ARLN) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7918 | CPO AST method (ARLN) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7919 | CPO PCR result (ARLN) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7920 | Interpretation codes (ARLN) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7921 | Specimen type (ARLN) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7922 | Microorganism (ARLN) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7923 | Medication Treatment (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7924 | Mother Infant Indicator (NND) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7925 | Type of Complication (STD) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7926 | Number of Cigarettes Smoked per Day (CO) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7927 | Dose Unit (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7928 | Lab Test Result Qualitative (Syphilis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7929 | Medication Route (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7930 | Route of Administration (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7931 | Medication Frequency Unit (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7932 | Duration Units (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7933 | Cause of Fetal Death ICD-10 | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7934 | Microorganism (STD) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7936 | Contact Type (COVID-19) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7937 | Case Probable Reason (COVID-19) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7938 | Detection Method (COVID-19) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7939 | Residence Type (COVID-19) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7940 | Healthcare Occupation (COVID-19) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7941 | Job Setting (COVID-19) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7942 | Exposure Setting (COVID-19) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7943 | Data Reporting Source (COVID-19) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7944 | Signs and Symptoms (COVID-19) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7945 | Clinical Finding (COVID-19) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7946 | Animal Type (COVID-19) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7947 | Risk Factor (COVID-19) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7948 | Lab Test Type (COVID-19) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7949 | Treatment Type (COVID-19) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7950 | Yes No Unknown NA (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7951 | Reason for Test (COVID-19) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7952 | Tribe Name (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7953 | Critical Infrastructure Sector (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7954 | Medication Administered (Hansen) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7955 | Location of Initial Diagnosis (Hansen) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7956 | Type of Leprosy (Hansen) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7957 | Relationship (Hansen) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7958 | Hospital Procedure (Leptospirosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7959 | Underlying Condition(s) (Leptospirosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7960 | Disease Outcome Type (Leptospirosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7961 | Medication (Leptospirosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7962 | Contact Type (Brucellosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7963 | Medication Administered (Anthrax) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7964 | US Vital Records Jurisdictions (NCHS) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7965 | Sick Animal Type (Leptospirosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7966 | Rodent Type (Leptospirosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7967 | Animal Type (Leptospirosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7968 | Clinical Manifestations (Leptospirosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7969 | Specimen Type (Brucellosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7970 | Disease Stage (Brucellosis) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7971 | Animal Type (Brucellosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7972 | Medication (Brucellosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7973 | Diagnostic Test Finding (Anthrax) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7974 | Specimen Type (Leptospirosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7975 | Specimen Source Site (Leptospirosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7976 | Test Titer Type (Brucellosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7977 | Brucella Exposure (Brucellosis) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7978 | Exposure Risk (Brucellosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7979 | Previous Treatment Duration (Hansen) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7980 | Patient Case Status (Hansen) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7981 | Animal Ownership (Brucellosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7982 | Vaccine Exposure (Brucellosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7983 | Time of Day (Anthrax) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7984 | Hospital Procedure (Anthrax) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7985 | Actual Route of Administration (Anthrax) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7986 | Performing Lab Type (Anthrax) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7987 | Country of Product Acquisition (Brucellosis) | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7988 | Location Type (Leptospirosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7989 | Clinical Outcome (Anthrax) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7990 | Specimen Type (Anthrax) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7991 | Procedure Type (Anthrax) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7992 | Public TransportationType (Anthrax) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7994 | Exposure Type (Leptospirosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7995 | Diet Type (Anthrax) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7996 | Post-exposure or Treatment (NND) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7997 | Treatment Type (Anthrax) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7998 | Severe Weather Type (Leptospirosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.7999 | Animal Type (Anthrax) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.800 | Abnormal Flag (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8000 | Test Results Anthrax | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8001 | Time of Day (CDC) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8002 | Reason Medication Not Completed (BSP) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8003 | Smoking Status (Anthrax) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8004 | Test Results (Brucellosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8005 | Antimicrobials (Anthrax) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8006 | Contact Type (Anthrax) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8007 | Clinical Manifestations (Brucellosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8008 | Clinical Manifestations (Anthrax) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8009 | Exposure Location (Brucellosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.801 | Address Type (HL7) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8010 | Organism Name (Brucellosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8011 | Activity Type (Leptospirosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8012 | Activity Type (Brucellosis) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8013 | Exposure Source (Anthrax) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8014 | Activity Type Anthrax | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8015 | Food Product Consumed (Brucellosis) | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8016 | Fresh Water or Mud Type (Leptospirosis) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8017 | Exposure Source (Brucellosis) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8018 | Related Person Relationship Type (NCHS) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8019 | Alcohol Use Frequency (Anthrax) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.802 | Administration Device (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8020 | Anthrax Vaccine Exposure (Anthrax) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8021 | Total Doses of Vaccine (Anthrax) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8022 | Skin Smear Interpretation (Hansen) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8024 | Medication Completed (Brucellosis) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8025 | Industry CDC NAICS 2012 | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8026 | Occupation CDC Census 2012 | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8027 | Industry CDC Census 2012 | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8028 | Occupation CDC SOC 2010 | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8029 | Division Vital Statistics (County) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.803 | Administration Method (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8030 | Lab Test (Hansen) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8031 | Decedent Birthplace (Country) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8032 | Decedent Resident (Country) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8033 | Frequency Duration Unit (Hansen) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8034 | Medication Duration Unit (Hansen) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8035 | Subject of Medication Received (Hansen) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8036 | Antibiotic Dose Units (Brucellosis) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8037 | Test Type (Brucellosis) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8038 | Specimen Source Site (Brucellosis) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8039 | Test Results (Leptospirosis) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8040 | Pregnancy Outcome (Leptospirosis) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8041 | Lab Test Type (Leptospirosis) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8042 | Test Result (Hepatitis A) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8043 | HBeAg Test Result (Hepatitis B Perinatal) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8044 | Infant Nucleic Acid Test Result (Hepatitis C) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8045 | Infant HCV Antigen Test Result (Hepatitis C) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8046 | Mother Nucleic Acid Test Result (Perinatal Hep) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8047 | Common-Source Outbreak (Hepatitis A) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8048 | Common-Source Outbreak (Hepatitis B) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8049 | Common-Source Outbreak (Hepatitis C) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8050 | Other Case Hepatitides (Hepatitis) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8051 | Patient Epidemiological Risk Factors (Hepatitis A) | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8052 | Patient Epidemiological Risk Factors (Hepatitis B) | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8053 | Patient Epidemiological Risk Factors (Hepatitis C) | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8054 | Alanine aminotransferase (ALT) Result (Hepatitis) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8055 | Source of Laboratory Test (Hepatitis) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8056 | HBsAg Test Result (Hepatitis B Perinatal) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8057 | Infant Anti-HCVTest Result (Hepatitis C Perinatal) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8058 | Nucleic Acid Viral Load Test Result (Hepatitis) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8059 | Signs and Symptoms (Hepatitis) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.806 | Allergen Type (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8060 | Test Result (Hepatitis) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8061 | HBV DNA Test Result (Hepatitis B Perinatal) | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8062 | Gender Identity (USCDI) | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8063 | Sexual Orientation (USCDI) | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8064 | Travel Purpose (CDC) | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8065 | Occupation CDC Census 2018 | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8066 | Industry CDC Census 2018 | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8067 | Industry CDC NAICS 2017 | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.8068 | Occupation CDC SOC 2018 | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.807 | Allergy Severity (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.808 | Degree License Certification (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.809 | Marital Status (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.810 | Name Type (HL7) | active | 2011-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.811 | Observation Result Status (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.812 | Production Class (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.813 | Relationship (HL7) | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.814 | Religion (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.815 | Result status (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.816 | Route of Administration (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.817 | Telecommunication Equipment Type (HL7) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.818 | Telecommunication Use Code (HL7) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.819 | Yes No Indicator (HL7) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.820 | Expanded Yes No (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.821 | Treatment Completion Status (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.822 | Referral Priority (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.823 | Referral Reason (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.825 | Referral Disposition (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.826 | Manufacturers of vaccines (MVX) | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.827 | Diagnosis Type (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.828 | Country | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.829 | County | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.830 | State | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.831 | Language | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.834 | Allergen | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.836 | Race Category | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.837 | Ethnicity group | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.838 | Units of Measure | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.856 | Diagnosis (ICD-9 CM) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.875 | Null Flavor (HL7 V3) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.876 | Detailed Race | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.877 | Detailed Ethnicity | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.878 | Age unit | active | 2015-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.879 | Weight Unit | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.883 | PHIN Questions | active | 2013-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.887 | Occupation | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.888 | Yes No Unknown (YNU) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.891 | Height Unit | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.909 | Disease | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.912 | Admission Level of Care (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.913 | Admission Type (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.914 | Diagnosis Priority (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.915 | Discharge Disposition (HL7) | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.916 | Medical Specialty (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.917 | Patient Class (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.918 | Admission Source (HL7) | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.919 | Temperature Unit | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.920 | Blood Pressure Unit | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.921 | Emergency Department Acuity | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.922 | Diagnostic service section ID (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.923 | Order Control Code (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.925 | Pharmacy Order Type (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.927 | Administrative Sex (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.928 | True False (TF) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.929 | Positive Negative Unknown Not Done | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.930 | Chest XRay Result | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.931 | Vaccine Not Given Reason | active | 2021-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.934 | Vaccines administered (CVX) | active | 2022-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.941 | Susceptibility Result | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.945 | Industry (SIC) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.946 | Specimen | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.950 | Passed Failed Unknown | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.954 | BioSense Observations | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.957 | Abnormal Chest X-Ray Finding (TB) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.958 | Acknowledgment Code (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.959 | Additional Site of Disease (TB) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.960 | Specimen Additive or Preservative (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.961 | Address Type | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.962 | Procedure (ICD-9 CM) | active | 2010-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.963 | Consequence of Adverse Event | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.964 | Adverse Event Previously Reported | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.965 | Amplification and Extraction Kit | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.967 | Body site | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.968 | Case Classification Status | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.969 | Case investigation closure reason | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.970 | Case Investigation Status | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.972 | Case Verification (TB) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.973 | City | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.974 | Message Error Condition Codes (HL7) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.975 | Comment Type | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.976 | Confidentiality Code (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.977 | Contact Role | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.979 | Type of Correctional Facility | active | 2019-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.980 | Diagnosed by (VZ) | active | 2017-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.981 | Diagnosed Pneumonia By (VZ) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.982 | Directly Observed Therapy (TB) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.983 | Sites of Directly Observed Therapy (TB) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.984 | Dwelling Type | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.985 | Employment Status | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.986 | Encoding Type (HL7) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.988 | Countermeasure Encounter Purpose | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.989 | Countermeasure Encounter Type | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.990 | Specimen Handling Code | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.991 | Environmental Investigation Reason | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.992 | Epilinked Case Type (VZ) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.993 | Error Severity (HL7) | active | 2018-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.994 | General Condition Status | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.995 | Health Care Practice Type (TB) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.996 | History Source (CRA) | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.997 | HIV Diagnosis Based On | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.998 | HIV Status | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.11.999 | Identifier Type | active | 2008-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.3.20 | Specimen Source Site (Anthrax) | active | 2020-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/2.16.840.1.114222.4.5.301 | Immunization Service Funding Eligibility Value Set | active | 2009-01 | |
| us.cdc.phinvads | R4 | http://phinvads.cdc.gov/fhir/ValueSet/6.1.4.1.19376.1.7.3.1.1.13.8.64 | Limb Reduction Defect (NCHS) | active | 2014-01 | |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/qualification | Qualification | active | 2022-04 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/region | SignalRegion | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/SignalServiceReferred | SignalServiceReferred | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/SignalServiceRequestAuthorizedAmount | SignalServiceRequestAuthorizedAmount | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/SignalServiceRequestDateOfReferral | SignalServiceRequestDateOfReferral | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/SignalServiceRequestGuardian | SignalServiceRequestGuardian | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/SignalServiceRequestNoOfUnits | SignalServiceRequestNoOfUnits | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/SignalServiceRequestParentFee | SignalServiceRequestParentFee | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/SignalServiceRequestParentFlatRate | SignalServiceRequestParentFlatRate | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/SignalServiceRequestPatient | SignalServiceRequestPatient | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/SignalServiceRequestProvider | SignalServiceRequestProvider | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/SignalServiceRequestReferringOrg | SignalServiceRequestReferringOrg | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/SignalServiceRequestTrailsClientID | SignalServiceRequestTrailsClientID | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/SignalServiceRequestTrailsCountyHouseholdID | SignalServiceRequestTrailsCountyHouseholdID | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/SignalServiceRequestTrailsID | SignalServiceRequestTrailsID | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/StateActivityStatus | SurveyStateActivityStatus | draft | | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/StructureDefinition/patient-adoptionInfo | Patient Adoption Info | draft | 2023-06 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/StructureDefinition/no-fixed-address | Patient No Fixed Address | draft | 2023-05 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/documentreference | DocumentReference Profile | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/account | Account Profile | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/encounter | Encounter Profile | active | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/episodeofcare | EpisodeOfCare Profile | active | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/healthcareservice | HealthcareService Profile | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/invoice | Invoice | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/location | Location Profile | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/organization | Organization Profile | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/patient | Patient Profile | draft | 2023-06 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/practitionerrole | PractitionerRole Profile | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/SignalQuestionnaireResponse | SignalQuestionnaireResponse | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/StructureDefinition/servicerequest | ServiceRequest Profile | draft | | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/us/core/ValueSet/omb-race-category | OMB Race Categories | active | 2022-09 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/contact-attempt-results | Contact Attempt Results | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/signal-healthcare-service-category | Signal Healthcare Service Category | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/signal-program | Signal Program | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/signal-healthcare-service-type | Signal Healthcare Service Type | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/signal-organization-license | Signal Organization License | active | 2019-11 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/us/core/CodeSystem/signal-organization-type | Signal Organization Type | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/place-of-service | Place Of Service | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/progress-made-towards-goals | Progress Made Towards Goals | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/provider-taxonomy-na | Provider Taxonomy NA | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-action-types | Questionnaire CCARS Action Types | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-activity-involvement-rating | Questionnaire CCARS Overall Activity Involvement Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-aggression-danger-to-others-rating | Questionnaire CCARS Aggression Danger To Others Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-alcohol-use-rating | Questionnaire CCARS Alcohol Use Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-cognition-rating | Questionnaire CCARS Cognition Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-considerations-for-providers | Questionnaire CCARS Considerations For Providers | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-current-issues | Questionnaire CCARS Current Issues | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-current-living-arrangement | Questionnaire CCARS Current Living Arrangement | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-current-non-prescription-substance-use | Questionnaire CCARS Current Non-Prescription Substance Use | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-current-primary-role | Questionnaire CCARS Current Primary Role | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-depressive-issues-rating | Questionnaire CCARS Depressive Issues Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-disabilities | Questionnaire CCARS Disabilities | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-drug-use-rating | Questionnaire CCARS Drug Use Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-empowerment-rating | Questionnaire CCARS Empowerment Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-enrollment-payer | Questionnaire CCARS Enrollment Payer | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-ethnicity | Questionnaire CCARS Ethnicity | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-existence-presenting-problem | Questionnaire CCARS Existence Presenting Problem | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-family-rating | Questionnaire CCARS Family Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-gender | Questionnaire CCARS Gender | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-highest-education-level | Questionnaire CCARS Highest Education Level | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-history-current-victimization | Questionnaire CCARS History Current Victimization | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-history-of-issues | Questionnaire CCARS History Of Issues | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-history-of-mental-health-services | Questionnaire CCARS History Of Mental Health Services | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-hope-rating | Questionnaire CCARS Hope Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-interpersonal-rating | Questionnaire CCARS Interpersonal Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-legal-rating | Questionnaire CCARS Legal Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-legal-status | Questionnaire CCARS Legal Status | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-marital-status | Questionnaire CCARS Marital Status | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-medication-psychiatric-service | Questionnaire CCARS Medication Psychiatric Service | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-mental-health-services-program | Questionnaire CCARS Mental Health Services Program | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-multiple-issues-rating | Questionnaire CCARS Multiple Issues Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-overall-level-of-functioning-rating | Questionnaire CCARS Overall Level Of Functioning Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-overall-recovery-rating | Questionnaire CCARS Overall Recovery Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-overall-symptom-severity-rating | Questionnaire CCARS Overall Symptom Severity Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-physical-health-rating | Questionnaire CCARS Physical Health Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-place-of-residence | Questionnaire CCARS Place Of Residence | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-previous-concurrent-services | Questionnaire CCARS Previous Concurrent Services | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-psychosis-rating | Questionnaire CCARS Psychosis Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-race | Questionnaire CCARS Race | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-rae-aso-identification-codes | Questionnaire CCARS RAE ASO Identification Codes | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-reason-for-discharge | Questionnaire CCARS Reason For Discharge | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-role-performance-rating | Questionnaire CCARS Role Performance Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-school-development | Questionnaire CCARS School Development | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-school-problems | Questionnaire CCARS School Problems | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-security-supervision-rating | Questionnaire CCARS Security Supervision Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-self-care-basic-needs-rating | Questionnaire CCARS Self Care Basic Needs Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-sexual-orientation | Questionnaire CCARS Sexual Orientation | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-social-support-rating | Questionnaire CCARS Social Support Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-socialization-rating | Questionnaire CCARS Socialization Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-suicide-danger-to-self-rating | Questionnaire CCARS Suicide Danger To Others Rating | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-tobacco-use | Questionnaire CCARS Tobacco Use | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-type-of-discharge | Questionnaire CCARS Type Of Discharge | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-type-of-update | Questionnaire CCARS Type Of Update | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-yes-no-na | Questionnaire CCARS Yes No NA | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-yes-no-unable-to-assess | Questionnaire CCARS Yes No Unable To Assess | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-ccars-yes-no | Questionnaire CCARS Yes No | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-admission-route-of-administration | Questionnaire DACODS Admission Route Of Administration | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-client-disability | Questionnaire DACODS Client Disability | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-clinician-diagnostic-impression | Questionnaire DACODS Clinician Diagnostic Impression | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-discharge-progress-towards-measurable-treatment-goals | Questionnaire DACODS Discharge Progress Towards Measurable Treatment Goals | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-discharge-route-of-administration | Questionnaire DACODS Discharge Route Of Administration | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-discharge-status | Questionnaire DACODS Discharge Status | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-drug-type-code | Questionnaire DACODS Drug Type Code | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-education-employment-problems | Questionnaire DACODS Education Employment Problems | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-employment-status | Questionnaire DACODS Employment Status | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-family-issues-and-problems | Questionnaire DACODS Family Issues And Problems | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-health-insurance-status | Questionnaire DACODS Health Insurance Status | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-living-situation | Questionnaire DACODS Living Situation | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-marital-status | Questionnaire DACODS Marital Status | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-medical-physical-problems | Questionnaire DACODS Medical Physical Problems | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-reason-for-discharge | Questionnaire Dacods Reason For Discharge | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-secondary-tertiary-drug-type-code | Questionnaire DACODS Secondary Tertiary Drug Type Code | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-sexual-orientation | Questionnaire DACODS Sexual Orientation | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-socialization-problems | Questionnaire DACODS Socialization Problems | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-source-of-illicit-drugs | Questionnaire DACODS Source Of Illicit Drugs | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-source-of-income | Questionnaire DACODS Source Of Income | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-source-of-payment-for-treatment | Questionnaire DACODS Source Of Payment For Treatment | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-statutory-commitment | Questionnaire DACODS Statutory Commitment | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-tobacco-use | Questionnaire DACODS Tobacco Use | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-transfer-referral-source | Questionnaire DACODS Transfer Referral Source | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-yes-no-na | Questionnaire DACODS Yes No NA | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-yes-no-unable-to-assess | Questionnaire DACODS Yes No Unable To Assess | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-yes-no-unknown | Questionnaire DACODS Yes No Unknown | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/questionnaire-dacods-yes-no | Questionnaire DACODS Yes No | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/reason-for-discharge | Reason For Discharge | draft | 2023-08 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/us/core/CodeSystem/signal-filerepo-classification | Signal FileRepo Classification | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://signalbhn.org/fhir/us/core/CodeSystem/signal-filerepo-docreviewstatus | Signal FileRepo Doc Review DocStatus | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/CodeSystem/signal-region | Signal Region | active | 2023-09 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/us/core/CodeSystem/signal-state-activity-status | Signal State Activity Status | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/us/core/ValueSet/us-core-screening-assessment-observation-category | US Core Screening Assessment Observation Category | active | 2023-03 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/account-status | AccountStatus | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/account-type | Account Types | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/fips-county-co | CO FIPS Counties | draft | 2023-06 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/address-type | AddressType | active | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/address-use | AddressUse | active | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/us/core/ValueSet/birthsex | Birth Sex | active | 2022-09 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/chargeitem-status | ChargeItemStatus | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/composition-status | CompositionStatus | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/condition-clinical | Condition Clinical Status Codes | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/condition-severity | Condition/Diagnosis Severity | draft | | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/condition-ver-status | ConditionVerificationStatus | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/contact-attempt-results | Contact Attempt Results | draft | | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/coverage-class | Coverage Class Codes | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/coverage-copay-type | Coverage Copay Type Codes | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/coverage-financial-exception | Example Coverage Financial Exception Codes | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/data-absent-reason | DataAbsentReason | active | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/days-of-week | DaysOfWeek | active | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/us/core/ValueSet/detailed-ethnicity | Detailed ethnicity | active | 2022-09 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/us/core/ValueSet/detailed-race | Detailed Race | active | 2022-09 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/device-action | Procedure Device Action Codes | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/device-kind | FHIR Device Types | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/diagnosis-role | DiagnosisRole | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/document-classcodes | Document Class Value Set | active | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/document-reference-status | DocumentReferenceStatus | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/document-relationship-type | DocumentRelationshipType | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/encounter-admit-source | Admit source | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/encounter-diet | Diet | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/encounter-location-status | EncounterLocationStatus | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/encounter-participant-type | Participant type | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/encounter-special-arrangements | Special arrangements | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/encounter-special-courtesy | Special courtesy | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/encounter-status | EncounterStatus | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/episode-of-care-status | EpisodeOfCareStatus | draft | 2019-10 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/episodeofcare-type | Episode of care type | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/event-status | EventStatus | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/c80-facilitycodes | Facility Type Code Value Set | active | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/fm-status | Financial Resource Status Codes | draft | 2019-10 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/formatcodes | DocumentReference Format Code Set | active | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.32 | Gender Identity | active | 2022-03 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/signal-healthcare-service-category | Signal Healthcare Service Category | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/healthcare-service-procedure-code-cpt | HealthCare Service Procedure Code CPT | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/signal-program | Signal Program | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/signal-healthcare-service-type | Signal Healthcare Service Type | draft | | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/identifier-use | IdentifierUse | draft | 2019-10 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/invoice-priceComponentType | InvoicePriceComponentType | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/invoice-status | InvoiceStatus | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/languages | Common Languages | draft | 2016-08 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/location-mode | LocationMode | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/location-physical-type | Location type | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/location-status | LocationStatus | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/observation-category | Observation Category Codes | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/observation-status | ObservationStatus | active | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/us/core/ValueSet/omb-ethnicity-category | OMB Ethnicity Categories | active | 2022-09 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/organization-role | Organization Affiliation Role | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/signal-organization-license | Signal Organization License | draft | 2023-07 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/us/core/ValueSet/signal-organization-type | Signal Organization Type | draft | 2023-07 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/performer-role | Procedure Performer Role Codes | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/place-of-service | Place Of Service | draft | | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/procedure-category | Procedure Category Codes (SNOMED CT) | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/procedure-followup | Procedure Follow up Codes (SNOMED CT) | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/procedure-not-performed-reason | Procedure Not Performed Reason (SNOMED-CT) | active | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/procedure-outcome | Procedure Outcome Codes (SNOMED CT) | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/progress-made-towards-goals | Progress Made Towards Goals | draft | | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/provider-taxonomy | Provider Taxonomy Codes | draft | 2023-03 | hl7 |
| signal.core.r4 | R4 | http://terminology.hl7.org/ValueSet/v2-2.7-0360 | v2 table 0360, Version 2.7 | active | | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/questionnaire-answers-status | QuestionnaireResponseStatus | draft | 2019-10 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-action-types | Questionnaire CCARS Action Types | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-activity-involvement-rating | Questionnaire CCARS Overall Activity Involvement Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-aggression-danger-to-others-rating | Questionnaire CCARS Aggression Danger To Others Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-alcohol-use-rating | Questionnaire CCARS Alcohol Use Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-cognition-rating | Questionnaire CCARS Cognition Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-considerations-for-providers | Questionnaire CCARS Considerations For Providers | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-current-issues | Questionnaire CCARS Current Issues | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-current-living-arrangement | Questionnaire CCARS Current Living Arrangement | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-current-non-prescription-substance-use | Questionnaire CCARS Current Non-Prescription Substance Use | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-current-primary-role | Questionnaire CCARS Current Primary Role | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-depressive-issues-rating | Questionnaire CCARS Depressive Issues Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-disabilities | Questionnaire CCARS Disabilities | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-drug-use-rating | Questionnaire CCARS Drug Use Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-empowerment-rating | Questionnaire CCARS Empowerment Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-enrollment-payer | Questionnaire CCARS Enrollment Payer | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-ethnicity | Questionnaire CCARS Ethnicity | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-existence-presenting-problem | Questionnaire CCARS Existence Presenting Problem | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-family-rating | Questionnaire CCARS Family Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-gender | Questionnaire CCARS Gender | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-highest-education-level | Questionnaire CCARS Highest Education Level | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-history-current-victimization | Questionnaire CCARS History Current Victimization | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-history-of-issues | Questionnaire CCARS History Of Issues | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-history-of-mental-health-services | Questionnaire CCARS History Of Mental Health Services | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-hope-rating | Questionnaire CCARS Hope Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-interpersonal-rating | Questionnaire CCARS Interpersonal Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-legal-rating | Questionnaire CCARS Legal Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-legal-status | Questionnaire CCARS Legal Status | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-marital-status | Questionnaire CCARS Marital Status | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-medication-psychiatric-service | Questionnaire CCARS Medication Psychiatric Service | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-mental-health-services-program | Questionnaire CCARS Mental Health Services Program | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-multiple-issues-rating | Questionnaire CCARS Multiple Issues Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-overall-level-of-functioning-rating | Questionnaire CCARS Overall Level Of Functioning Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-overall-recovery-rating | Questionnaire CCARS Overall Recovery Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-overall-symptom-severity-rating | Questionnaire CCARS Overall Symptom Severity Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-physical-health-rating | Questionnaire CCARS Physical Health Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-place-of-residence | Questionnaire CCARS Place Of Residence | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-previous-concurrent-services | Questionnaire CCARS Previous Concurrent Services | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-psychosis-rating | Questionnaire CCARS Psychosis Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-race | Questionnaire CCARS Race | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-rae-aso-identification-codes | Questionnaire CCARS RAE ASO Identification Codes | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-reason-for-discharge | Questionnaire CCARS Reason For Discharge | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-role-performance-rating | Questionnaire CCARS Role Performance Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-school-development | Questionnaire CCARS School Development | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-school-problems | Questionnaire CCARS School Problems | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-security-supervision-rating | Questionnaire CCARS Security Supervision Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-self-care-basic-needs-rating | Questionnaire CCARS Self Care Basic Needs Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-sexual-orientation | Questionnaire CCARS Sexual Orientation | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-social-support-rating | Questionnaire CCARS Social Support Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-socialization-rating | Questionnaire CCARS Socialization Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-suicide-danger-to-self-rating | Questionnaire CCARS Suicide Danger To Others Rating | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-tobacco-use | Questionnaire CCARS Tobacco Use | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-type-of-discharge | Questionnaire CCARS Type Of Discharge | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-type-of-update | Questionnaire CCARS Type Of Update | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-yes-no-na | Questionnaire CCARS Yes No NA | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-yes-no-unable-to-assess | Questionnaire CCARS Yes No Unable To Assess | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-ccars-yes-no | Questionnaire CCARS Yes No | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-admission-route-of-administration | Questionnaire DACODS Admission Route Of Administration | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-client-disability | Questionnaire DACODS Client Disability | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-clinician-diagnostic-impression | Questionnaire DACODS Clinician Diagnostic Impression | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-discharge-progress-towards-measurable-treatment-goals | Questionnaire DACODS Discharge Progress Towards Measurable Treatment Goals | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-discharge-route-of-administration | Questionnaire DACODS Discharge Route Of Administration | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-discharge-status | Questionnaire DACODS Discharge Status | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-drug-type-code | Questionnaire DACODS Drug Type Code | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-education-employment-problems | Questionnaire DACODS Education Employment Problems | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-employment-status | Questionnaire DACODS Employment Status | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-family-issues-and-problems | Questionnaire DACODS Family Issues And Problems | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-health-insurance-status | Questionnaire DACODS Health Insurance Status | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-living-situation | Questionnaire DACODS Living Situation | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-marital-status | Questionnaire DACODS Marital Status | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-medical-physical-problems | Questionnaire DACODS Medical Physical Problems | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-reason-for-discharge | Questionnaire Dacods Reason For Discharge | draft | 2023-09 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-secondary-tertiary-drug-type-code | Questionnaire DACODS Secondary Tertiary Drug Type Code | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-sexual-orientation | Questionnaire DACODS Sexual Orientation | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-socialization-problems | Questionnaire DACODS Socialization Problems | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-source-of-illicit-drugs | Questionnaire DACODS Source Of Illicit Drugs | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-source-of-income | Questionnaire DACODS Source Of Income | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-source-of-payment-for-treatment | Questionnaire DACODS Source Of Payment For Treatment | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-statutory-commitment | Questionnaire DACODS Statutory Commitment | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-tobacco-use | Questionnaire DACODS Tobacco Use | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-transfer-referral-source | Questionnaire DACODS Transfer Referral Source | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-yes-no-na | Questionnaire DACODS Yes No NA | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-yes-no-unable-to-assess | Questionnaire DACODS Yes No Unable To Assess | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-yes-no-unknown | Questionnaire DACODS Yes No Unknown | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/questionnaire-dacods-yes-no | Questionnaire DACODS Yes No | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/reason-for-discharge | Reason For Discharge | active | 2023-06 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/referencerange-appliesto | Observation Reference Range Applies To Codes | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/referencerange-meaning | Observation Reference Range Meaning Codes | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/service-provision-conditions | ServiceProvisionConditions | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/service-referral-method | ReferralMethod | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/request-intent | RequestIntent | draft | 2019-10 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/servicerequest-orderdetail | Service Request Order Details Codes | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/request-priority | RequestPriority | draft | 2016-07 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/request-status | RequestStatus | draft | 2019-10 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/service-type | Service type | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/us/core/ValueSet/signal-filerepo-classification | Signal FileRepo Classification | draft | 2023-09 | hl7 |
| signal.core.r4 | R4 | http://signalbhn.org/fhir/us/core/ValueSet/signal-filerepo-docreviewstatus | Signal FileRepo DocStatus | draft | 2023-09 | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/signal-organization-qualification | Signal Organization Qualification | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/ValueSet/signal-region | Signal Region | draft | | hl7 |
| signal.core.r4 | R4 | https://signalbhn.org/fhir/us/core/ValueSet/signal-state-activity-status | Signal State Activity Status | draft | 2023-09 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/subscriber-relationship | SubscriberPolicyholder Relationship Codes | draft | 2019-11 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/contact-point-system | ContactPointSystem | draft | 2019-10 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/ValueSet/contact-point-use | ContactPointUse | draft | 2019-10 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/us/core/ValueSet/us-core-discharge-disposition | US Core Discharge Disposition | active | 2022-09 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/us/core/ValueSet/us-core-encounter-type | US Core Encounter Type | active | 2022-09 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/us/core/ValueSet/us-core-problem-or-health-concern | US Core Problem or Health Concern | active | 2022-09 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/us/core/ValueSet/us-core-screening-assessment-condition-category | US Core Screening Assessment Condition Category | active | 2023-04 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/us/core/ValueSet/us-core-servicerequest-category | US Core ServiceRequest Category Codes | active | 2022-09 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/us/core/ValueSet/us-core-simple-observation-category | US Core Simple Observation Category | active | 2022-09 | hl7 |
| signal.core.r4 | R4 | http://hl7.org/fhir/us/core/ValueSet/us-core-usps-state | USPS Two Letter Alphabetic Codes | active | 2022-09 | hl7 |
| tiga.health.clinical | R4 | http://tigahealth.com/SearchParameter/tiga-allergyintolerance-encounter | TigaAllergyIntoleranceEncounter | active | 2022-09 | |
| tiga.health.clinical | R4 | http://tigahealth.com/SearchParameter/tiga-immunization-encounter | TigaImmunizationEncounter | active | 2022-10 | |
| tiga.health.clinical | R4 | https://www.ama-assn.org/cdt | CDT, The Code on Dental Procedures and Nomenclature, produced by American Dental Association (ADA) | active | | |
| tiga.health.clinical | R4 | http://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx | HL7 Table 0292, Vaccine Administered (CVX) is a product of the National Center of Immunization and Respiratory Diseases (NCIRD). NCIRD is part of the Centers for Disease Control and Prevention (CDC). | active | | |
| tiga.health.clinical | R4 | http://dicom.nema.org/ | DICOM defines how to format images and image quality requirements that aid the exchange of images for clinical use. | active | | |
| tiga.health.clinical | R4 | http://tigahealth.com/fhir/ConceptMap/cpt-hcpcs | | active | | |
| tiga.health.clinical | R4 | http://tigahealth.com/fhir/ConceptMap/dicom-loinc | | active | | |
| tiga.health.clinical | R4 | http://tigahealth.com/fhir/ConceptMap/hcpcs-cpt | | active | | |
| tiga.health.clinical | R4 | http://tigahealth.com/fhir/ConceptMap/loinc-dicom | | active | | |
| tiga.health.clinical | R4 | http://tigahealth.com/fhir/ConceptMap/snomed-dicom | | active | | |
| fhir.argonaut.pd | R3 | http://fhir.org/guides/argonaut-pd/CapabilityStatement/client | Argonaut Provider Directory Client | draft | 2016-11 | hl7 |
| fhir.argonaut.pd | R3 | http://fhir.org/guides/argonaut-pd/CapabilityStatement/server | Argonaut Provider Directory Server | draft | 2017-04 | hl7 |
| fhir.argonaut.pd | R3 | http://fhir.org/guides/argonaut-pd/ImplementationGuide/ig | Argonaut Provider Directory Implementation Guide | draft | | hl7 |
| fhir.argonaut.pd | R3 | http://fhir.org/guides/argonaut-pd/StructureDefinition/argo-endpoint | Argonaut Provider Directory Endpoint | draft | 2016-11 | hl7 |
| fhir.argonaut.pd | R3 | http://fhir.org/guides/argonaut-pd/StructureDefinition/argo-location | Argonaut Provider Directory Location | draft | 2016-11 | hl7 |
| fhir.argonaut.pd | R3 | http://fhir.org/guides/argonaut-pd/StructureDefinition/argo-organization | Argonaut Provider Directory Organization | draft | 2016-11 | hl7 |
| fhir.argonaut.pd | R3 | http://fhir.org/guides/argonaut-pd/StructureDefinition/argo-practitioner | Argonaut Provider Directory Practitioner | draft | 2016-11 | hl7 |
| fhir.argonaut.pd | R3 | http://fhir.org/guides/argonaut-pd/StructureDefinition/argo-practitionerrole | Argonaut Provider Directory PractitionerRole | draft | 2016-11 | hl7 |
| fhir.argonaut.pd | R3 | http://fhir.org/guides/argonaut-pd/ValueSet/provider-role | Argonaut Provider Directory Provider Role (NUCC) | draft | 2016-08 | hl7 |
| fhir.argonaut.pd | R3 | http://fhir.org/guides/argonaut-pd/ValueSet/provider-specialty | Argonaut Provider Directory Provider Speciality (NUCC) | draft | 2016-08 | hl7 |
| hl7.fhir.us.patient-reported-outcomes | R4 | CapabilityStatement/server | Server | draft | 2017-03 | hl7 |
| hl7.fhir.us.patient-reported-outcomes | R4 | ImplementationGuide/ig | Patient Reported Outcomes | draft | | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ConceptMap/ndc-cvx | Argonaut NDC to CVX Code Mapping | active | 2016-06 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ImplementationGuide/ig | Implementation Guide Template | draft | | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/OperationDefinition/docref | Argonaut Get DocumentReferences | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/SearchParameter/ethnicity | ArgonautEthnicity | draft | 2016-12 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/SearchParameter/race | ArgonautRace | draft | 2016-12 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-allergyintolerance | Argonaut AllergyIntolerance Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-birthsex | Sex of patient assigned at birth | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-careplan | Argonaut CarePlan Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-careteam | Argonaut CareTeam Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-condition | Argonaut Condition Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-device | Argonaut Device Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-diagnosticreport | Argonaut DiagnosticReport Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-documentreference | Argonaut DocumentReference Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-ethnicity | Argonaut ethnicity Extension | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-goal | Argonaut Goal Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-immunization | Argonaut Immunization Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-medication | Argonaut Medication Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-medicationorder | Argonaut MedicationOrder Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-medicationstatement | Argonaut MedicationStatement Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-observationresults | Argonaut Observation Results Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-patient | Argonaut Patient Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-procedure | Argonaut Procedure Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-profile-link | Profile-Resource Association | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-race | Argonaut Race Extension | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-resource-documentation | Resource level Documentation | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-smokingstatus | Argonaut Smoking Status Observation Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/StructureDefinition/argo-vitalsigns | Argonaut Vital Signs Observation Profile | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/argo-codesystem | Argonaut Extension Codes | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/condition-category | Argonaut Condition Category Codes | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/detailed-ethnicity | US-Core Detailed ethnicity | draft | 2016-08 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/detailed-race | US-Core Detailed Race | draft | 2016-08 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/device-kind | Argonaut Device Types | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/languages | All Languages | draft | 2016-11 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/medication-codes | Medication Clinical Drug (RxNorm) | draft | 2016-05 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/narrative-status | Narrative Status | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/ndc-vaccine-codes | Vaccine National Drug Code (NDC) | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/observation-ccdasmokingstatus | Smoking Status | active | 2016-08 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/observation-ccdavitalsignresult | Argonaut Vital Sign Codes | active | 2016-08 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/observation-value-codes | Observation Value Codes (SNOMED-CT) | draft | 2016-08 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/omb-ethnicity | OMB Ethnicity Categories | draft | 2016-08 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/omb-race | OMB Race Categories | active | 2016-05 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/procedure-icd10pcs | Argonaut Procedure Type ICD-10-PCS Codes | draft | 2016-08 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/procedure-type | Argonaut ProcedureType | draft | 2016-05 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/provider-role | Care Team Provider Roles | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/substance-ndfrt | DAF Substance ND-FRT codes | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/substance-rxnorm | DAF Substance RxNorm Codes | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/substance-sct | DAF SNOMED CT Substances Other Than Clinical Drugs | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/substance | Argonaut Substance-Reactant for Intolerance and Negation Codes | draft | 2016-10 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/ucum-vitals-common | Argonaut Vital Signs Units | draft | 2016-05 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/ucum | UCUM units | draft | 2016-08 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/usrealm-birthsex | USRealm Birth Sex Value Set | active | 2016-08 | hl7 |
| fhir.argonaut.r2 | R2 | http://fhir.org/guides/argonaut/ValueSet/vacc-status | Argonaut Immunization Status | draft | 2016-10 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/CapabilityStatement/daf-datamart | Data Mart | draft | 2016-08 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/CapabilityStatement/daf-datasource | Data Source | draft | 2016-08 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/CapabilityStatement/daf-research-queryrequester | Research Query Requester | draft | 2016-08 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/CapabilityStatement/daf-research-queryresponder | Research Query Responder | draft | 2016-08 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/CodeSystem/daf-research-data-models | DAF Research Data Models | draft | 2017-04 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/CodeSystem/daf-research-query-formats | DAF Research Query Formats | draft | 2017-04 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/ImplementationGuide/ig | Implementation Guide Template | draft | | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/OperationDefinition/daf-execute-query | Execute Query | draft | 2016-07 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/OperationDefinition/daf-extract | Extract Data | draft | 2016-07 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/OperationDefinition/daf-load | Load Data | draft | 2016-07 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/StructureDefinition/daf-capabilitystatement | U.S. Data Access Framework (DAF) Capability Statement Profile | draft | 2016-08 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/StructureDefinition/daf-data-model | Data Models | draft | 2016-08 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/StructureDefinition/daf-operationdefinition | U.S. Data Access Framework (DAF) OperationDefinition Profile | draft | 2016-08 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/StructureDefinition/daf-provenance | U.S. Data Access Framework (DAF) Provenance | draft | 2014-08 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/StructureDefinition/daf-query-format | Query Formats | draft | 2016-08 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/StructureDefinition/daf-queryresults | U.S. Data Access Framework (DAF) Query Results | draft | 2014-08 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/StructureDefinition/daf-task | U.S. Data Access Framework (DAF) Task Profile | draft | 2016-08 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/ValueSet/daf-research-data-models | DAF Research Data Models | active | 2016-07 | hl7 |
| hl7.fhir.us.daf | R3 | http://hl7.org/fhir/us/daf-research/ValueSet/daf-research-query-formats | DAF Research Query Formats | active | 2016-07 | hl7 |
| fhir.tx.support.r4 | R4 | urn:oid:2.16.840.1.113883.3.1937.98.5.8 | TemplateStatusCode LifeCycle | active | 2013-12 | hl7 |
| fhir.tx.support.r4 | R4 | https://www.humanservices.gov.au/organisations/health-professionals/enablers/air-vaccine-code-formats | Australian Immunisation Register Vaccine | active | 2021-03 | hl7 |
| fhir.tx.support.r4 | R4 | http://cap.org/eCP | College of American Pathologists Electronic Cancer Protocol (eCP) Codes | active | 2023-03 | hl7 |
| fhir.tx.support.r4 | R4 | http://terminology.hl7.org/CodeSystem/ICHContextOfUse | ICH Context of Use | active | 2025-05 | hl7 |
| fhir.tx.support.r4 | R4 | http://devices.fhir.org/CodeSystem/MDC-concept-status | MDC Concept Status | active | | hl7 |
| fhir.tx.support.r4 | R4 | http://devices.fhir.org/CodeSystem/MDC-designation-use | MDC Designation Use | active | | hl7 |
| fhir.tx.support.r4 | R4 | http://standardterms.edqm.eu | EDQM Standard Terms | active | 2019-03 | hl7 |
| fhir.tx.support.r4 | R4 | http://terminology.hl7.org/CodeSystem/hl7-document-format-codes | HL7 Document Format Codes | active | 2019-07 | hl7 |
| fhir.tx.support.r4 | R4 | urn:oid:2.16.840.1.113883.2.9.6.2.7 | International Standard Classification of Occupations (ISCO) | active | 2007-12 | hl7 |
| fhir.tx.support.r4 | R4 | http://hl7.org/fhir/spdx-license | SPDXLicense | draft | 2021-01 | hl7 |
| fhir.tx.support.r4 | R4 | https://www.usps.com/ | US State Codes | active | 2013-12 | hl7 |
| fhir.tx.support.r4 | R4 | http://hl7.org/fhir/resource-names-r2-r3 | Resource Names R2 to R3 | active | 2019-01 | hl7 |
| fhir.tx.support.r4 | R4 | http://hl7.org/fhir/resource-names-r2-r4 | Resource Names R2 to R4 | active | 2019-01 | hl7 |
| fhir.tx.support.r4 | R4 | http://hl7.org/fhir/resource-names-r3-r2 | Resource Names R3 to R2 | active | 2019-01 | hl7 |
| fhir.tx.support.r4 | R4 | http://hl7.org/fhir/resource-names-r3-r4 | Resource Names R3 to R4 | active | 2019-01 | hl7 |
| fhir.tx.support.r4 | R4 | http://hl7.org/fhir/resource-names-r4-r2 | Resource Names R4 to R2 | active | 2019-01 | hl7 |
| fhir.tx.support.r4 | R4 | http://hl7.org/fhir/resource-names-r4-r3 | Resource Names R4 to R3 | active | 2019-01 | hl7 |
| fhir.tx.support.r4 | R4 | http://fhir.org/packages/fhir.tx.support.r4/ImplementationGuide/fhir.tx.support.r4 | FHIR Terminology Support Package | active | | hl7 |
| fhir.tx.support.r4 | R4 | http://devices.fhir.org/ValueSet/MDC-dimension | MDC Unit of Measurement | active | | hl7 |
| fhir.tx.support.r4 | R4 | http://devices.fhir.org/ValueSet/MDC-metric | MDC Metric nomenclature | active | | hl7 |
| fhir.tx.support.r4 | R4 | http://devices.fhir.org/ValueSet/MDC-object | MDC Object infrastructure and Device nomenclature | active | | hl7 |
| fhir.tx.support.r4 | R4 | http://devices.fhir.org/ValueSet/MDC-partition | MDC Partition codes | active | | hl7 |
| fhir.tx.support.r4 | R4 | http://devices.fhir.org/ValueSet/MDC | MDC Nomenclature | active | | hl7 |
| fhir.tx.support.r4 | R4 | http://hl7.org/fhir/uv/ips/ValueSet/allergy-intolerance-substance-product-gps-uv-ips | Allergy-intolerance substance-product - GPS - IPS | active | 2021-05 | hl7 |
| fhir.tx.support.r4 | R4 | http://hl7.org/fhir/uv/ips/ValueSet/allergy-intolerance-substance-product-snomed-extended-uv-ips | Allergy intolerance substance product - SNOMED CT extended - IPS | active | 2021-05 | hl7 |
| fhir.tx.support.r4 | R4 | http://hl7.org/fhir/ValueSet/covid-19-cond | COVID-19 related Condition codes | draft | 2020-03 | hl7 |
| fhir.tx.support.r4 | R4 | http://hl7.org/fhir/ValueSet/covid-19-obs | COVID-19 related Observation codes | draft | 2020-03 | hl7 |
| fhir.tx.support.r4 | R4 | http://hl7.org/fhir/ValueSet/jurisdiction-common | Common Jurisdiction Codes | active | 2020-09 | hl7 |
| fhir.tx.support.r4 | R4 | http://terminology.hl7.org/ValueSet/snomed-intl-ips | SNOMED CT® International Patient Set (IPS) | active | 2022-06 | hl7 |
| fhir.tx.support.r4 | R4 | https://www.iana.org/time-zones | IANA Timezones | draft | 2021-01 | hl7 |
| hl7.fhir.us.sdcde | R3 | CapabilityStatement/sdc-de-curator | SDC Data Element Curator | draft | 2014-07 | hl7 |
| hl7.fhir.us.sdcde | R3 | CapabilityStatement/sdc-de-registry | SDC Data Element Manager | draft | 2014-07 | hl7 |
| hl7.fhir.us.sdcde | R3 | ImplementationGuide/sdcde | Structured Data Capture - Data Element Exchange | draft | | hl7 |
| hl7.fhir.us.sdcde | R3 | StructureDefinition/sdcde-codesystem | Structured Data Capture Code System | draft | 2014-07 | hl7 |
| hl7.fhir.us.sdcde | R3 | StructureDefinition/sdcde-dataelement | Structured Data Capture Data Element Exchange | draft | 2014-04 | hl7 |
| hl7.fhir.us.sdcde | R3 | StructureDefinition/sdcde-valueset | Structured Data Capture Data Element Exchange Value Set | draft | 2014-07 | hl7 |
| hl7.fhir.us.sdcde | R3 | ValueSet/dataelement-sdccode | DataElement SDC Concept | draft | 2017-04 | hl7 |
| hl7.fhir.us.immds | R4 | CodeSystem/ForecastReason | Forecast Reason | active | 2021-06 | hl7 |
| hl7.fhir.us.immds | R4 | CodeSystem/ForecastStatus | Forecast Status | active | 2021-06 | hl7 |
| hl7.fhir.us.immds | R4 | CodeSystem/StatusReason | Evaluation Status Reason | active | 2021-06 | hl7 |
| hl7.fhir.us.immds | R4 | ImplementationGuide/hl7.fhir.us.immds | Immunization Decision Support Forecast (ImmDS) Implementation Guide | active | 2021-06 | hl7 |
| hl7.fhir.us.immds | R4 | OperationDefinition/ImmDSForecastOperation | Immunization Decision Support Forecast | draft | 2021-06 | hl7 |
| hl7.fhir.us.immds | R4 | StructureDefinition/immds-immunization | ImmDS Immunization | active | 2021-06 | hl7 |
| hl7.fhir.us.immds | R4 | StructureDefinition/immds-immunizationevaluation | ImmDS Immunization Evaluation | active | 2021-06 | hl7 |
| hl7.fhir.us.immds | R4 | StructureDefinition/immds-immunizationrecommendation | ImmDS Immunization Recommendation | active | 2021-06 | hl7 |
| hl7.fhir.us.immds | R4 | StructureDefinition/immds-patient | ImmDS Patient | active | 2021-06 | hl7 |
| hl7.fhir.us.immds | R4 | ValueSet/ForecastReason | Forecast Reason | active | 2021-06 | hl7 |
| hl7.fhir.us.immds | R4 | ValueSet/ForecastStatus | Forecast Status | active | 2021-06 | hl7 |
| hl7.fhir.us.immds | R4 | ValueSet/StatusReason | Evaluation Status Reason | active | 2021-06 | hl7 |
| hl7.fhir.us.immds | R4 | ValueSet/targetDisease | Vaccine Target Disease | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | ImplementationGuide/us.nlm.vsac | US VSAC Package | active | | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.13925.17760.1280649 | Sneezing and Itching Grouping | active | 2017-06 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.13925.17760.15972546 | Conditions Indicating Appropriate Sinonasal Imaging | active | 2017-06 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.13925.17760.16432390 | Cerumen Impaction | active | 2017-06 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.13925.17760.16929355 | Allergic Rhinitis Grouping | active | 2017-06 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.13925.17760.18316962 | Severe Asthma | active | 2017-06 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.13925.17760.19613338 | Immunoglobulin G Testing Grouping | active | 2022-03 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.13925.17760.23618223 | Hearing Aids Grouping | active | 2017-06 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.13925.17760.24927846 | Specific IgE testing | active | 2017-06 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.13925.17760.26050446 | Ear Surgery Affecting the Tympanic Membrane | active | 2017-06 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.13925.17760.26878039 | Specific IgE Testing | active | 2022-03 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.13925.17760.29996863 | Immunoglobulin G testing | active | 2017-06 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.13925.17760.4352590 | Benign Prostatic Hyperplasia | active | 2017-08 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.2.91.8867.26816.649902 | Office or Outpatient Encounter | active | 2017-07 | |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.12009.10.2.5 | LOINC Imaging Document Codes | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.33895.1.3.0.45 | Comfort Measures | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.13.13.1.15.1.999.1 | Selected non pharmaceutical therapies for moderate to severe chronic pain | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.13.13.1.16.1.1.999.3 | selected first line medications for pain control | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.13.13.1.16.1.11.1.999.3 | selected muscle relaxants for pain control | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.13.13.1.16.1.12.1.999.3 | Selected topical agents for pain control | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.13.13.1.17.1.1.999.2 | selected non opioids for moderate to severe pain | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.13.13.1.17.1.11.1.999.2 | Selected opioids for moderate to severe pain | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.13.18.1.1.11.1.999.1 | pain medication action plan | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.15.2.1.1.999.1 | Selected urine drug screens for opioids indicating testing is complete | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.15.7.1.1.11.1.999.1 | selected follow up visit intervals for opioid monitoring | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.999.2 | Selected urine screening for patients receiving opioid therapy | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.999.3.1 | Opioids used for pain control | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.999.3.2 | All prescribable opioids used for pain control including Inactive Medications | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.999.4.1 | malignant neoplasms and cancer pain | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.999.4.2 | malignant neoplasms and cancer pain | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.999.4.7 | malignant neoplasms and cancer pain | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.234.999.4.9 | malignancy or cancer related pain | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31172.1.1.999.150 | Cerumen on Otoscopy | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31172.1.1.999.151 | Cerumen on Otoscopy | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31172.1.1.999.152 | Cerumen on Otoscopy | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31182.1.12.1.999.172 | Hearing Loss | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31182.1.12.1.999.173 | Hearing Loss | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31182.1.12.1.999.174 | Hearing Loss | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31182.1.13.1.999.175 | Tinnitus | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31182.1.13.1.999.176 | Tinnitus | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31182.1.13.1.999.177 | Tinnitus | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31182.1.14.1.999.178 | Ear Congestion | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31182.1.15.1.999.179 | Ear Pruritus | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31182.1.16.1.999.180 | Otalgia | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31182.1.16.1.999.181 | Otalgia | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31182.1.16.1.999.182 | Otalgia | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31441.1.2.999.96 | Initial Encounter with Otolaryngologist or undefined clinician | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31471.1.11.1.999.204 | Hearing Aids | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31471.1.11.1.999.205 | Hearing Aids | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.13.31471.1.11.1.999.206 | Hearing Aids | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31212.1.1.999.81 | Cerumen Impaction | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31212.1.1.999.82 | Cerumen Impaction | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31305.1.11.1.999.188 | Radiotherapy | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31305.1.11.1.999.189 | Radiotherapy | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31305.1.11.1.999.190 | Radiotherapy | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31305.1.11.2.999.191 | Head and Neck Anatomic Locations | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31305.1.11.2.999.192 | Conditions Associated with Head and Neck Radiotherapy | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31305.1.11.2.999.193 | Conditions Associated with Head and Neck Radiotherapy | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31317.1.1.999.194 | Ear Canal Stenosis | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31317.1.1.999.195 | Ear Canal Stenosis | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31317.1.1.999.196 | Ear Canal Stenosis | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31329.1.1.999.197 | Exostoses | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31329.1.1.999.198 | Exostoses | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31329.1.1.999.199 | Exostoses | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31341.1.1.999.200 | Non intact Tympanic Membrane | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31341.1.1.999.201 | Non Intact Tympanic Membrane | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31341.1.1.999.202 | Non Intact Tympanic Membrane | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31481.1.11.1.999.246 | Hearing Aids | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31481.1.11.1.999.250 | DO NOT USE | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31481.1.12.1.999.251 | Cerumenolytics | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31481.1.12.1.999.252 | Irrigation | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31481.1.12.1.999.253 | Irrigation | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31593.1.12.1.999.288 | Otoscopy performed on exam | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.15.31663.1.1.999.291 | Otolaryngologist as a Clinician or Service | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.8.31102.1.1.999.123 | Cerumen Impaction | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.9.31104.1.1.999.275 | Dermatologic Diseases of the Ear | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.9.31108.1.1.999.20 | Keratoses Obturans | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.9.31112.1.11.1.999.221 | Tympanoplasty | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.9.31112.1.11.1.999.222 | Tympanoplasty | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.9.31112.1.12.1.999.223 | Myringoplasty | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.9.31112.1.12.1.999.224 | Myringoplasty | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.9.31112.1.13.1.999.225 | Mastoidectomy | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.9.31112.1.13.1.999.229 | Mastoidectomy | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.9.31112.1.14.1.999.227 | Ear Surgery, Other | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.265.9.31112.1.14.1.999.228 | Ear Surgery, Other | active | 2018-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.12.31833.1.1.999.334 | Sleep Apnea | active | 2018-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.12.31833.1.1.999.335 | Sleep Apnea | active | 2018-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.12.31833.1.1.999.336 | Sleep Apnea | active | 2018-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.34853.1.1.999.237 | Allergic Rhinitis | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.34853.1.1.999.238 | Allergic Rhinitis | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.34853.1.1.999.239 | Allergic Rhinitis | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.34951.1.11.1.999.263 | Uncontrolled or severe asthma | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.34951.1.11.1.999.264 | Uncontrolled or severe asthma | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.34951.1.11.1.999.265 | Uncontrolled or severe asthma | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35031.1.11.1.999.300 | Rhinosinusitis | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35031.1.11.1.999.301 | Rhinosinusitis | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35031.1.11.1.999.302 | Rhinosinusitis | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35031.1.12.1.999.303 | Nasal Polyposis | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35031.1.12.1.999.304 | Nasal Polyposis | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35031.1.12.1.999.305 | Nasal Polyposis | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35031.1.13.1.999.306 | Suspected Nasal Neoplasm | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35031.1.13.1.999.307 | Suspected Nasal Neoplasm | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35031.1.13.1.999.308 | Suspected Nasal Neoplasm | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35031.1.14.1.999.309 | Other sinus conditions potentially requiring imaging | active | 2017-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35031.1.14.1.999.310 | Other sinus conditions potentially requiring imaging | active | 2017-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35211.1.11.1.999.319 | Intranasal Antihistamines | active | 2017-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35211.1.12.1.999.320 | Mast Cell Stabilizers | active | 2017-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35211.1.13.1.999.321 | Ophthalmic Antihistamines | active | 2017-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35282.1.11.1.999.215 | Sneezing as a finding | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35282.1.11.1.999.216 | Sneezing as a Clinical Condition | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35282.1.12.1.999.217 | Pruritus Unspecified or Other Location | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.13.35282.1.12.1.999.218 | Pruritus Unspecified or Other Location | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.34907.1.11.1.999.272 | Specific IgE Testing for Allergies | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.34907.1.12.1.999.273 | Immunoglobulin G Testing | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.34907.1.13.1.999.274 | Total IgE Testing | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.34920.1.1.999.290 | Clinicians who perform allergy testing | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.35043.1.1.999.279 | Radiography of face, head or neck | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.35221.1.11.1.999.315 | Intranasal Corticosteroids | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.35221.1.13.1.999.316 | Eustachian Tube Dysfunction | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.35221.1.13.1.999.317 | Eustachian Tube Dysfunction | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.35221.1.13.1.999.318 | Eustachian Tube Dysfunction | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.35292.1.1.999.287 | Oral Second Generation and Less Sedating Antihistamines | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.35464.1.1.999.266 | Leukotriene antagonist | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.35607.1.11.1.999.267 | Immunotherapy that is not Identified as Subcutaneous | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.268.15.35607.1.14.1.999.268 | Immunotherapy | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.12.37641.1.1.999.653 | Fidaxomicin | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.12.37696.1.1.999.654 | Proton Pump Inhibitors not including for H. pylori treatment | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.37752.1.1.999.655 | Clostridium difficile infection | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.37752.1.1.999.656 | Clostridium difficile infection | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.37752.1.1.999.657 | Clostridium difficile infection | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38167.1.1.999.594 | Complete Blood Count (with Diff) | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38256.1.1.999.662 | Metronidazole Systemic | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38266.1.1.999.663 | Vancomycin non injectable | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38343.1.1.999.665 | Creatinine | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38398.1.11.1.999.722 | Ileus due to infection | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38398.1.11.1.999.723 | Ileus due to infection | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38398.1.11.1.999.724 | Ileus due to infection | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38398.1.12.1.999.725 | Vomiting potentially due to CDI | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38398.1.12.1.999.726 | Vomiting potentially due to CDI | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38398.1.12.1.999.727 | Vomiting potentially due to CDI | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38398.1.13.1.999.728 | Toxic Megacolon in adults | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38398.1.13.1.999.729 | Toxic Megacolon in adults | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38398.1.13.1.999.730 | Toxic Megacolon in adults | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38398.1.14.1.999.731 | Abdominal Distension | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38398.1.14.1.999.732 | Abdominal Distension | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38493.1.1.999.688 | Septic Shock due to C. Diff | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38493.1.1.999.689 | Septic Shock due to C. Diff | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.13.38493.1.1.999.690 | Septic Shock due to C. Diff | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.15.37872.1.1.999.658 | Antiperistaltic agents to avoid in C. diff | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.15.37872.1.1.999.734 | Systemic Antimicrobial Medications not used for CDI | active | 2019-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.15.37937.1.11.1.999.659 | Recurrent Clostridium difficile infection | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.15.37937.1.13.2.999.660 | History of CDI | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.15.38112.1.1.999.661 | Consult Infectious Disease | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.15.38827.1.1.999.691 | Abdominal Xrays for CDI | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.15.38839.1.1.999.692 | CT of abdomen with contrast for fulminant CDI | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.15.38904.1.1.999.693 | Surgical consult for CDI | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.15.39406.1.1.999.694 | Fecal microbiota transplantation | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.4.37623.1.1.999.645 | Hospitalist | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.8.37627.1.1.999.697 | Positive result indicator | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.8.37627.1.1.999.698 | Clostridium Difficile Test | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.8.37631.1.11.1.999.646 | Body Temperature | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.8.37631.1.11.1.999.647 | Body Temperature | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.8.37631.1.12.1.999.648 | Diarrhea Potentially due to CDI | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.8.37631.1.12.1.999.649 | Diarrhea Potentially due to CDI | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.8.37631.1.12.1.999.650 | Diarrhea Potentially due to CDI | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.8.37631.1.13.1.999.651 | Leukocyte count | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/1.3.6.1.4.1.6997.4.1.2.271.9.37637.1.1.999.652 | Inpatient Setting | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1 | ONC Administrative Sex | active | 2015-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1010.1 | Substance Reactant for Intolerance | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1010.2 | Clinical Substance | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1010.4 | Medication Clinical Drug | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1010.5 | Medication Clinical Brand specific Drug | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1010.6 | CVX Vaccines Administered Vaccine Set | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1010.7 | Clinical Drug Ingredient | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1010.8 | Vaccine Clinical Drug | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1010.9 | Substance Other Than Clinical Drug | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1018.240 | SNOMED CT CORE Problem List | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1018.98 | Route of Administration | active | 2019-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.101 | Gender Identity USCDI core | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.102 | Unknown or did not answer | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.103 | Other or unknown or refused to answer | active | 2021-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.12 | Low Molecular Weight Heparin for VTE prophylaxis ingredient specific | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.120 | Patient Sex for Quality Measurement | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.121 | Federal Administrative Sex | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.14 | Published test VS | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.24 | Birth Sex | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.30 | AdministrationUnitDoseForm | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.33 | Sexual Orientation | active | 2021-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.40 | MDP Test Intensional | active | 2019-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.41 | MDP Test HL7 Intensional | active | 2019-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.46 | Device Magnetic resonance (MR) Safety | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.47 | Device Latex Safety | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.48 | Implantable Device Status | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1021.56 | Medical Reason Not Done SCT | active | 2019-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.119 | Phototherapy | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.120 | Phototherapy | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.121 | Phototherapy | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.122 | Neonatal Jaundice | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.123 | Neonatal Jaundice | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.124 | Neonatal Jaundice | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.125 | Maternal Drug Use | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.126 | Maternal Drug Use | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.127 | Maternal Drug Use | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.128 | Fetal Conditions | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.129 | Fetal Conditions | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.130 | Fetal Conditions | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.131 | Congenital Malformations | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.132 | Congenital Malformations | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.133 | Congenital Malformations | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.134 | Social Indications | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.135 | Social Indications | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.136 | Social Indications | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.137 | Neonatal Severe Birth Trauma | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.138 | Neonatal Severe Birth Trauma | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.139 | Neonatal Severe Birth Trauma | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.140 | Neonatal Severe Hypoxia or Asphyxia | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.141 | Neonatal Severe Hypoxia or Asphyxia | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.142 | Neonatal Severe Hypoxia or Asphyxia | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.143 | Neonatal Severe Shock and Resuscitation | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.144 | Neonatal Severe Shock and Resuscitation | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.145 | Neonatal Severe Shock and Resuscitation | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.146 | Neonatal Severe Respiratory Complications | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.147 | Neonatal Severe Respiratory Complications | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.148 | Neonatal Severe Respiratory Complications | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.149 | Neonatal Severe Infection | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.150 | Neonatal Severe Infection | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.151 | Neonatal Severe Infection | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.152 | Neonatal Severe Neurological Complications | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.153 | Neonatal Severe Neurological Complications | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.154 | Neonatal Severe Neurological Complications | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.155 | Neonatal Severe Shock and Resuscitation Procedures | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.156 | Neonatal Severe Shock and Resuscitation Procedures | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.157 | Neonatal Severe Shock and Resuscitation Procedures | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.158 | Neonatal Severe Respiratory Procedures | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.159 | Neonatal Severe Respiratory Procedures | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.160 | Neonatal Severe Respiratory Procedures | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.161 | Neonatal Severe Neurological Procedures | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.162 | Neonatal Severe Neurological Procedures | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.163 | Neonatal Severe Neurological Procedures | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.164 | Neonatal Severe Septicemia | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.165 | Neonatal Severe Septicemia | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.166 | Neonatal Severe Septicemia | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.167 | Neonatal Moderate Birth Trauma | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.168 | Neonatal Moderate Birth Trauma | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.169 | Neonatal Moderate Birth Trauma | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.170 | Neonatal Moderate Respiratory Complications | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.171 | Neonatal Moderate Respiratory Complications | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.172 | Neonatal Moderate Respiratory Complications | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.173 | Neonatal Moderate Respiratory Complications Procedures | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.174 | Neonatal Moderate Respiratory Complications Procedures | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.175 | Neonatal Moderate Respiratory Complications Procedures | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.176 | Neonatal Moderate Birth Trauma with LOS | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.177 | Neonatal Moderate Birth Trauma with LOS | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.178 | Neonatal Moderate Birth Trauma with LOS | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.179 | Neonatal Moderate Respiratory Complications with LOS | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.180 | Neonatal Moderate Respiratory Complications with LOS | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.181 | Neonatal Moderate Respiratory Complications with LOS | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.182 | Moderate Neurological Complications with LOS Procedures | active | 2019-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.183 | Neonatal Moderate Neurological Complications with LOS Procedures | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.184 | Neonatal Moderate Neurological Complications with LOS Procedures | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.185 | Neonatal Moderate Respiratory complications with LOS Procedures | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.186 | Neonatal Moderate Respiratory complications with LOS Procedures | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.187 | Neonatal Moderate Respiratory complications with LOS Procedures | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.188 | Single Liveborn Newborn Vaginal | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.189 | Single Liveborn Newborn Vaginal | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.190 | Single Liveborn Newborn Vaginal | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.191 | Single Liveborn Newborn Cesarean | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.192 | Single Liveborn Newborn Cesarean | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.193 | Single Liveborn Newborn Cesarean | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.194 | Birth Weight | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.195 | Neonatal Moderate Infection with LOS | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.196 | Neonatal Moderate Infection with LOS | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.197 | Neonatal Moderate Infection with LOS | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.203 | Neonatal Intensive Care Unit | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.204 | Intensive Care Unit | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.205 | Neonatal Intensive Care Unit | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.206 | Intensive Care Unit | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.208 | Blood Transfusion Administration | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.209 | Blood Transfusion Administration | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.213 | Blood Transfusion | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.214 | Acute Respiratory Distress Syndrome | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.217 | Amniotic Fluid Embolism | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.219 | Aortic Aneurysm | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.220 | Aortic Aneurysm | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.221 | Cardiac Arrest Ventricular Fibrillation | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.223 | Disseminated Intravascular Coagulation | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.225 | Eclampsia | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.227 | Heart Failure Cardiac Arrest Related to Procedure or Surgery | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.228 | Heart Failure Cardiac Arrest Related to Procedure or Surgery | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.229 | Puerperal Cerebrovascular Disorder | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.231 | Pulmonary Edema | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.233 | Acute Heart Failure | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.235 | Severe Anesthesia Complications | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.237 | Sepsis | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.239 | Shock | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.24 | Blood Transfusion Administration | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.241 | Sickle Cell Disease with Crisis | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.243 | Air and Thrombotic Embolism | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.245 | Blood Transfusion | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.246 | Blood Transfusion | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.247 | Conversion of Cardiac Rhythm | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.248 | Conversion of Cardiac Rhythm | active | 2021-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.249 | Hysterectomy | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.250 | Hysterectomy | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.251 | Tracheostomy | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.252 | Tracheostomy | active | 2021-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.253 | Ventilation | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.254 | Ventilation | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.255 | Severe Maternal Morbidity Diagnoses | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.256 | Severe Maternal Morbidity Procedures | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.267 | Gestational Diabetes | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.269 | Gestational Diabetes | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.271 | HIV in Pregnancy Childbirth and Puerperium | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.272 | HIV in Pregnancy Childbirth and Puerperium | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.274 | Preexisting Diabetes | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.275 | Preexisting Diabetes | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.277 | Previous Cesarean | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.278 | Previous Cesarean | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.279 | Pulmonary Hypertension | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.281 | Pulmonary Hypertension | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.282 | Multiple Pregnancy | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.284 | Multiple Pregnancy | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.286 | Bleeding Disorder | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.287 | Bleeding Disorder | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.289 | Morbid or Severe Obesity | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.290 | Morbid or Severe Obesity | active | 2022-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.291 | Economic Housing Instability | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.292 | Economic Housing Instability | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.295 | Thyrotoxicosis | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.296 | Thyrotoxicosis | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.297 | Preterm Birth | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.299 | Preterm Birth | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.300 | Placenta Accreta | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.302 | Placenta Accreta | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.303 | Placental Abruption | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.305 | Placental Abruption | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.306 | Neuromuscular Disease | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.308 | Neuromuscular Disease | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.309 | Autoimmune Disease | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.311 | Autoimmune Disease | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.312 | Mental Health Disorder | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.314 | Mental Health Disorder | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.315 | Bariatric Surgery | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.317 | Bariatric Surgery | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.318 | Substance Abuse | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.320 | Substance Abuse | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.321 | Anemia | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.323 | Anemia | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.324 | Severe Preeclampsia | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.326 | Mild or Moderate Preeclampsia | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.327 | Severe Preeclampsia | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.329 | Mild or Moderate Preeclampsia | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.330 | Hypertension | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.332 | Hypertension | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.333 | Renal Disease | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.335 | Renal Disease | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.336 | Gastrointestinal Disease | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.338 | Gastrointestinal Disease | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.339 | Cardiac Disease | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.341 | Cardiac Disease | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.344 | Aortic Aneurysm | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.357 | Conversion of Cardiac Rhythm | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.358 | Hysterectomy | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.359 | Tracheostomy | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.360 | Ventilation | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.361 | Venous Thromboembolism in Pregnancy | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.363 | Venous Thromboembolism in Pregnancy | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.364 | Long Term Anticoagulant Use | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.366 | Long Term Anticoagulant Use | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.368 | Preadmission Observation Undelivered Mother | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.369 | ED Visit and OB Triage | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.370 | Present on Admission is No or Unable To Determine | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.371 | COVID 19 Confirmed | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.372 | COVID 19 Confirmed | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.373 | COVID 19 Confirmed | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.374 | Respiratory Conditions Related to COVID 19 | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.375 | Respiratory Conditions Related to COVID 19 | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.376 | Respiratory Conditions Related to COVID 19 | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.377 | Respiratory Support Procedures | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.378 | Respiratory Support Procedures | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.379 | Respiratory Support Procedures Related to COVID 19 | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.387 | Placenta Increta or Percreta | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.388 | Placenta Increta or Percreta | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1029.67 | Other Health Care Facility | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.10 | Non essential Hypertension SNOMEDCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.102 | Suicide Attempt | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.11 | Cirrhosis ICD9CM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.12 | Cirrhosis ICD10CM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.13 | Cirrhosis SNOMEDCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.14 | Cirrhosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.151 | Polycystic Ovary Syndrome | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.16 | Low Intensity Statin Therapy/Branded | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.17 | Moderate Intensity Statin Therapy/Branded | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.18 | High Intensity Statin Therapy/Branded | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.21 | ALT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.230 | Gestational Diabetes SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.231 | Gestational Diabetes ICD10CM | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.233 | All Results of High Risk HPV Test | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.234 | High Risk HPV Positive Results | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.248 | Suicide Attempt SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.26 | Nonopioid pain medications | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.263 | High Risk Positive HPV Results Without HPV16 or HPV18 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.264 | CDS Pregnancy | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.265 | CDS Pregnancy Intensional | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.266 | Rhabdomyolysis Intensional | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.267 | CDS Rhabdomyolysis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.268 | HPV Negative Results | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.27 | Non pharmacologic treatments for chronic pain ICD10PCS | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.28 | Urine drug screen for pain management | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.29 | Non pharmacologic treatments for chronic pain SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.292 | Non pharmacologic treatments for chronic pain NCI | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.296 | SCT Findings 202209 | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.298 | Cervical Cytology Test | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.299 | HPV 16 Tests | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.300 | HPV 18 Tests | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.302 | Test Cervical Excision Procedures | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.303 | Statin Combinations | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.305 | Counseling for Physical Activity CPT | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.306 | Counseling for Physical Activity ICD10CM | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.307 | Counseling for Physical Activity CDS | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.308 | Cardiovascular disease 10Y risk | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.309 | SCT Findings 202309 | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.311 | SCT Procedures 202209 | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.312 | SCT Procedures 202309 | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.313 | Statin Allergen Grouping | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.319 | Steward Transfer Test | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.320 | Opioids ATCPROD N02A | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.322 | Test 123 | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.34 | Opioid pain medications | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.36 | Non pharmacologic treatments for chronic pain | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.40 | Suicide attempt | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.42 | Naloxone and Nalmefene medications | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.43 | Benzodiazepine medications | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.44 | Stool softeners and laxatives | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.47 | Anxiety | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.48 | Anxiety | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.50 | Sleep disordered breathing | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.51 | Sleep disordered breathing | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.52 | Anxiety | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.53 | Sleep disordered breathing | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.54 | Adjuvant pain medications | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.55 | Risk assessments relevant to pain management | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.6 | Non essential Hypertension ICD9CM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.7 | Non essential Hypertension ICD10CM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.79 | Behavioral Counseling for Nutrition and Activity Referral | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.85 | Impaired Glucose Tolerance | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.87 | Fasting Plasma Glucose | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.88 | Waist Circumference | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.9 | Hypertension | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.90 | Gestational Diabetes | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.92 | First Degree Family Member | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.94 | Glucose Tolerance Test Results | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.96 | Dependence on dialysis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1032.99 | Gestational Diabetes | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.460 | Cluster Headache (ICD10CM) | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.461 | Cluster Headache (ICD9CM) | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.464 | Cluster Headache | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.467 | Medication Therapy for Cluster Headache (RXNORM) | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.555 | Patient Declines Treatment for Cluster Headache (SNOMEDCT) | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.558 | Acute Cluster Headache Medication (RXNORM) | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.559 | Long Term Preventive Medication for Cluster Headache | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.561 | Oral Steroid for Cluster Headache | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.569 | Migraine Preventive Medication | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.601 | Acute Migraine Attack Medication | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.605 | NSAID OTC Migraine Attack Medication | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.606 | NSAID Prescribable Migraine Attack Medication | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.640 | Neurologic Disorders | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.641 | Neuromodulation for migraine | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.642 | No pain with headache | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.643 | Antiplatelets | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.644 | Anticoagulants | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.645 | Statin Medications | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.646 | Anxiety Disorders (ICD10 and SNOMED) | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.648 | Depression Diagnosis (ICD10 and SNOMED) | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.649 | Psychosis (ICD10 and SNOMED) | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.650 | Cluster Headache (SNOMED) | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.651 | Galcanezumab (RxNorm) | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.652 | Lithium (RxNorm) | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.653 | Verapamil | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.654 | Long term preventive medications for cluster headache | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.655 | Short term preventive medication for cluster headache | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.656 | Zolmitriptan | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.657 | Sumatriptan | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.658 | Dihydroergotamine | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.659 | Acute cluster headache medication | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.660 | Acute cluster headache treatment | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.661 | Short term preventive treatment for cluster headache | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.662 | Long term preventive treatment for cluster headache | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.663 | Migraine diagnosis (ICD) | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1034.664 | Prescribable NSAIDs and Acute Migraine Attack Medication | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.103 | Abnormal Presentation | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.105 | Abnormal Presentation | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.114 | Hematocrit Lab Test | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.117 | Potassium Lab Test | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.119 | Sodium Lab Test | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.127 | Platelet Count Lab Test | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.129 | White Blood Cells Count Lab Test | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.130 | Respiratory Rate | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.134 | Glucose Lab Test | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.139 | Bicarbonate Lab Test | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.15 | Intravenous Thrombolytic tPA Therapy | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.151 | Oxygen Saturation by Pulse Oximetry | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.152 | Body Temperature | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.159 | Body Weight | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.16 | Intraarterial Thrombolytic tPA Therapy | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.163 | Systolic Blood Pressure | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.171 | Abnormal Presentation | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.173 | Delivery of Singleton | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.21 | Intravenous or Intraarterial Thrombolytic tPA Therapy | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.26 | Estimated Gestational Age at Delivery | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.27 | Cornual Ectopic Pregnancy | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.38 | General Or Neuraxial Anesthesia | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.39 | Low Dose Unfractionated Heparin for VTE Prophylaxis | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.41 | Glycoprotein IIb IIIa Inhibitors | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.55 | Oxytocin | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.56 | Dinoprostone | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.58 | Delivery Procedures | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.59 | Delivery Procedures | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.66 | PCI | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.67 | PCI | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.68 | Endotracheal Intubation | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.69 | Endotracheal Intubation | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.98 | Delivery of Singleton | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1045.99 | Delivery of Singleton | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.225 | Opioid Medication Assisted Treatment (MAT) SNOMED | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.241 | Schedule II, III and IV Opioid Medications | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.242 | Opioid Use Disorder | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.243 | Opioid Use Disorder | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.265 | Inpatient, Emergency, and Observation Locations | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.269 | Medications for Opioid Use Disorder (MOUD) | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.274 | NHSN Inpatient Encounter Class Codes | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.277 | Emergency Department Location | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.278 | Emergency Department Treatment Location | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.279 | Triage | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.283 | Emergency Department Location | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.284 | Emergency Department Location | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.285 | Mental Health Diagnosis without Substance Use Disorders | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.286 | Decision to Transfer | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1046.35 | Healthcare Agent or Proxy Choices | active | 2022-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.10 | Breastfeeding | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.100 | Familial Hypercholesterolemia | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.102 | Rhabdomyolysis | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.107 | Low Intensity Statin Therapy | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.12 | Liver Disease | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.13 | Rhabdomyolysis | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.19 | Atherosclerosis and Peripheral Arterial Disease | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.20 | Atherosclerosis and Peripheral Arterial Disease | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.21 | Atherosclerosis and Peripheral Arterial Disease | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.22 | Liver Disease ICD9 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.37 | Stable and Unstable Angina | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.39 | Cerebrovascular Disease Stroke or TIA | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.41 | Ischemic Heart Disease or Related Diagnoses | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.42 | Liver Disease | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.43 | Liver Disease | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.44 | Cerebrovascular Disease Stroke or TIA | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.46 | Ischemic Heart Disease or Related Diagnoses | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.47 | Stable and Unstable Angina | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.501 | Overweight or Obese | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.502 | Overweight or Obese | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.512 | Elevated Blood Pressure Reading | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.513 | Elevated Blood Pressure Reading | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.514 | Finding of Elevated Blood Pressure or Hypertension | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.515 | Bariatric Procedures | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.517 | Age related macular degeneration intermediate dry | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.518 | Ophthalmologist visit | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.519 | Posterior vitreous detachment (PVD) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.521 | Ophthalmoscopic exam | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.523 | Opthalmoscopic exams with Scleral Depression | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.525 | Referral (ophthalmology) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.526 | Retina Ultrasound | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.527 | Retina visualization inadequate | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.528 | Refusal or Noncompliance with treatment | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.529 | Vitreous hemorrhage | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.530 | Vitreous hemorrhage | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.536 | Macula examination | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.539 | Fluorescein angiography | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.541 | Optical coherence tomography (OCT) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.542 | Intravitreal injection | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.543 | Bevacizumab injection | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.544 | Ranibizumab injection | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.545 | Aflibercept injection | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.552 | Uveitis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.553 | Uveitis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.554 | Post Cataract Surgery Cystoid Macular Edema AND Idiopathic Macular Edema | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.555 | Macular edema | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.556 | Corticosteroids for Injection | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.557 | Corticosteroids for Injection | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.560 | Tonometry | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.561 | Intraocular pressure | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.571 | Retinal Vein Occlusion Related Macular Edema | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.576 | Vitreous hemorrhage | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.580 | Intravitreal and Periocular Injections | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.581 | Intravitreal and Periocular Injections | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.582 | Corticosteroids for Injection | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.583 | Endophthalmitis in the Right Eye | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.584 | Endophthalmitis in the Left Eye | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.585 | Panophthalmitis in the Right Eye | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.586 | Panophthalmitis in the Left Eye | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.587 | Lost to follow up | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.588 | Uveitis | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.610 | Scleral depressed exam | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.611 | 3 Mirror Goldmann exam | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.612 | Scleral depressed exam | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.615 | Physical Disability | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.616 | Financial difficulty | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.617 | Vitreous exam findings | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.619 | Scleral depressed exam | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.629 | Post operative follow up | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.67 | Breastfeeding | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.69 | Stable and Unstable Angina | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.70 | Ischemic Heart Disease or Related Diagnoses | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.71 | Cerebrovascular Disease Stroke or TIA | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.73 | Breastfeeding | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.85 | Familial Hypercholesterolemia | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.89 | Rhabdomyolysis | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.9 | Outpatient Encounters for Preventive Care | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.91 | Familial Hypercholesterolemia | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.93 | Hypercholesterolemia ICD 9 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.97 | High Intensity Statin Therapy | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.98 | Moderate Intensity Statin Therapy | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1056.50 | HIV Lab Tests | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1056.51 | Indicators of Human Immunodeficiency Virus (HIV) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1056.52 | Indicators of Human Immunodeficiency Virus (HIV) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1056.53 | Indicators of Human Immunodeficiency Virus (HIV) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1056.71 | Human Immunodeficiency Virus (HIV) Viral Load | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.10 | ARBs (Angiotensin Receptor Blockers) | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1000 | OIA_V2_GLP1s_RxNorms | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1001 | OIA_V2_PCSK9s_RxNorms | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1002 | OIA_RFs_Secondary_Prevention_ICD10 | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1003 | OIA_RFs_Secondary_Prevention_SNOMED | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1004 | OIA_RFs_Secondary_Prevention_CPT | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1005 | OIA_RFs_Secondary_Prevention_ICD_SM_CPT | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1006 | OIA_Asthma_COPD_Combo_Meds | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1007 | OIA_Asthma_COPD_Combo_Meds_SABA_SAMA | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1008 | OIA_Asthma_COPD_Combo_Meds_LABA_LAMA_ICS | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1009 | PAE_Patient_Conditions | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1012 | PAE Conditions Short | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1016 | OIA_TEST_VS | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1017 | Triptan Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1018 | NSAID Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1019 | Statin Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1021 | Penicillin Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1022 | Macrolide Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1023 | Quinolone Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1025 | Beta blocker Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1026 | ACE inhibitor Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1027 | ARB Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1028 | Sulfonylurea Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1030 | DPP4i Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1031 | GLP1RA Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1032 | Beta blocker allergy intolerance | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1033 | SGLT2i Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1034 | MRA Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1036 | Meglitinide Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1037 | Alpha glucosidase inhibitor Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1038 | TZD Allergy NDFRT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1041 | Hemoglobin | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1042 | Hematocrit | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1043 | Anemia for Erythropoesis Simulating Agents I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1044 | Anemia for Erythropoesis Simulating Agents SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1045 | Anemia for Erythropoesis Simulating Agents | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1046 | AZT Meds | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1047 | Ferritin | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1048 | Knee pain I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1049 | Knee pain SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.105 | conditions_heartfailure | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1050 | Knee pain | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1051 | Knee decreased ROM SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1052 | Knee effusion I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1054 | Knee effusion | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1055 | Knee crepitus SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1056 | OIA_Antiemetics | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1057 | OIA_PDE5is | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1058 | OIA_Vitamins | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1059 | OIA_Plavix | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1061 | OIA_Oral_Contraceptives | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1063 | OIA_Topical_Steroids | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1064 | OIA_Cough_Cold_Meds | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1065 | Antiperspirant aluminum salts | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1066 | Antiperspirant anticholinergics | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1067 | Antieplieptic medications | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1068 | Antidepressant medications | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1069 | Urinary incontinence SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1070 | Urinary incontinence I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1071 | Urinary incontinence | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1073 | Hemifacial spasm SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1074 | Hemifacial spasm I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1075 | Hemifacial spasm | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1076 | Spasmodic dysphonia SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1077 | Physical therapy procedure SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1078 | Occupational therapy SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1079 | Hyperhidrosis SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1080 | Hyperhidrosis I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1081 | Hyperhidrosis | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1082 | Tic disorder I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1083 | Tic disorder SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1084 | Tic disorder | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1085 | Esophageal achalasia SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1086 | Esophageal achalasia I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1087 | Esophageal achalasia | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1088 | ET propanolol or primidone | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1089 | ET topiramate alprazolam or gabapentin | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.109 | CKD stage4above I10 | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1090 | Blephraospasm SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1091 | Blepharospasm I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1092 | Blepharospasm | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1093 | Strabismus SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1094 | Strabismus I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1095 | Strabismus | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1096 | Overactive bladder SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1097 | Overactive bladder I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1098 | Overactive bladder | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1099 | Movement disorders SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.110 | CKD stage4above SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1100 | Movement disorders I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1101 | Movement disorders | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1102 | Lateral epicondylitis SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1103 | Lateral epicondyltisis I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1104 | Lateral epicondylitis | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1105 | Plantar fasciitis SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1106 | Plantar fasciitis I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1107 | Plantar fasciitits | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1108 | Cardiac CT SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1109 | Cardiac CT CPT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.111 | CKD stage4above | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1111 | Cardiac CT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1112 | Cardiac MRI SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1113 | Cardiac MRI CPT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1114 | Cardiac MRI | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1115 | CT Angiography of Coronary Artery SCT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1116 | CT Angiography of Coronary Artery CPT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.1117 | CT Angiography of Coronary Artery | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.112 | Chronic kidney disease I10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.113 | Chronic kidney disease SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.116 | DigTx Cognitive Impairment I10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.117 | DigTx Cognitive Impairment SCT | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.120 | Diabetic ketoacidosis SCT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.121 | Diabetic ketoacidosis | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.124 | DKD | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.146 | Long Acting Muscarinic Antagonists (LAMA) | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.147 | HFrEF SCT | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.148 | HFrEF I10 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.15 | Kidney tansplant | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.150 | History of Hypoglycemia I10 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.151 | History of Hypoglycemia SCD | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.153 | Hyperlipidemia | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.159 | conditions_COPD I10 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.168 | medications_COPD | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.17 | Atrial fibrillation | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.173 | Asthma I10 | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.175 | Asthma | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.184 | DigTx Virtual Reality Contraindications Visual Impairment | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.186 | Beta blockers GDMT for heart failure | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.188 | medications_heart failure | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.189 | SGLT2i | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.193 | relatedconditions_COPD I10 | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.197 | Blood (Serum and Plasma) Potassium | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.202 | Serum Creatinine | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.21 | Thoracic aorta disease | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.214 | Type 1 Diabetes Mellitus SCT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.224 | Systolic Heart Failure I10 | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.226 | Systolic Heart Failure | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.238 | MRA mineralocorticoid receptor antagonists | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.244 | MRA Mineralocorticoid Receptor Antagonist Allergy | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.252 | relatedconditions_Heart failure I10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.260 | UACR SCT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.263 | Pregnancy I10 | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.281 | Statins Allergy SCT | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.282 | Statin Allergy Intolerance | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.292 | Metabolic syndrome I10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.3 | Delivery I10 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.314 | relatedconditions_hyperlipidemia I10 | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.322 | Angina I10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.325 | Tachyarrhythmia I10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.337 | Migraine I10 | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.34 | Blood pressure panel | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.35 | Systolic Blood Pressure | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.350 | Coronary artery disease I10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.367 | Trandolapril | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.369 | Candesartan | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.37 | relatedconditions_hypertension SCT | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.377 | Valsartan | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.38 | relatedconditions_hypertension I10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.397 | eGFR | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.409 | Hypertension I10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.412 | Statin Moderate Intensity | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.415 | LDL Cholesterol | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.43 | Urinalysis | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.434 | Insulin | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.437 | TZD Thiazolidinediones | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.438 | medications_T2DM | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.439 | relatedconditions_T2DM I10 | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.440 | relatedconditions_T2DM SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.442 | Blood Glucose | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.45 | ACE inhibitor allergy RXNORM | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.455 | Metabolic acidosis I10 | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.459 | Liver cancer | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.47 | ACE inhibitor allergy SCT | active | 2022-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.473 | Tetanus toxoid, diphtheria (Td) Vaccine | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.474 | Allergy to Tdap Vaccine | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.475 | Allergy to Td Vaccine | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.476 | Allergy To Vaccine Component | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.478 | Allergy to HPV Vaccine | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.481 | medications_hypertension | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.492 | Inhaled Corticosteroids Allergy | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.498 | Metformin AllergyIntolerance SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.5 | Delivery - Procedure | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.508 | Abdominal aortic imaging CPT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.516 | Allergy to Herpes Zoster Vaccine SCT | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.517 | Hemoglobin A1c | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.518 | Drug hypersensitivity I10 | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.519 | Drug hypersensitivity SCT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.520 | Drug hypersensitivity | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.521 | Diabetic Kidney Disease I10 | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.523 | Diabetic kidney disease | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.524 | Chronic Hepatitis SCT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.525 | Chronic Hepatitis | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.527 | OCS_Prednisone | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.528 | High Dose Non Combo ICS Adult | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.529 | Medium Dose Non Combo Asthma ICS Adult | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.530 | Low Dose Non Combo ICS | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.531 | Anti IgE Medications | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.532 | IL5 Antagonists | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.533 | Mast cell stabilizers for asthma | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.534 | Vasospastic disease I10 | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.535 | Vasospastic disease SCT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.536 | Vasospastic disease | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.537 | Hemiplegic and basilar migraine I10 | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.538 | Hemiplegic and basilar migraine SCT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.539 | Hemiplegic and basilar migraine | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.540 | Peptic ulcer disease I10 | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.541 | Peptic ulcer disease SCT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.542 | Peptic ulcer disease | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.544 | Bleeding disorder I10 | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.545 | Bleeding disorder SCT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.548 | Electronic cigarettes or Vaping | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.549 | Bleeding disorder | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.551 | Heart Rate | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.552 | Triptans | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.553 | CGRP receptor antagonists | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.554 | Ditans | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.555 | Ergots | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.556 | Migraine specific NSAIDs | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.557 | OTC migraine analgesics | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.558 | Butalbital analgesics | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.559 | medications_migraine_acute | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.560 | relatedconditions_migraine I10 | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.561 | conditions_migraine | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.562 | relatedconditions_migraine SCT | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.563 | relatedconditions_migraine | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.564 | Triptan Allergy Intolerance SCT | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.565 | Triptan Allergy Intolerance | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.566 | Ischemic bowel disease SCT | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.567 | Ischemic bowel disease I10 | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.568 | Ischemic bowel disease | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.569 | Allergen Immunotherapy | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.570 | Allergy to house dust mites SCT | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.571 | Allergy to house dust mites I10 | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.572 | Allergy to house dust mites | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.573 | conditions_hyperlipidemia I10 | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.574 | conditions_hyperlipidemia SCT | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.575 | conditions_hyperlipidemia | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.578 | PIM_Schedule V | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.580 | PIM_Acarbose | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.581 | PIM_Avandamet | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.582 | PIM_Dulaglutide | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.583 | PIM_Glimepiride | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.585 | PIM_Glucophage | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.587 | PIM_Glucovance | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.588 | Glyburide PIM | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.590 | Alpha glucosidase inhibitors | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.592 | Azotemia | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.594 | Intolerance to ARB SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.595 | ICS Low | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.596 | ICS Medium | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.597 | ICS High | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.598 | Low Dose ICS Formoterol | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.599 | PIM_Vitamin B12 Level_LOINC_CPT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.600 | PIM_Vitamin B12 Level_LOINC | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.601 | PIM_Vitamin B12 Level_CPT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.604 | PIM_Glyburide | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.605 | PIM_Pioglitazone | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.606 | PIM_Semaglutide | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.607 | PIM_Linagliptin | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.609 | Macrolide_Azithromycin | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.61 | Secondary antihypertensives | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.610 | Long Acting Beta Agonists (LABA) Non_Formoterol | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.611 | relatedconditions_Asthma I10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.612 | Wolff Parkinson White SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.613 | Wolff Parkinson White I10 | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.614 | Wolff Parkinson White | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.615 | medications_Asthma | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.617 | HighICS_LABA_NonFormoterol | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.618 | relatedconditions_Asthma SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.619 | ICS_LABA_LAMA | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.620 | Low Dose ICS_LABA_Non Formoterol | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.621 | Medium ICS_LABA Non Formoterol | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.622 | relatedconditions_Asthma | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.623 | LAMA Allergy SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.624 | LABA Allergy SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.625 | BetaBlock NonCS Secondary Allergy SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.626 | Eplerenone Allergy SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.627 | Spironolactone Allergy SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.628 | SGLT2 Inhibitors Allergy SCT | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.629 | PIM_Refill_Request_Antilipemics_LFTs | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.630 | Angiotensin Receptor Neprilysin Inhibitor(ARNI) Allergy SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.631 | Pneumococcal Vaccine Allergy SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.632 | Meglitinides Allergy SCT | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.633 | DPP4i Allergy SCT | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.635 | Alpha_glucosidase inhibitors allergy SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.636 | Glucagon_Like Peptide 1 Receptor Agonist (GLP1RA) Allergy SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.637 | Insulins Allergy SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.638 | TZD Allergy SCT | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.639 | T2DM_Medications Allergy SCT | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.642 | T2DM_Medications Allergy RXNORM | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.643 | T2DM_Medications Allergy SNOMED | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.646 | T2DM_Medication Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.647 | Statins Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.649 | ACE Inhibitors Allergy Intolerance | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.650 | ARB Allergy Intolerance | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.652 | Long Acting Muscarinic Antagonists (LAMA) Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.653 | Long Acting Beta Agonists (LABA) Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.654 | BetaBlocker NonCS Secondary Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.656 | MRA Allergy Intolerance | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.657 | Eplerenone Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.658 | Spironolactone Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.659 | SGLT2i Allergy Intolerance | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.660 | Angiotensin Receptor Neprilysin Inhibitor(ARNI) Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.661 | Tetanus, Diphtheria, Pertusis (Tdap) Vaccine Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.665 | Tetanus toxoid, diphtheria (Td) Vaccine Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.666 | Human Papillomavirus (HPV) vaccine Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.667 | Herpes Zoster Vaccine Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.670 | Pneumococcal Vaccine Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.671 | Inhaled Corticosteroids(ICS) Allergy Intolerance | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.672 | LABA(Formoterol only) | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.674 | PIM_Tirzepatide | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.675 | GLP1RA Allergy Intolerance | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.676 | PIM_Diabetes_Testing_Supplies | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.677 | PIM_H2_Antagonists | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.678 | SGLT2i DM CKD | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.679 | SGLT2i DM ASCVD | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.680 | GLP1RA DM ASCVD | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.683 | OIA_Gout_Medications | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.684 | GlumetzaSubstitution | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.685 | MetforminER500mg | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.686 | PIM_Metformin | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.687 | PIM_Glipizide | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.689 | PIM_Glipizide_Glyburide_Glimepiride | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.690 | PIM_Insulin_Meglitinides | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.691 | PIM_Glyxambi | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.692 | PIM_Farxiga | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.693 | PIM_Invokana | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.694 | PIM_Jardiance | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.695 | PIM_Invokana_Jardiance | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.696 | Reclast | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.697 | LAMA_LABA Combination 1 Inhaler | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.698 | PIM_Contraceptives | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.699 | Selected Oral Antiemetics for Migraine | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.700 | PIM_DEXA_Scan | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.701 | PIM_DEXA_Scan_CPT_LOINC | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.702 | PIM_SSRIs | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.703 | PIM_SNRIs | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.704 | PIM_NRIs | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.705 | PIM_TCAs | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.706 | PIM_Citalopram | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.707 | PIM_Hydroxyzine | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.708 | PIM_Buspirone | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.709 | PIM_Bupropion | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.710 | PIM_Mirtazapine | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.711 | PIM_Trazodone | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.712 | PIM_IHD_CHD_CAD_ICD10 | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.713 | PIM_IHD_CHD_CAD_SNOMED | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.714 | PIM_Gabapentin | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1078.715 | PIM_Allergy_Nasal_Sprays | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.105 | Pathological N Stage pN1mi | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.106 | Pathological N Stage N2b | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.107 | Pathological N Stage N2a | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.108 | Pathological N Stage N2 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.109 | Pathological N Stage N1b | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.110 | Pathological N Stage N1a | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.112 | Pathological N Stage N0 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.114 | Pathological T Stage T4d | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.115 | Pathological T Stage T4c | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.116 | Pathological T Stage T4b | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.117 | Pathological T Stage T4a | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.118 | Pathological T Stage T4 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.120 | N Stage N2C | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.121 | T Stage T3c | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.122 | T Stage T3b | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.123 | T Stage T3a | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.124 | Pathological T Stage T3 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.125 | T Stage T2c | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.126 | T Stage T2b | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.127 | T Stage T2a | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.128 | Pathological T Stage T2 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.129 | Pathological T Stage T1c | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.132 | Pathological T Stage T1b | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.135 | Pathological T Stage T1a | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.136 | Pathological T Stage T1 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.137 | Pathological T Stage T1mic | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.139 | Pathological T Stage T0 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.142 | Cancer Stage III | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.143 | Cancer Stage IIIA | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.144 | Cancer Stage IIIB | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.145 | Cancer Stage IIIC | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.146 | Cancer Stage IV | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.147 | Cancer Stage IVA | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.148 | Cancer Stage IVB | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.149 | Cancer Stage IVC | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.151 | Cisplatin Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.153 | Vinorelbine Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.154 | Gemcitabine Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.155 | Docetaxel | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.156 | Pemetrexed Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.158 | Vinblastine Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.160 | ECOG Performance Status | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.161 | ECOG Performance Status | active | 2020-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.162 | ECOG Performance Status | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.164 | Karnofsky Performance Status | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.165 | Carboplatin Injectable | active | 2020-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.166 | Paclitaxel | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.168 | Doxorubicin Injectable | active | 2022-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.169 | Irinotecan Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.179 | Bevacizumab Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.181 | Methotrexate | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.184 | Breast Cancer | active | 2022-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.185 | Breast Cancer | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.191 | Cancer Stage II | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.192 | Cancer Stage IIA | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.193 | Cancer Stage IIB | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.194 | Pertuzumab Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.196 | Ixabepilone Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.197 | Goserelin | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.200 | Epirubicin Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.202 | Ramucirumab Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.204 | Letrozole | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.206 | Exemestane | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.209 | Fluorouracil | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.210 | Capecitabine Oral | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.222 | Aprepitant Oral | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.223 | Fosaprepitant Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.255 | Colorectal Cancer | active | 2021-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.256 | Colorectal Cancer | active | 2021-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.257 | Colorectal Cancer Chemotherapy | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.280 | Cancer Stage IA | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.281 | Cancer Stage IB | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.286 | Cancer Stage IIC | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.291 | Positive Result | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.292 | Negative Result | active | 2015-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.300 | Pathological N Stage N1C | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.332 | Daunorubicin Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.336 | Palonosetron Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.341 | External Beam Radiotherapy | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.349 | Metastatic Cancer | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.365 | Hospice Care Referral or Admission | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.439 | T Category | active | 2018-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.440 | N Category | active | 2018-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.441 | M Category | active | 2018-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.442 | TNM Stage Group | active | 2018-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.449 | Opioids | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.492 | Pharmacological interventions for depression | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.535 | Ovarian Cancer | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.536 | Ovarian Cancer | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.537 | Fallopian Tube Cancer | active | 2022-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.539 | Fallopian Tube Cancer | active | 2022-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.541 | Peritoneal Cancer | active | 2022-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.542 | Peritoneal Cancer | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.547 | Cancer Stage 1C | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.555 | Gender Female | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.556 | Gender Male | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.557 | Pathological N Stage N3a | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.558 | Pathological N Stage N3b | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.560 | Rolapitant Oral | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.599 | Obinutuzumab Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.600 | Ofatumumab Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.602 | Neurokinin 1 Receptor Antagonist | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.604 | Serotonin Receptor Antagonist | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.61 | Cetuximab Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.63 | Panitumumab Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.81 | Palonosetron Oral | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.88 | Lung Cancer | active | 2015-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.89 | Lung Cancer | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.95 | M Stage M0 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.97 | Pathological M Stage M1 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.98 | Pathological M Stage M1a | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.99 | Pathological M Stage M1b | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1121.5 | Most/Moderately Effective Contraceptive Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1121.6 | Most/Moderately Effective Contraceptive SNOMED Findings | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1125.1 | Schedule IV Benzodiazepines | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1125.7 | PROMIS Depression Assessment | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.11 | Sleep Apnea | active | 2018-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.12 | Toxic Megacolon in adults | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.13 | Septic Shock due to C. Diff | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.15 | Body Temperature | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.16 | Diarrhea Potentially due to CDI | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.17 | Abdominal Distension | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.18 | Vomiting potentially due to CDI | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.19 | Ileus due to infection | active | 2019-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.20 | Clostridium difficile infection | active | 2019-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.3 | Radiation Therapy Indicators from CPT | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.4 | Diagnostic Radiology Surrounding Face and Sinus | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.5 | Ear Surgery Affecting the Tympanic Membrane | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.6 | Allergic Rhinitis Immunotherapy | active | 2017-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.8 | Radiology to Head and Sinus | active | 2017-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.9 | Immunotherapy For Allergic Rhinitis | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1136.63 | Aortic Dissection or Ruptured Aortic Aneurysm | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1138.564 | CABG or PCI Procedure | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1138.565 | CABG or PCI Procedure | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1138.566 | CABG or PCI Procedure | active | 2018-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.1 | C2S Alcohol Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.11 | C2S Amphetamine Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.12 | C2S Cannabis Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.13 | C2S Cannabis Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.14 | C2S Cannabis Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.15 | C2S Cannabis Use DIsorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.16 | C2S Cocaine Use Disorder | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.17 | C2S Cocaine Use Disorder | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.18 | C2S Cocaine Use Disorder | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.19 | C2S Hallucinogens | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.2 | C2S Alcohol Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.20 | C2S Hallucinogens | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.21 | C2S Hallucinogens | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.22 | C2S Hallucinogens | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.23 | C2S HIV/AIDS Information Sensitivity | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.24 | C2S HIV/AIDS Information Sensitivity | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.25 | C2S HIV/AIDS Information Sensitivity | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.26 | C2S HIV/AIDS Information Sensitivity | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.27 | C2S HIV/AIDS Information Sensitivity | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.28 | C2S Inhalants | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.29 | C2S Inhalants | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.3 | C2S Alcohol Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.30 | C2S Inhalants | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.32 | C2S Mental Health Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.33 | C2S Mental Health Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.34 | C2S Mental Health Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.35 | C2S Mental Health Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.36 | C2S Mental Health Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.38 | C2S Opioids | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.39 | C2S Opioids | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.4 | C2S Alcohol Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.40 | C2S Opioids | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.42 | C2S Opioids | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.43 | C2S Other Psychoactive Substance
Use Disorder | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.44 | C2S Other Psychoactive Substance Use Disorder | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.45 | C2S Other Psychoactive Substance Use Disorder | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.46 | C2S Sedative Hypnotic, or anxiolytic related disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.47 | C2S Sedative Hypnotic, or anxiolytic related disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.48 | C2S Sedative Hypnotic, or anxiolytic related disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.49 | C2S Sexuality and reproductive health information sensitivity | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.5 | C2S Alcohol Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.51 | C2S Tobacco Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.52 | C2S Tobacco Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.53 | C2S Tobacco Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.54 | C2S Tobacco Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.55 | C2S Substance Use Information Sensitivity | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.56 | C2S Substance Use Information Sensitivity | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.58 | C2S Sensitive Categories | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.59 | C2S Opioids | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.6 | C2S Amphetamine Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.60 | C2S HIV/AIDS information Sensitivity | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.65 | Test C2S Alcohol Use Disorders | active | 2019-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.67 | Test C2S HIV/AIDS Information Sensitivity | active | 2019-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.7 | C2S Amphetamine Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.8 | C2S Amphetamine Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.9 | C2S Amphetamine Use Disorders | active | 2016-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.10 | Diphtheria (Tests for Corynebacterium diphtheriae by Culture and Identification Method) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1002 | Tuberculosis (Tests for Mycobacterium species by Culture and Identification Method) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1012 | S. Typhi Infection (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1016 | S. Paratyphi Infection (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1017 | S. Typhi Infection (Tests for S. Typhi by Culture and Identification Method) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1021 | Dark Urine (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1022 | Acute Onset [Qualifier Value] (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1024 | Acute Viral Hepatitis (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1027 | Sepsis [Septicemia] [Bacterial] [Unspecified Organism] (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1029 | Listeriosis [Listeria species] (Organism or Substance in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1030 | Meningitis [Unspecified Cause] (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1032 | Encephalitis [Unspecified Cause] (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1033 | Encephalitis [Unspecified Cause] (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1035 | Indeterminate or Equivocal Lab Result Value | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1037 | Smoking Status [Current Nonsmoker] (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1040 | Organisms (Tests by Unspecified Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1041 | Organisms (Tests by Culture and Identification) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1044 | Candida auris Infection (Tests for Candida auris by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1045 | Candida auris Infection (Tests for Candida auris Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1047 | Parkinson’s disease (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1048 | Parkinson’s disease (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1049 | Parkinsonism [Secondary] (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1050 | Parkinsonism [Secondary] (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1053 | Carbidopa Levodopa Combination (RXNORM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1065 | Consciousness [Decreased Level] (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1071 | Drug Use [IV Evidence] (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1072 | Miosis (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1076 | Opioid Overdose and Poisoning (Tests for Opioids [Quantitative]) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1077 | Poisoning or Overdose by Other Opioids (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1078 | Opioid Overdose and Poisoning (Naloxone) (RxNorm) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1083 | Rash [Pustular Vesicular] (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1084 | Salivary Gland Swelling [Unspecified Cause] (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1090 | Syphilis [Congenital] (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1091 | Cataracts [Nonspecific]/Congenital glaucoma [Unspecified Cause] (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1092 | Congenital heart disease (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1093 | Hearing impairment (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1095 | Microcephaly (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1096 | Developmental delay (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1099 | Congenital heart disease (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1100 | Hearing impairment (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1104 | Developmental delay (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1106 | Listeriosis (Tests for Listeria monocytogenes Nucleic Acid in Specimen from Normally Sterile Site) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.112 | Tetanus (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1123 | COVID_19 (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1124 | COVID_19 (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1130 | Tickborne Relapsing Fever (Tests for Borrelia hermsii/miyamotoi/parkerii/turicatae Nucleic Acid) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1131 | Lyme Disease (Tests for Borrelia afzelii/garinii IgG Antibody by Immunoassay | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1138 | Staphylococcus Aureus (Tests by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1139 | VISA/VRSA (Tests for Vancomycin Resistance Gene) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1142 | COVID_19 (Tests for SARS_CoV_2 Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1143 | COVID_19 (Organism or Substance in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1145 | Resistant Lab Result Value | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1148 | Tests for Vancomycin Susceptibility [Ord] | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1149 | Proteinuria (Tests for Total Protein in 24H Urine) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.115 | Mumps (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1150 | Thrombocytopenia (Tests for Platelets [#/volume] in Blood) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1156 | Staphylococcus aureus (Organism or Substance in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1158 | COVID_19 (Tests for SARS_CoV_2 Antigen) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1169 | Chikungunya Virus Disease (Tests for Chikungunya virus Nucleic Acid) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.117 | Mumps (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1180 | Chikungunya Virus Disease (Tests for Chikungunya Virus Antibody [Quantitative]) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1186 | Eastern Equine Encephalitis Virus Disease (Tests for Eastern Equine Encephalitis Virus Antibody [Qualitative]) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1188 | Western Equine Encephalitis Virus Disease (Tests for Western Equine Encephalitis Virus Antibody [Qualitative]) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1189 | California Serogroup Virus Diseases (Tests for California Serogroup Virus Antibody [Qualitative]) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1196 | Anthrax (Tests for Bacillus cereus by Culture and Identification Method) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1197 | Cervical Lymphadenitis (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1207 | CRE (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1210 | Enterobacter spp., E. coli, or Klebsiella spp. (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1212 | Enterobacteriaceae species [Carbapenem Resistant] (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1213 | NU_Enterobacteriaceae [Carbapenemase Producing] (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1214 | Carbapenemase resistance mechanism (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1215 | Tests for carbapenemase production | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1216 | Tests for carbapenemase resistance mechanism | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1217 | Tests for carbapenem susceptibility [Meropenem, imipenem, and doripenem] | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1218 | Tests for carbapenem susceptibility [Ertapenem] | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1219 | Tests for Enterobacter spp., E. coli, or Klebsiella spp. by Culture and Identification Method | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1220 | NU_Tests for Enterobacteriaceae species by Culture and Identification Method | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1224 | Therapeutic Response to Medication [Improved] | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1225 | Altered Mental Status (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1230 | Eschar (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1231 | Hypotension (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1233 | Localized Edema (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1234 | Localized Edema (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1237 | Tachycardia (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1238 | Tachycardia (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1239 | RCKMS Conditions (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.124 | Poliomyelitis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1240 | Maternal Condition Puerperium (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1242 | Non pestis Yersiniosis Infection (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1244 | Blastomycosis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1246 | Blastomycosis (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1249 | Blastomycosis (Tests for Blastomyces species by Culture and Identification Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1250 | Non pestis Yersiniosis Infection (Tests for Yersinia non pestis species Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1251 | Blastomycosis (Tests for Blastomyces species Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1252 | Blastomycosis (Tests for Blastomyces species Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1253 | Blastomycosis (Tests for Blastomyces species Antigen) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1265 | Fatigue (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1269 | Tuberculosis [Latent Infection] (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1274 | Histoplasmosis (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1275 | Histoplasmosis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1281 | Histoplasmosis (Tests for Histoplasma capsulatum H band or M band Antibody) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1294 | Abscess [Liver, Lung, Spleen, Prostate, or Brain] (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1295 | Seizure [Unspecified Cause] (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1298 | Abscess [Liver, Lung, Spleen, Prostate, or Brain] (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1299 | Seizure [Unspecified Cause] (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.130 | Influenza (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1304 | Mycobacteria_Infection_NonTB_ExPulm (Tests for Mycobacterium species in Extrapulmonary Specimen by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1305 | Mycobacteria_Infection_NonTB_ExPulm (Tests for Mycobacterium species Nucleic Acid in Extrapulmonary Specimen) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1306 | Body Temperature (Vital Sign) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1307 | Respiratory Rate (Vital Sign) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1309 | RSV (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1310 | RSV (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1312 | RSV (Tests for RSV Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1314 | Wheezing (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1317 | Bronchiolitis (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1325 | Tobacco Use and Exposure (Social History) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1330 | Tobacco Smoking Status [Current] (Social History) (LOINC) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1335 | Hospitalized [Inpatient] (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1336 | Creutzfeldt Jakob Disease (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1337 | Variant Creutzfeldt Jakob Disease (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1340 | Prion Disease (Tests for 14_3_3 Protein) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1341 | Prion Disease (Tests for Abnormal Prion Protein) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1349 | Cerebrospinal Fluid (Specimen Type) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.135 | Chronic Hepatitis B Virus Infection (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1350 | Endocervical (Specimen Type) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1351 | Tissue (Specimen Type) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1352 | Specimen from a Normally Sterile Site (Specimen Type)(SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1353 | Urethral Swab (Specimen Type) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1355 | Wound (Specimen Type) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1359 | Hepatitis E (Tests for hepatitis E virus IgM Antibody) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.136 | Invasive Pneumococcal Disease (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1360 | Hepatitis E (Tests for hepatitis E virus Antibody) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1363 | Epiglottitis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1364 | Organisms (Tests by Microscopic Observation by Gram Stain) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1369 | Serum (Specimen Type) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1378 | Tests for Mycobacterium species Nucleic Acid in Unspecified XXX Specimen | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1379 | Fish Poisoning (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1388 | Occupational Asthma (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1389 | Asthma (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1390 | Asthma (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1391 | Respiratory Condition, due to inhalation of chemicals, gases, fumes or vapors (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1393 | WRA (Occupational Exposure to Potential Asthma Inducing Risk Factor) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1400 | Colorado tick fever (Tests for Colorado Tick Fever Virus Antibody [Qualitative]) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1402 | Cancer [Malignant Neoplasms] (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1403 | Cancer [Benign or Borderline CNS Tumors] (Disorders) (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1404 | Cancer [Unspecified Skin Cancer, Benign Carcinoid Tumor, in situ Cervical Cancer, Intraepithelial Neoplasia, History Cancer, Complication of Cancer or Treatment] (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1405 | Cancer [Unspecified Skin Cancer, Benign Carcinoid Tumor, in situ Cervical Cancer, Intraepithelial Neoplasia, History Cancer, Complication of Cancer or Treatment] (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1407 | Cancer [Malignant Neoplasms] (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1409 | COVID_19 (Tests for SARS_CoV_2 Genomic Sequence) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1418 | Alpha gal syndrome (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1420 | Alpha gal syndrome (Tests for Alpha gal IgE Antibody [Quantitative]) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1422 | Ptosis of Eyelid [Unspecified Cause] (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1423 | Ptosis of Eyelid [Unspecified Cause] (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1424 | Constipation [Unspecified Cause] (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1426 | Intubation [Respiratory Tract] (Procedure) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1430 | Infant Botulism (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1446 | Viral Hemorrhagic Fever [Suspected] (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1447 | MRSA (Disorders (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1449 | Staphylococcus aureus infection (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.145 | Varicella (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1450 | Staphylococcus aureus infection (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1452 | MRSA (Tests by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1453 | MRSA (Tests for Methicillin Resistance Gene) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1454 | Staphylococcus aureus (Tests for Staph aureus Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1458 | Tests for Cefoxitin Susceptibility [OrdQn] | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1459 | Organisms (Tests in Blood by Culture and Identification) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1460 | Bacteria (Tests in Blood by Culture and Identification Method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1461 | Organisms (Tests in Specimen from Normally Sterile Site by Culture and Identification) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1462 | Staphylococcus aureus (Tests for Staph aureus Nucleic Acid in Blood) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1463 | VRE (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1464 | VRE (Organism or Substance in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1465 | VRE (Tests by Culture and Identification Method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1466 | Enterococcus species (Tests by Culture and Identification Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1468 | Enterococcus gallinarum or E. casseliflavus/E. flavescens (Organism or Substance in Lab Results) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1469 | Enterococcus faecium or E. faecalis (Organism or Substance in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1470 | Enterococcus species (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1471 | Amebiasis (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1473 | Amebiasis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1476 | Amebiasis (Tests for Entamoeba histolytica Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1482 | Norovirus (Tests for Norovirus Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1485 | Norovirus (Organism or Substance in Lab Results) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1487 | Clostridioides difficile infection (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1491 | C. diff infection (Tests for C diff Toxin Nucleic Acid) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1492 | C. diff infection (Tests for C diff Toxin Nucleic Acid in Stool) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1505 | Acanthamoeba Disease [Keratitis] (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1507 | Arsenic Exposure and Toxicity (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1509 | Arsenic Exposure and Toxicity (Tests for Arsenic [Quantitative] in Unspecified Specimen) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1513 | Urine (Specimen Type) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1514 | Mercury Exposure and Toxicity (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1515 | Cryptococcosis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1516 | Cryptococcosis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1520 | Cryptococcosis (Tests for Cryptococcus species by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1523 | Cryptococcosis (Tests for Cryptococcus species Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1524 | Cryptococcosis (Tests for Cryptococcus species Antigen) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1525 | Mercury Exposure and Toxicity (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1528 | Mercury Exposure and Toxicity (Tests for Mercury [Quantitative] in Unspecified Specimen) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1532 | Drug Overdose and Poisoning [Non opioid] [CNS Stimulant] (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1533 | Drug Overdose and Poisoning [Non opioid] [CNS Depressant] (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1534 | Drug Overdose and Poisoning [Non opioid] [Cannabinoid] (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1538 | Drug Overdose and Poisoning [Non opioid] [Other Drug] (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.154 | Hepatitis C Virus Infection (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1540 | Drug Overdose and Poisoning [Non opioid] [CNS Stimulant] (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1541 | Drug Overdose and Poisoning [Non opioid] [CNS Depressant] (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1542 | Drug Overdose and Poisoning [Non opioid] [Hallucinogen] (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1543 | Drug Overdose and Poisoning [Non opioid] [Cannabinoid] (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1544 | Drug Overdose and Poisoning [Non opioid] [Analgesic] (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1545 | Drug Overdose and Poisoning [Non opioid] [Other Drug] (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1546 | Drug Overdose and Poisoning [Non opioid] (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1551 | Meningitis (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1552 | Bacterial Meningitis (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1553 | Fungal Meningitis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1554 | Parasitic Meningitis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1555 | Bacterial Meningitis (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1559 | Photophobia (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1562 | Bacteria [Causing Meningitis] (Organism or Substance in Lab Results) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1563 | Fungi [Causing Meningitis and Encephalitis] (Organism or Substance in Lab Results) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1564 | Viruses [Causing Meningitis] (Organism or Substance in Lab Results) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1565 | Viruses [Causing Meningitis] (Tests for Nucleic Acid) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1566 | Viruses [Causing Meningitis] (Tests for Nucleic Acid in Cerebrospinal Fluid) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1567 | Bacteria [Causing Meningitis] (Tests by Culture and Identification Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1574 | Invasive Group B Streptococcus (Disorders) (ICD10CM)) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1577 | Group A Streptococcus (Tests for Group A Strep by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1578 | Group B Streptococcus (Tests for Group B Strep by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1580 | Animal Bite [Dog] (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1581 | Animal Bite [Mammal, Excluding Dogs] (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1582 | Animal Bite [Excluding Mammals] (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1584 | Animal Bite [Unspecified Animal] (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1585 | Animal Bite [Dog] (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1586 | Animal Bite [Mammal, Excluding Dogs] (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1587 | Animal Bite [Excluding Mammals] (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1588 | Cadmium Exposure and Toxicity (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1594 | HIV Infection (ARV Nucleoside Reverse Transcriptase Inhibitors [NRTIs]) (RXNORM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1595 | HIV Infection (ARV Non nucleoside Reverse Transcriptase Inhibitors [NNRTIs]) (RXNORM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1597 | HIV Infection (ARV Combination Treatment for HIV) (RXNORM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1598 | HIV Infection (ARV Protease Inhibitors [PIs]) (RXNORM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1600 | HIV Infection (ARV Integrase Strand Transfer Inhibitors [INSTIs]) (RXNORM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1604 | Vaccine Adverse Event (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1605 | Vaccine Adverse Event (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1606 | Vaccinia disease or adverse event  (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.161 | Vibriosis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1612 | Blepharitis [Unspecified Cause] (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1613 | Keratitis [Unspecified Cause] (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1614 | Keratitis [Unspecified Cause] (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1618 | Smallpox Vaccine (RXNORM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1620 | Anaphylaxis [Unspecified Cause] (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1626 | Thrombocytopenic Purpura [Unspecified Cause] (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1634 | Sofosbuvir Velpatasvir Combination (RXNORM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1640 | Typhus Fever (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1641 | Typhus Fever (Tests for Rickettsia Typhus Group IgG Antibody) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1642 | Typhus Fever (Tests for Rickettsia Typhus Group IgM Antibody) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1643 | Typhus Fever (Tests for Rickettsia Typhus Fever Group IgG Antibody [Quantitative] by Immunofluorescence) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1651 | Chagas Disease (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1654 | Chagas Disease (Tests for Trypanosoma cruzi Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1661 | Cervical lymphadenopathy [Unspecified Cause] (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1662 | Conjunctival injection (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1663 | Drying of lips (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1667 | Edema of hands or feet (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1676 | Tests for Acinetobacter baumannii Nucleic Acid | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1677 | Tests for Pseudomonas aeruginosa by Culture and Identification Method | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1678 | Tests for Pseudomonas aeruginosa Nucleic Acid | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1679 | Pseudomonas aeruginosa (Organism or Substance in Lab Results) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1687 | NU_Gunshot Wound (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1688 | NU_Gunshot Wound (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.169 | Gonorrhea [Neisseria gonorrhoeae] (Organism or Substance in Lab Results) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.170 | Chlamydia trachomatis Infection (Organism or Substance in Lab Results) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1700 | Encephalitis [Viral] (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1702 | Encephalitis [Parasitic] (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1712 | Bacteria [Causing Encephalitis] (Organism or Substance in Lab Results) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1714 | Parasites [Causing Encephalitis] (Organism or Substance in Lab Results) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1715 | Viruses [Causing Encephalitis] (Organism or Substance in Lab Results) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1716 | Drowning and Submersion (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1717 | Drowning and Submersion (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1718 | Motor Vehicle Injury (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1719 | Motor Vehicle Injury (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1720 | Enterovirus Infection [Non polio] (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1721 | Enterovirus Infection [Non polio] (Disorders) (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1722 | Enterovirus Infection [Non polio] (Organism or Substance in Lab Results) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1723 | Enterovirus Infection [Non polio] (Tests for Non Polio Enterovirus by Culture and Identification Method) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1725 | Enterovirus Infection [Non polio] (Tests for Non Polio Enterovirus Nucleic Acid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1726 | Enterovirus Infection [Non polio] (Tests for Non Polio Enterovirus in Cerebrospinal Fluid Nucleic Acid) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1735 | Clostridium perfringens Infection (Tests for C perfringens by Culture and Identification Method) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1739 | Head Injury (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1740 | Head Injury (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1742 | Brain Injury [Traumatic] (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1745 | Rotavirus Disease (Organism or Substance in Lab Results) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1746 | Rotavirus Disease (Tests for Rotavirus Nucleic Acid) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1748 | Chemical Pneumonitis (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1749 | Chemical Pneumonitis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1753 | Staphylococcal Enterotoxin B Poisoning (Tests for Staph aureus Enterotoxin B Nucleic Acid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1755 | Vomitus (Specimen Type) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1758 | Asbestosis (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.176 | West Nile Virus Infection (Disorders) (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1763 | Byssinosis (Disorders) (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1769 | Farmers Lung (Tests for Aspergillus fumigatus, Saccharopolyspora rectivirgula, or Thermoactinomyces vulgaris Antibody) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1772 | Farmers Lung (Aspergillus fumigatus, Saccharopolyspora rectivirgula, or Thermoactinomyces vulgaris Antibody in Lab Results) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1773 | CLABSI (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1775 | Ophthalmia neonatorum (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1778 | Genital herpes (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1779 | Genital herpes (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1781 | Herpes (Tests for Herpes simplex virus Nucleic Acid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1785 | Elevated liver enzyme (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1786 | Elevated liver enzyme (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1788 | Typhus Fever (Tests for Rickettsia Typhus Fever Group IgM Antibody [Quantitative] by Immunofluorescence) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1789 | Granuloma Inguinale (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1791 | Ulcer [Genital, Perineal, or Perianal Area] (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1792 | Ulcer [Genital, Perineal, or Perianal Area] (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1797 | Bronchial Wash (Specimen Type) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1800 | Nontuberculous Mycobacteria Infection, Pulmonary (Organism or Substance in Lab Results) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1803 | Bacteria (Tests in Sputum Specimen by Culture and Identification Method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.181 | Coccidioidomycosis (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1819 | Louseborne relapsing fever (Tests for Borrelia species) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1820 | Louseborne relapsing fever (Tests for Borrelia species in Blood) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1823 | Borrelia species (Organism or Substance in Lab Results) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1824 | Spirochetes (Organism or Substance in Lab Results) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1829 | Polyarthritis [Unspecified Cause] (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1835 | Rheumatoid nodules (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1842 | Ventilator associated event (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1844 | Leishmaniasis (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1846 | Leishmaniasis (Tests for Leishmania species Nucleic Acid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1847 | Leishmaniasis (Tests for Leishmania species Antibody) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1848 | Leishmania species (Tests by Microscopic Observation in Tissue) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.185 | Brucellosis (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1864 | Taeniasis (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1866 | Taeniasis (Organism or Substance in Lab Results) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.187 | Dengue Virus Infection (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1875 | Cysticercosis (Tests for Taenia solium Antibody) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1878 | Surgical Site Infection (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1880 | Tests for Enterobacter spp., E. coli, or Klebsiella spp. Nucleic Acid | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1881 | NU_Tests for Enterobacteriaceae species Nucleic Acid | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1882 | Carbapenemase production (Organism or Substance in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1892 | Toxoplasmosis (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1893 | Toxoplasmosis (Disorders) (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1895 | Toxoplasmosis (Organism or Substance in Lab Results) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1897 | Toxoplasmosis (Tests by Microscopic Observation) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1898 | Toxoplasmosis (Tests for Toxoplasma gondii Nucleic Acid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1901 | Toxoplasmosis (Tests for Toxoplasma gondii Antibody) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1902 | Orthopox (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1908 | Organisms (Tests by Electron Microscopic Observation) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1912 | Penicillin G [Aqueous Crystalline] [Injectable] (RXNORM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1913 | Penicillin G [Procaine] [Injectable] (RXNORM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1919 | Fungi [Causing Meningitis] (Tests by Culture and Identification Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1923 | Coronary artery aneurysm (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1924 | Coronary artery dilatation (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1925 | Ectatic coronary artery (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1926 | Left ventricular ejection fraction [Decreased Level] (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1927 | Coronary artery aneurysm (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1928 | Shock (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1929 | Shock (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1930 | Troponin [Elevated Level] (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1931 | Oral mucosa Inflammation (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1932 | Oral mucosa Inflammation (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1933 | C reactive protein (Tests by Any Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1934 | Lymphocytes [Concentration] (Tests by Any Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1935 | Strongyloidiasis (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1936 | Strongyloidiasis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1937 | Strongyloidiasis (Tests for Strongyloides Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1938 | Strongyloidiasis (Tests for Strongyloides stercoralis IgG Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1939 | Strongyloidiasis (Tests for Strongyloides stercoralis IgG Antibody in Blood) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1940 | Organisms (Tests by Microscopic Observation in Stool) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1941 | Strongyloidiasis (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1942 | Strongyloidiasis [Strongyloides stercoralis] (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1943 | Jamestown Canyon Virus Diseases (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1944 | Jamestown Canyon Virus Diseases (Tests for Jamestown Canyon Virus Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1945 | Jamestown Canyon Virus Diseases (Tests for Jamestown Canyon Virus IgM Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1946 | Jamestown Canyon Virus Diseases (Tests for Jamestown Canyon Virus Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1947 | Jamestown Canyon Virus Diseases (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1948 | Keystone Virus Diseases (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1949 | La Crosse Virus Diseases (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1950 | Snowshoe hare Virus Diseases (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1951 | Trivittatus Virus Diseases (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1952 | La Crosse Virus Diseases (Tests for La Crosse Virus Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1953 | Snowshoe hare Virus Diseases (Tests for Snowshoe hare Virus Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1954 | La Crosse Virus Diseases (Tests for La Crosse Virus IgM Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1955 | Snowshoe hare Virus Diseases (Tests for Snowshoe hare Virus IgM Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1956 | La Crosse Virus Diseases (Tests for La Crosse Virus Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1957 | Snowshoe hare Virus Diseases (Tests for Snowshoe hare Virus Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1958 | Trivittatus Virus Diseases (Tests for Trivittatus Virus Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1959 | Keystone Virus Diseases (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1960 | La Crosse Virus Diseases (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1961 | Snowshoe hare Virus Diseases (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1962 | Trivittatus Virus Diseases (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1963 | Hepatitis C Virus Infection, Perinatal (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1964 | Encephalomyelitis (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1965 | Encephalomyelitis (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1966 | Drug Overdose and Poisoning [Non opioid] [Muscle Relaxant] (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1967 | Drug Overdose and Poisoning [Non opioid] [Muscle Relaxant] (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1968 | Hepatitis D Virus Infection (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1969 | Hepatitis D Virus Infection (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1970 | NU_Hepatitis D Virus Infection (Tests for hepatitis D virus total or IgG Antibody) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1971 | Hepatitis D Virus Infection (Tests for hepatitis D virus IgM Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1972 | Hepatitis D Virus Infection (Tests for hepatitis D virus Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1973 | Hepatitis D Virus Infection (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1974 | Baylisascariasis (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1975 | Baylisascariasis (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1976 | Baylisascariasis (Tests for Baylisascaris species Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1978 | Larva Migrans (Neural, Ocular, or Visceral) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1979 | Larva Migrans (Neural, Ocular, or Visceral) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1980 | California Serogroup Virus Disease [Unspecified] (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1981 | California Serogroup Virus Disease [Unspecified] (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1982 | California Serogroup Virus Disease [Unspecified] (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1983 | California Serogroup Virus Disease [Unspecified] (Tests for California Serogroup Virus Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1984 | California Serogroup Virus Disease [Unspecified] (Tests for California Serogroup Virus IgM Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1985 | California Serogroup Virus Disease [Unspecified] (Tests for California Serogroup Virus Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1986 | Pregnant (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1987 | Flank Pain (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1988 | Bone Pain (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1989 | Abscess (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1990 | Abscess (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1991 | Focal Brain Lesions (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1992 | Pathologic Fractures [Unspecified Cause] (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1993 | Pathologic Fractures [Unspecified Cause] (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1994 | Granulomas (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1995 | Granulomas (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1996 | Skin Lesions (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1997 | Skin Lesions (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1998 | Angiostrongyliasis (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1999 | Lymphocytic Choriomeningitis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2000 | Lymphocytic Choriomeningitis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2001 | Lymphocytic Choriomeningitis (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2002 | Lymphocytic Choriomeningitis (Tests for LCMV Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2003 | Lymphocytic Choriomeningitis (Tests for LCMV Nucleic Acid in CSF or Blood) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2004 | Lymphocytic Choriomeningitis (Tests for LCMV Antibody) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2005 | Lymphocytic Choriomeningitis (Tests for LCMV Antibody in CSF or Serum) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2006 | Angiostrongyliasis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2007 | Eosinophilic meningitis (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2009 | Angiostrongyliasis (Tests for Angiostrongylus Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2010 | Eosinophils [Concentration] (Tests in CSF by Any Method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2011 | Eosinophils [Percentage] (Tests in CSF by Any Method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2012 | Mpox (Tests for mpox virus by Genomic Sequencing) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2013 | Mpox (Test Panels for mpox virus by Genomic Sequencing) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2017 | Rash [Macular, Papular, Vesicular, Pustular, or Centrifugal] (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2018 | Interpretation of an Observation (High) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2019 | Interpretation of an Observation (Low) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.202 | Trichinellosis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2020 | Lymphadenopathy [Acute] (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2023 | Tick Paralysis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2024 | Bacillary angiomatosis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2025 | Animal Bite or Scratch [Cat] (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2026 | Animal Bite or Scratch [Cat] (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2027 | Bartonellosis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2028 | Bartonellosis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2029 | Bartonellosis (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2030 | Bartonella henselae infection (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2031 | Bartonella quintana infection (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2032 | Bartonella bacilliformis infection (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2033 | Bartonella henselae infection (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2034 | Bartonella quintana infection (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2036 | Bartonella henselae (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2037 | Bartonella quintana (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2038 | Bartonella bacilliformis (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2039 | Bartonella quintana infection (Tests for Bartonella quintana Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.204 | Giardiasis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2040 | Bartonella quintana infection (Tests for Bartonella quintana IgM Antibody in a clinical specimen by any method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2041 | Bartonella quintana infection (Tests for Bartonella quintana IgG or Total Antibody in a clinical specimen by any method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2042 | Bartonella henselae infection (Tests for Bartonella henselae Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2043 | Bartonella henselae infection (Tests for Bartonella henselae IgM Antibody in a clinical specimen by any method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2044 | Bartonella henselae infection (Tests for Bartonella henselae IgG or Total Antibody in a clinical specimen by any method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2045 | Bartonella bacilliformis infection (Tests for Bartonella bacilliformis IgM Antibody in a clinical specimen by any method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2046 | Bartonella bacilliformis infection (Tests for Bartonella bacilliformis IgG or Total Antibody in a clinical specimen by any method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2047 | Bartonellosis (Tests for Bartonella spp. Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2048 | Bartonellosis (Tests for Bartonella spp. IgM Antibody in a clinical specimen by any method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2049 | Bartonella spp. (Tests by Microscopic Observation) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2050 | Bartonellosis (Tests for Bartonella spp. by Culture and Identification Method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2051 | Bartonellosis (Tests for Bartonella spp. IgG or Total Antibody in a clinical specimen by any method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2052 | Echinococcosis (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2053 | Echinococcosis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2054 | Cystic Echinococcosis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2055 | Cystic Echinococcosis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2056 | Alveolar Echinococcosis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2057 | Alveolar Echinococcosis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2058 | Echinococcosis (Tests for Echinococcus species Antibody) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2059 | Echinococcus species (Tests by Microscopic Observation) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2060 | Echinococcosis (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2061 | Genital Warts (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2062 | Pseudomembrane [Nose, pharynx, tonsils, or larynx] (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2063 | Genital Warts (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2064 | Diphyllobothriasis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2065 | Diphyllobothriasis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2066 | Diphyllobothriasis (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2067 | Nontuberculous Mycobacteria Infection, Pulmonary (Tests for Mycobacterium species Nucleic Acid in a Pulmonary Specimen) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2068 | Angiostrongyliasis (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2069 | Pelvic Inflammatory Disease (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2070 | Pelvic Inflammatory Disease [nonGC and nonCT] (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2071 | Pelvic Inflammatory Disease [Unspecified] (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2072 | Pelvic Inflammatory Disease (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2073 | Pelvic Inflammatory Disease [nonGC and nonCT] (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2074 | Pelvic Inflammatory Disease [Unspecified] (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2075 | Lower Abdominal Tenderness (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2076 | Lower Abdominal Tenderness (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2077 | Tenderness with motion of the cervix (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2078 | Adnexal Tenderness (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2079 | Uterine Tenderness (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2080 | Leukocytosis (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2081 | Leukocytosis (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2082 | Purulent material in the peritoneal cavity (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2083 | Pelvic Abscess (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2084 | Pelvic Abscess (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2085 | Leukocytes [Concentration] (Tests in Blood by Any Method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2087 | Nongonococcal Urethritis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2088 | Nongonococcal Urethritis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2089 | Urethritis (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2090 | Urethritis (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2091 | Urethral discharge (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2092 | Urethral discharge (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2093 | Dysuria (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2094 | Dysuria (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2095 | Gonorrhea (Tests for Neisseria gonorrhoeae Antigen) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2096 | Cyanobacteria and Cyanotoxin Poisoning (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2098 | Rhinitis (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2100 | Rhinitis (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2101 | Pleuritis (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2102 | Pleuritis (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2103 | Gamma Glutamyl Transferase in Serum (Tests for Gamma Glutamyl Transferase in Serum) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2105 | Methemoglobinemia (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2106 | Methemoglobinemia [Non Congenital] (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2107 | Methemoglobinemia (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2108 | Methemoglobinemia [Non Congenital] (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2109 | Methemoglobinemia (Tests for Methemoglobin in Blood [Quantitative]) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2110 | Anencephaly (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2111 | Anencephaly (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2112 | Fetal Anencephaly (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2113 | Fetal Anencephaly (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2114 | Cleft Lip Alone (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2115 | Cleft Lip Alone (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2116 | Fetal Cleft Lip (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2117 | Cleft Palate Alone (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2118 | Cleft Palate Alone (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2119 | Cleft Lip with Cleft Palate (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2120 | Cleft Lip with Cleft Palate (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2121 | Fetal Spina Bifida (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2122 | Spina Bifida (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2123 | Spina Bifida (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2124 | Down Syndrome (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2125 | Down Syndrome (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2126 | Fetal Down Syndrome (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2127 | Fetal Down Syndrome (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2128 | Down Syndrome (Tests for Trisomy 21 Chromosomal Anomaly) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2129 | Bacteremia (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2130 | Bacteremia (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2131 | Gastroschisis (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2132 | Gastroschisis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2133 | Fatal Familial Insomnia (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2134 | Fatal Familial Insomnia (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2135 | Gerstmann Straussler Scheinker Syndrome (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2136 | Gerstmann Straussler Scheinker Syndrome (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2137 | Prion Disease (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2138 | Prion Disease (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2139 | Prion Disease (Tests for Abnormal PRNP Gene Variant) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2140 | Phenylketonuria (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2141 | Phenylketonuria (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2142 | Linezolid (RXNORM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2143 | Tuberculosis (Pretomanid) (RXNORM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2144 | Tuberculosis (Bedaquiline) (RXNORM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2145 | Tuberculosis [Suspected] (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2146 | Congenital Rubella Syndrome [Suspected] (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2147 | Limb Reduction (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2148 | Limb Reduction (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2149 | NU_Influenza (Test Panels for Novel influenza A virus Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2150 | Congenital Hearing Loss (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2151 | Congenital Hearing Loss (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2152 | Naegleria fowleri PAM (Test Panels for Naegleria fowleri Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2153 | Primary Congenital Hypothyroidism (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2154 | Congenital Hypothyroidism [Unspecified] (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2155 | Congenital Hypothyroidism [Unspecified] (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2156 | Thyroid_stimulating hormone (TSH) [Quantitative] (Tests in serum or plasma by any method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2157 | Mpox (Combination Tests that include mpox virus Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2158 | Orthopox (Combination Tests that include Orthopoxvirus Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2159 | Mpox (Test Panels for mpox virus Nucleic Acid) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.216 | Pertussis (Tests for Bordetella pertussis Antibody [Excluding Pertussis Toxin Antibody]) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2160 | Orthopox (Test Panels for orthopoxvirus Nucleic Acid) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2161 | COVID_19 (Combination Tests that include SARS_CoV_2 Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2163 | Dengue Virus Infection [Suspected] (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2164 | Mumps [Suspected] (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2165 | Pertussis [Suspected] (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2166 | Hantavirus Infection (Test Panels for Hantavirus IgM IgG Total Antibody) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2167 | Organisms (Tests in Cerebrospinal Fluid by Culture and Identification Method) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2168 | Viruses [Causing Encephalitis] (Tests for Viruses Causing Encephalitis in Unspecified Specimen by Culture and Identification) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2169 | Viruses [Causing Encephalitis] (Tests for Viruses Causing Encephalitis in Cerebrospinal Fluid by Culture and Identification) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2170 | Bacteria [Causing Encephalitis] (Tests for Bacteria Causing Encephalitis in Unspecified Specimen by Culture and Identification) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2171 | Fungi [Causing Encephalitis] (Tests for Fungi Causing Encephalitis in Unspecified Specimen by Culture and Identification) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2172 | Viruses [Causing Encephalitis] (Tests for Viruses Causing Encephalitis Nucleic Acid in Unspecified Specimen) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2173 | Bacteria [Causing Encephalitis] (Tests for Bacteria Causing Encephalitis Nucleic Acid in Unspecified Specimen) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2174 | Fungi [Causing Encephalitis] (Tests for Fungi Causing Encephalitis Nucleic Acid in Unspecified Specimen) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2175 | Parasites [Causing Encephalitis] (Tests for Parasites Causing Encephalitis Nucleic Acid in Unspecified Specimen) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2176 | Viruses [Causing Encephalitis] (Tests for Viruses Causing Encephalitis Antigen in Unspecified Specimen) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2177 | Fungi [Causing Encephalitis] (Tests for Fungi Causing Encephalitis Antigen in Unspecified Specimen) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2178 | Bacteria [Causing Encephalitis] (Tests for Bacteria Causing Encephalitis Antigen in Unspecified Specimen) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2179 | Parasites [Causing Encephalitis] (Tests for Parasites Causing Encephalitis Antigen in Unspecified Specimen) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.218 | Listeriosis (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2180 | Parasites [Causing Encephalitis] (Tests for Parasites Causing Encephalitis in Unspecified Specimen by Microscopic Observation) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2181 | Organisms (Tests by Microscopic Observation in Cerebrospinal Fluid) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2183 | Bacteria [Causing Encephalitis] (Tests for Bacteria Causing Encephalitis Nucleic Acid in Cerebrospinal Fluid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2187 | Fungi [Causing Encephalitis] (Tests for Fungi Causing Encephalitis Nucleic Acid in Cerebrospinal Fluid) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2188 | Fungi [Causing Encephalitis] (Tests for Fungi Causing Encephalitis Antigen in Cerebrospinal Fluid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2189 | Parasites [Causing Encephalitis] (Tests for Parasites Causing Encephalitis in Cerebrospinal Fluid by Microscopic Observation) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2190 | Parasites [Causing Encephalitis] (Tests for Parasites Causing Encephalitis Nucleic Acid in Cerebrospinal Fluid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2192 | Viruses [Causing Encephalitis] (Tests for Viruses Causing Encephalitis Nucleic Acid in Cerebrospinal Fluid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2193 | Viruses [Causing Encephalitis] (Tests for Viruses Causing Encephalitis Antigen in Cerebrospinal Fluid) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2194 | Organisms (Combination Tests by Culture and Identification) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2195 | Organisms (Combination Tests for Nucleic Acid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2196 | Lung Tissue (Specimen Type) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2197 | Granuloma [Unspecified] (Finding by Microscopic Observation in Lab Results) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2198 | Anaplasmosis (Disorders) (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2199 | NU_Organisms (Tests in Specimen from Wound by Culture and Identification Method | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2200 | Organisms (Tests by Animal Inoculation Method) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2201 | Agricultural Chemical Poisoning [Unspecified Chemical] (Disorders) (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2202 | Abnormal Lung Sounds (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2203 | Abnormal Lung Sounds (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2204 | Anemia [Unspecified Cause] (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2205 | Anemia [Unspecified Cause] (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2206 | Creatinine (Tests in Serum by Any Method) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2207 | Microangiopathic Changes (Schistocytes, Burr cells, or Helmet cells) (Tests by Microscopic Observation in Unspecified Specimen) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2208 | Microangiopathic Changes (Schistocytes, Burr cells, or Helmet cells) (Tests by Microscopic Observation in Blood) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2209 | Microangiopathic Changes (Schistocytes, Burr cells, or Helmet cells) (Organism or Substance in Lab Results) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2210 | Histopathology or Cytopathology Tests by Microscopic Observation | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2211 | Ehrlichiosis (Tests for Ehrlichia species IgG Antibody) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2212 | Invasive Cronobacter Infection (Organism or Substance in Lab Results) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2213 | Invasive Cronobacter Infection (Tests for Cronobacter species by Culture and Identification Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2214 | Necrotizing Enterocolitis (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2215 | Necrotizing Enterocolitis (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2216 | Abscess [Brain] (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2217 | Abscess [Brain] (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2218 | Urinary Tract Infection (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2219 | Urinary Tract Infection (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2220 | Amniotic Fluid (Specimen Type) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2221 | Congenital Cytomegalovirus (Organism or Substance in Lab Results) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2222 | Organisms (Tests in Amniotic Fluid by Culture and Identification Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2223 | Congenital Cytomegalovirus (Tests for CMV Antigen by Immunohistochemical Stain) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2224 | Congenital Cytomegalovirus (Tests for CMV Antigen in Tissue by Immunohistochemical Stain) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2225 | Congenital Cytomegalovirus (Tests for CMV in Amniotic Fluid by Culture and Identification Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2226 | Congenital Cytomegalovirus (Tests for CMV Nucleic Acid in Amniotic Fluid by NAAT) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2227 | Congenital Cytomegalovirus (Tests for CMV Antigen in Whole Blood) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2228 | Congenital Cytomegalovirus (Tests for CMV Antigen) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2229 | Congenital Cytomegalovirus (Tests for CMV by Culture and Identification Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2230 | Congenital Cytomegalovirus (Tests for CMV Nucleic Acid by NAAT) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2231 | Congenital Cytomegalovirus Infection (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2232 | Congenital Cytomegalovirus Infection (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2233 | Cytomegalovirus Disease (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2234 | Cytomegalovirus Disease (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2235 | Toxoplasmosis (Tests for Toxoplasma gondii Antigen by Immunohistochemical Stain) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2236 | Toxoplasmosis (Tests for Toxoplasma gondii Antigen in Tissue by Immunohistochemical Stain) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2237 | Toxoplasmosis (Tests for Toxoplasma gondii IgG IgM IgA or IgE Antibody) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2238 | Toxoplasmosis (Tests for Toxoplasma gondii IgG IgM IgA or IgE Antibody in Blood) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2239 | Toxoplasmosis (Tests for Toxoplasma gondii IgG or IgM Antibody) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2240 | Toxoplasmosis (Tests for Toxoplasma gondii IgG or IgM Antibody in Cerebrospinal Fluid) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2241 | Stillbirth (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2242 | Stillbirth (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2243 | Zika Virus Disease (Tests for Zika virus IgM Antibody in Blood or CSF) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2244 | Candida species (Tests by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2245 | Organisms (Tests in Extrapulmonary Specimen by Culture and Identification) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2246 | Organisms (Tests for Nucleic Acid in Extrapulmonary Specimen) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2247 | Extrapulmonary [NTM] (Specimen Type) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2248 | Plasmodium species (Tests by Microscopic Observation) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2249 | Baylisascariasis (Tests for Baylisascaris species Antibody in Serum or CSF) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2250 | Lower Respiratory [Excluding Sputum] (Specimen Type) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2251 | Organisms (Tests in Sputum Specimen by Culture and Identification Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2252 | Organisms (Tests in Lower Respiratory Specimen [Excluding Sputum] by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2253 | Organisms (Tests for Nucleic Acid in Lower Respiratory Specimen [Including Sputum]Â ) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2254 | Nontuberculous Mycobacteria Infection, Pulmonary (Tests for Mycobacterium species in Lower Respiratory Specimen [Excluding Sputum] by Culture and Identification Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2255 | Carbapenem Resistant Bacterial Infection [Carbapenemase Producing] (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2256 | CP_CRE (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2257 | Organisms (Tests in Stool by Culture and Identification Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2258 | Loss of Consciousness (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2259 | Neonatal Abstinence Syndrome (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.226 | Lyme Disease (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2260 | Neonatal Abstinence Syndrome (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2261 | High Pitched Cry (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2262 | Inability to Console (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2263 | Inability to Console (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2264 | Hypertonia (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2265 | Hypertonia (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2266 | Tremors (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2267 | Tremors (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2268 | Myoclonus (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2269 | Myoclonus (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.227 | Lyme Disease (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2270 | Poor Sleep (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2271 | Poor Sleep (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2272 | Alterations in Feeding (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2273 | Alterations in Feeding (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2274 | Excoriation (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2275 | Excoriation (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2276 | Sneezing (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2277 | Sneezing (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2278 | Nasal Congestion (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2279 | Nasal Congestion (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2280 | Yawning (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2281 | Cutaneous Mottling (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2282 | Sweating (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2283 | Sweating (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2284 | Feeding Intolerance (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2285 | Feeding Intolerance (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2286 | Respiratory Distress or Nasal Flaring (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2287 | Respiratory Distress or Nasal Flaring (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2288 | In Utero Exposure to Opioids, Benzodiazepines, or Barbiturates (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2289 | In Utero Substance Exposure (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2290 | In Utero Substance Exposure (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2291 | Childbirth (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2292 | Childbirth (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2293 | Opioids, Benzodiazepines, or Barbiturates (Tests by Any Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2294 | NonOpioid, NonBenzodiazepine, and NonBarbiturate Substances (Tests by Any Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2295 | Opioids, Benzodiazepines, or Barbiturates (Organism or Substance in Lab Results) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2296 | NonOpioid, NonBenzodiazepine, or NonBarbiturate Substances (Organism or Substance in Lab Results) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2297 | Exposure or suspected exposure to harmful algae or algae toxins (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2298 | Exposure or suspected exposure to harmful algae or algae toxins (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2299 | Group A Streptococcus (Tests for Group A Strep in Specimen from Normally Sterile Site by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2300 | Babesia species (Tests by Microscopic Observation) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2301 | Babesia species (Tests by Microscopic Observation in Blood by Giemsa, Wright, or Wright_Giemsa Stain) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2302 | Babesia species (Tests by Microscopic Observation by Giemsa, Wright, or Wright_Giemsa Stain) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2303 | Organisms (Tests by Microscopic Observation in Blood by Giemsa, Wright, or Wright_Giemsa Stain) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2304 | Organisms (Tests by Microscopic Observation by Giemsa, Wright, or Wright_Giemsa Stain) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2305 | Gram_negative Diplococcus (Organism or Substance in Lab Results) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2306 | Pertussis (Test Panels for Bordetella pertussis and Bordetella parapertussis Culture and Identification Method) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2307 | D_Transposition of the Great Arteries (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2308 | L_Transposition of the Great Arteries (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2309 | Transposition of the Great Arteries [Unspecified] (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2310 | Transposition of the Great Arteries [Unspecified] (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2311 | Interrupted Aortic Arch (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2312 | Interrupted Aortic Arch (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2313 | Coarctation of the Aorta (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2314 | Coarctation of the Aorta (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2315 | Ebstein Anomaly (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2316 | Ebstein Anomaly (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2317 | Pulmonary valve atresia (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2318 | Pulmonary valve atresia (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2319 | Pulmonary valve stenosis (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2320 | Pulmonary valve stenosis (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2321 | Fetal Pulmonary valve stenosis (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2322 | Double Outlet Right Ventricle (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2323 | Double Outlet Right Ventricle (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2324 | Hypoplastic left heart syndrome (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2325 | Hypoplastic left heart syndrome (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2326 | Single Ventricle (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2327 | Single Ventricle (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2328 | Tetralogy of Fallot (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2329 | Tetralogy of Fallot (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2330 | Truncus Arteriosus (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2331 | Truncus Arteriosus (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2332 | Atrioventricular septal defect (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2333 | Atrioventricular septal defect (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2334 | Total Anomalous Pulmonary Venous Connection (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2335 | Total Anomalous Pulmonary Venous Connection (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2336 | Tricuspid valve atresia (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2337 | Tricuspid valve atresia (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2338 | Tricuspid valve stenosis (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2339 | Tricuspid valve stenosis (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2340 | Fetal Tricuspid valve stenosis (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2341 | Exposure to Measles (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2342 | Increased Risk for Exposure to Measles (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2343 | Giardiasis (Tests by Microscopic Observation) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2344 | Diphtheria (Tests for Diphtheria Toxin Nucleic Acid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2345 | Lead in Blood (Tests for Lead in Venous Blood) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2346 | Lead in Blood (Tests for Lead in Capillary Blood) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2347 | Opioid Overdose and Poisoning (Test Panels for Opioids) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2348 | Rubella (Test Panels for rubella virus IgM Antibody) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2349 | Consistent with Tuberculosis (Finding in Chest Xray Imaging Results) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2350 | Acute Viral Hepatitis (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2351 | Shigellosis (Combination Tests that include Shigella species by Culture and Identification) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2352 | Acid Fast Bacilli (Tests by Microscopic Observation by Fite Stain) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2353 | Acid Fast Bacilli (Tests by Microscopic Observation in Skin or Unspecified Tissue by Fite Stain) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2354 | Organisms (Tests by Microscopic Observation by Unspecified Acid Fast Stain) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2355 | Organisms (Tests by Microscopic Observation by Unspecified Acid Fast Stain in Skin) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2356 | Skin (Specimen Type) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2357 | Organisms (Tests by Microscopic Observation in Skin) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2358 | Unspecified Tissue (Specimen Type) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2359 | Organisms (Tests by Microscopic Observation in Unspecified Tissue) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2360 | S. Paratyphi Infection (Tests for S. Paratyphi by Culture and Identification Method) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2361 | S. Paratyphi Infection (Tests for S. Paratyphi Nucleic Acid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2362 | Tuberculosis (Ethambutol) (RXNORM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2363 | Tuberculosis (Isoniazid [INH]) (RXNORM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2364 | Tuberculosis (Pyrazinamide [PZA]) (RXNORM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2365 | Tuberculosis (Rifabutin) (RXNORM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2366 | Tuberculosis (Rifampin) (RXNORM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2367 | Tuberculosis (Rifapentine) (RXNORM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2368 | Perinatal Hepatitis B (Maternal Hepatitis B Virus Infection) (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2369 | Necrotizing Fasciitis (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2370 | Necrotizing Fasciitis (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2371 | Renal Impairment [Acute or Unspecified] (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2372 | Renal Impairment [Acute or Unspecified] (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2373 | Coagulopathy [Unspecified Cause] (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2374 | Coagulopathy [Unspecified Cause] (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2375 | Rash [Erythematous, Macular, or Desquamating of Unspecified Cause] (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2376 | Rash [Erythematous, Macular, or Desquamating of Unspecified Cause] (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2377 | Soft Tissue Necrosis (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2378 | Soft Tissue Necrosis (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2379 | Group A Streptococcus (Tests for Group A Strep in Specimen from Nonsterile Site by Culture and Identification Method) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2380 | Organisms (Tests in Specimen from Nonsterile Site by Culture and Identification) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2381 | Specimen from a Nonsterile Site (Specimen Type) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2382 | Chagas Disease (Tests for Trypanosoma cruzi in specimen from donor) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2383 | Absence of Skin Lesions (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2384 | Neuralgia (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2385 | Neuralgia (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2386 | Peripheral Nerve Thickening (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2387 | Nerve (Specimen Type) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2388 | Hansen’s Disease (Tests for M. leprae or M. lepromatosis Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.239 | Chlamydia trachomatis Infection (Tests for Chlamydia trachomatis Nucleic Acid) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.240 | Chlamydia trachomatis Infection (Tests for Chlamydia trachomatis Antigen) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2403 | NU_Hepatitis D Virus Infection (Tests for hepatitis D virus Antibody) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2404 | Hepatitis D Virus Infection (Tests for hepatitis D virus IgG Antibody) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2405 | Hepatitis D Virus Infection (Test for hepatitis D virus Antigen) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2406 | Hepatitis B Virus Infection (Combination Tests that include hepatitis B virus Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2407 | Firearm Injury (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2408 | Firearm Injury (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2409 | Babesiosis (Tests for B. microti IgG or Total Antibody [Titer]) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2410 | Babesiosis (Tests for B. divergens IgG or Total Antibody [Titer]) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2411 | Babesiosis (Tests for B. duncani IgG or Total Antibody [Titer]) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2412 | Babesiosis (Tests for Babesia species IgG or Total Antibody) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2413 | Brucellosis (Tests for Brucella species IgG Antibody by ELISA) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2414 | Cranial Nerve Involvement (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2415 | Cranial Nerve Involvement (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2416 | Unusual Change in Behavior (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2417 | Radiculitis (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2418 | Subarachnoid Hemorrhage (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2419 | Subarachnoid Hemorrhage (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2420 | Discitis (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2421 | Discitis (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2423 | Respiratory Insufficiency [Unspecified Cause] (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2424 | Respiratory Insufficiency [Unspecified Cause] (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2425 | Conjunctival Suffusion (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2426 | Leptospira species (Tests by Microscopic Observation) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2427 | Leptospirosis (Tests for Leptospira Antibody by Agglutination) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2428 | Leptospirosis (Tests for Leptospira Antibody by Indirect Immunofluorescence) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2429 | Conjunctival Suffusion (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2430 | Pleural effusion (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2431 | Pleural effusion (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2432 | Abdominal swelling (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2433 | Abdominal swelling (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2434 | Neck swelling (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2435 | Neck swelling (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2436 | Diaphoresis (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2437 | Diaphoresis (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2438 | Edema (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2439 | Edema (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.244 | Gonorrhea (Tests for Neisseria gonorrhoeae Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2440 | Anthrax (Tests for Bacillus anthracis Protective Antigen Antibody) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2441 | Anthrax (Tests for Bacillus species by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2442 | Anthrax [Anthrax toxin lethal factor] (Organism or Substance in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2443 | Influenza A (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2444 | Influenza B (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2445 | Influenza [Unspecified] (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2446 | Influenza A (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2447 | Influenza [Unspecified] (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2448 | Influenza (Tests for unspecified influenza virus Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2449 | Influenza (Tests for influenza B virus Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2450 | Influenza (Tests for unspecified influenza virus Antigen) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2451 | Influenza (Tests for influenza B virus Antigen) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2452 | Influenza (unspecified influenza virus in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2453 | Influenza (influenza B virus in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2454 | Influenza (Tests for unspecified influenza virus by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2455 | Influenza (Tests for influenza B virus by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2456 | Hepatitis B Virus Infection (Tests for Hepatitis B Virus Total Core Antibody) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2457 | Hepatitis C Virus Infection (Combination Tests that include hepatitis C virus Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2458 | Louseborne relapsing fever (Tests for Borrelia recurrentis Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2459 | Louseborne relapsing fever (Tests for Borrelia recurrentis Nucleic Acid in Blood) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2460 | Borrelia species (Tests by Microscopic Observation) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2461 | Borrelia species (Tests by Microscopic Observation in Blood) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2462 | Spirochetes (Tests by Microscopic Observation) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2463 | Carbapenem Resistant Enterobacterales (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2464 | CP_ Carbapenem Resistant Enterobacterales (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2465 | CRE (Tests for Enterobacterales species [excluding Proteus spp., Providencia spp., and Morganella spp.] by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2466 | CRE (Tests for Proteus spp., Providencia spp., and Morganella spp. by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2467 | CRE (Tests for Enterobacterales species Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2468 | CRE (Combination Tests that include Enterobacterales by Culture and Identification) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2469 | Tests for Carbapenem Susceptibility [Meropenem and Doripenem] | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2470 | Enterobacterales species [excluding Proteus spp., Providencia spp., and Morganella spp.] (Organism or Substance in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2471 | Proteus spp., Providencia spp., and Morganella spp. (Organism or Substance in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2473 | Enterobacterales species [Carbapenem Resistant] (Organism or Substance in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2474 | Enterobacterales species [Carbapenemase Producing] (Organism or Substance in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2475 | Aortic valve stenosis (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2476 | Aortic valve stenosis (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2477 | Anotia (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2478 | Microtia (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2479 | Microtia (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2480 | Anotia (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2482 | Anophthalmia (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2483 | Anophthalmia (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2484 | Microphthalmia (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2485 | Microphthalmia (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2486 | Atrial septal defect (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2487 | Atrial septal defect (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2488 | Fetal Aortic valve stenosis (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2489 | Congenital Posterior Urethral Valves (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2490 | Congenital Posterior Urethral Valves (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2491 | Bladder Exstrophy (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2492 | Bladder Exstrophy (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2493 | Encephalocele (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2494 | Fetal Encephalocele (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2495 | Encephalocele (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2496 | Choanal Atresia (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2497 | Choanal Atresia (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2498 | Cloacal Exstrophy (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2499 | Cloacal Exstrophy (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2500 | Renal Agenesis or Hypoplasia (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2501 | Renal Agenesis or Hypoplasia (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2502 | Trisomy 13 (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2503 | Trisomy 13 (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2504 | Fetal Trisomy 13 (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2505 | Trisomy 13 (Tests for Trisomy 13 Chromosomal Anomaly) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2506 | Galactosemia (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2507 | Galactosemia (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2508 | Galactosemia (Tests for Galactose_1_Phosphate Uridyltransferase [Quantitative] in Blood) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2509 | Galactosemia (Tests for Galactokinase (GALK) [Quantitative] in Blood) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2510 | Galactosemia (Tests for UDP_galactose 4' epimerase (GALE) [Quantitative] in Blood) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2511 | Galactosemia (Tests for Galactose_1_Phosphate Uridyltransferase [Quantitative]) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2512 | Galactosemia (Tests for Galactokinase (GALK) [Quantitative]) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2513 | Galactosemia (Tests for UDP_galactose 4' epimerase (GALE) [Quantitative]) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2514 | Galactosemia (Tests for GALT gene allele 1) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2515 | Galactosemia (Tests for GALT gene allele 2) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2516 | Hypospadias (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2517 | Hypospadias (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2518 | Trisomy 18 (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2519 | Fetal Trisomy 18 (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2520 | Fetal Trisomy 18 (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2521 | Trisomy 18 (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2522 | Trisomy 18 (Tests for Trisomy 18 Chromosomal Anomaly) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2523 | Chlamydia trachomatis Infection (Tests for unspecified Chlamydia species by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2524 | Chlamydia trachomatis Infection (Tests for unspecified Chlamydia species Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2525 | Chlamydia trachomatis Infection (Tests for unspecified Chlamydia species Antigen) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2526 | Chlamydia trachomatis Infection (Combination Tests that include Chlamydia trachomatis Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2527 | Chlamydia species [Unspecified] (Organism or Substance in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2528 | Ventricular septal defect (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2529 | Ventricular septal defect (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2530 | Gonorrhea (Combination Tests that include Neisseria Gonorrhea Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2531 | Intracellular Gram Negative Diplococcus (Organism or Substance in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2532 | Congenital Cytomegalovirus (Tests for CMV Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2533 | Congenital Cytomegalovirus (Tests for CMV Antibody) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.264 | Viral Hemorrhagic Fever (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.265 | Viral Hemorrhagic Fever (Disorders) (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.268 | Mumps (Tests for mumps virus IgM Antibody) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.272 | Present or Positive Lab Result Value | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.282 | Varicella (Tests for Varicella zoster virus by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.283 | Varicella (Tests for Varicella zoster virus Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.285 | Encephalitis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.287 | Varicella (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.289 | Carbon Monoxide Poisoning (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.293 | Toxic Effects of Lead (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.297 | Measles (Tests for measles virus Nucleic Acid) | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.299 | Measles (Tests for measles virus IgM Antibody) | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.300 | Meningococcal Disease (Organism or Substance in Lab Results) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.301 | Shigellosis (Tests for Shigella species by Culture and Identification Method) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.304 | Pesticide Related Illness (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.305 | Organisms (Tests by Microscopic Observation in Specimen from Normally Sterile Site by Gram Stain) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.307 | Leptospirosis (Tests for Leptospira IgM Antibody) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.308 | Invasive Pneumococcal Disease (Tests for Streptococcus pneumoniae Nucleic Acid) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.310 | Bacteria (Tests by Culture and Identification Method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.311 | Viruses (Tests by Culture and Identification Method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.316 | Rubella (Tests for rubella virus IgM Antibody) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.317 | Shigellosis (Tests for Shigella species Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.319 | Fungi (Tests by Culture and Identification Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.322 | Pesticide Related Illness (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.326 | Arboviral Disease [Other] (Disorders) (ICD10CM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.329 | Apnea (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.330 | Apnea (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.333 | Shigellosis (Organism or Substance in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.335 | Influenza (Tests for influenza A virus by Culture and Identification Method) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.336 | Influenza (Tests for influenza A or B virus Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.340 | Influenza (influenza A or B virus in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.341 | Campylobacteriosis (Organism or Substance in Lab Results) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.342 | Campylobacteriosis (Tests for Campylobacter species by Culture and Identification Method) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.343 | Campylobacteriosis (Tests for Campylobacter species Nucleic Acid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.344 | Campylobacteriosis (Tests for Campylobacter species Antigen) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.349 | Hepatitis A (Tests for hepatitis A virus IgM Antibody) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.353 | Diarrhea (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.356 | HIV Infection (Organism or Substance in Lab Results) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.359 | Botulism (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.362 | Hansen’s Disease (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.365 | Silicosis (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.366 | Silicosis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.371 | Cryptosporidiosis (Organism or Substance in Lab Results) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.372 | Cryptosporidiosis (Tests for Cryptosporidium species Nucleic Acid) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.375 | Cyclosporiasis (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.376 | Cyclosporiasis (Tests for Cyclospora cayetanensis Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.379 | Giardiasis (Tests for Giardia species Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.384 | Listeriosis (Tests for Listeria monocytogenes Nucleic Acid) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.386 | Vibriosis (Organism or Substance in Lab Results) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.388 | Vibriosis (Tests for Vibrionaceae species [except Toxigenic Vibrio cholera O1 and O139] Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.390 | Trichinellosis (Tests for Trichinella species Antibody) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.395 | Syphilis (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.396 | Syphilis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.398 | Hepatitis C Virus Infection (Tests for hepatitis C virus Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.399 | Hepatitis C Virus Infection (Tests for hepatitis C virus Antigen) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.40 | STEC Infection (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.400 | Hepatitis B Virus Infection (Tests for hepatitis B virus IgM Antibody) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.401 | Hepatitis B Virus Infection (Tests for hepatitis B virus surface Antigen) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.403 | Hepatitis B Virus Infection (Tests for hepatitis B virus Nucleic Acid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.405 | Hantavirus Infection and Diseases (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.407 | Hepatitis C Virus Infection (Tests for hepatitis C virus Antibody) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.408 | Hepatitis B Virus Infection (Organism or Substance in Lab Results) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.422 | Tuberculosis (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.427 | STEC Infection (Tests for Shiga toxin genes, or STEC, EHEC, or E. coli O157 Nucleic Acid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.43 | Gonorrhea [Cervicitis Urethritis] (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.436 | Coccidioidomycosis (Tests for Coccidioides species IgM Antibody) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.437 | Coccidioidomycosis (Tests for Coccidioides species Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.438 | Coccidioidomycosis (Tests for Coccidioides species Antigen) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.44 | Gonorrhea [Cervicitis Urethritis] (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.445 | Legionellosis (Tests for Legionella species Antigen) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.446 | Legionellosis (Tests for Legionella species Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.451 | Tuberculosis (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.460 | HIV Infection or AIDS (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.464 | Malaria (Tests for Plasmodium species Nucleic Acid) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.468 | Leptospirosis (Tests for Leptospira Nucleic Acid) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.471 | Leptospirosis (Tests for Leptospira Antibody [Quantitative] by Agglutination) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.472 | Leptospirosis (Tests for Leptospira Antibody) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.476 | Babesia species (Tests by Microscopic Observation in Blood) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.478 | Anthrax (Tests for Bacillus anthracis by Culture and Identification Method) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.479 | Anthrax (Tests for Bacillus anthracis Nucleic Acid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.48 | Salmonellosis (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.480 | Anthrax (Tests for Bacillus anthracis Antigen) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.481 | Anthrax (Tests for Bacillus anthracis Antibody) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.494 | Ehrlichiosis (Organism or Substance in Lab Results) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.496 | Q Fever (Tests for Coxiella burnetii IgM IgG Antibody [Excluding Quantitative IFA Tests for IgG Antibody against Phase I or II Antigen]) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.500 | Q Fever (Tests for Coxiella burnetii Nucleic Acid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.505 | Toxic Shock Syndrome (TSS) (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.507 | Toxic Shock Syndrome (TSS) (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.512 | Brucellosis (Tests for Brucella species Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.515 | Brucellosis (Tests for Brucella species Antibody [Quantitative]) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.516 | Brucellosis (Organism or Substance in Lab Results) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.519 | Dengue Virus Infection (Tests for dengue virus Nucleic Acid) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.523 | Dengue Virus Infection (Tests for dengue virus Antigen) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.524 | Dengue Virus Infection (Tests for dengue virus IgG or Total Antibody [Quantitative]) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.525 | Dengue Virus Infection (Tests for dengue virus IgM Antibody) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.527 | Dengue Virus Infection (Tests for dengue virus IgG or Total Antibody [Qualitative]) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.530 | Borrelia species (Tests for Nucleic Acid) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.531 | Lyme Disease (Tests for Borrelia burgdorferi IgM IgG Antibody by Immunoblot) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.532 | Lyme Disease (Tests for Borrelia burgdorferi Antibody by Immunoassay) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.534 | Smallpox (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.542 | Spotted Fever Rickettsiosis (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.548 | St. Louis Encephalitis Virus Infection (Tests for Saint Louis encephalitis virus Antibody [Qualitative]) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.550 | Syphilis (Tests for Treponema pallidum Nucleic Acid) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.553 | Anaplasma species (Tests by Microscopic Observation) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.555 | Yellow Fever (Tests for yellow fever virus Nucleic Acid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.557 | Yellow Fever (Tests for yellow fever virus Antibody [Quantitative]) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.56 | Diarrhea (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.560 | West Nile Virus Infection (Tests for West Nile virus Nucleic Acid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.569 | Plague (Tests for Yersinia pestis Nucleic Acid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.575 | Arboviral Disease [Other] (Tests for Arbovirus [Other] Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.576 | Arboviral Disease [Other] (Tests for Arbovirus [Other] Antigen) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.577 | Arboviral Disease [Other] (Tests for Arbovirus [Other] IgM Antibody) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.578 | Arboviral Disease [Other] (Tests for Arbovirus [Other] Antibody [Quantitative]) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.579 | Arboviral Disease [Other] (Tests for Arbovirus [Other] Antibody [Qualitative]) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.58 | Pertussis (Tests for Bordetella pertussis Nucleic Acid) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.580 | Arboviral Disease [Other] (Organism or Substance in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.581 | Viral Hemorrhagic Fever (Tests for Viral Hemorrhagic Fever Virus Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.584 | Viral Hemorrhagic Fever (Tests for Viral Hemorrhagic Fever Virus IgG Antibody) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.586 | Viral Hemorrhagic Fever (Organism or Substance in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.595 | Tularemia (Tests for Francisella tularensis Nucleic Acid) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.598 | Tularemia (Tests for Francisella tularensis Antibody) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.6 | Diphtheria (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.605 | Organisms (Tests by Microscopic Observation by Acid Fast Stain) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.606 | Tuberculosis (Organism or Substance in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.614 | Pertussis (Tests for Bordetella pertussis Toxin Antibody) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.621 | Inspiratory Whoop (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.632 | Chlamydia trachomatis Infection [Secondary Sites Complications] (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.645 | Pertussis (Test Panels for Bordetella pertussis and Bordetella parapertussis Nucleic Acid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.648 | Vomiting (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.650 | Jaundice (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.652 | Bacteria (Tests in Specimen from Normally Sterile Site by Culture and Identification Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.660 | Hypertonia [Excluding Congenital Hypertonia] (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.662 | Chest Pain (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.663 | Erythema Nodosum (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.664 | Congenital Zika Syndromes (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.665 | Congenital Zika Syndromes (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.666 | Guillain Barré syndrome (Disorders) (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.668 | Rash (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.671 | Fever (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.672 | Arthralgia (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.673 | Arthralgia (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.674 | Conjunctivitis (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.675 | Conjunctivitis (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.676 | Pregnant (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.677 | Postpartum (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.678 | Postpartum (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.679 | Hearing Loss (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.680 | Abdominal Pain (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.681 | Abdominal Pain (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.686 | Erythema Multiforme (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.687 | Myalgia (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.689 | Periorbital Edema (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.691 | Eosinophilia (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.692 | Eosinophilia (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.70 | Salmonellosis (Tests for Salmonella except S. typhi and S. paratyphi by Culture and Identification Method) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.702 | Weight Loss (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.705 | Syphilis (Tests for Treponemal or Non Treponemal Antibody) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.709 | Cough [Non Productive] (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.71 | Salmonellosis (Tests for Salmonella except S. typhi and S. paratyphi Nucleic Acid) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.711 | Wound Infection (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.712 | Pneumonia (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.713 | Sepsis [Septicemia] [Unspecified Organism] (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.714 | Sepsis [Septicemia] [Unspecified Organism] (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.715 | Meningitis (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.717 | Cellulitis (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.718 | Cellulitis (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.719 | Myositis [Unspecified Cause] (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.720 | Myositis [Unspecified Cause] (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.721 | Otitis Media (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.722 | Otitis Media (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.723 | Otitis Externa (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.724 | Otitis Externa (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.727 | Acute Upper Respiratory Illness (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.728 | HIV Infection (Tests for HIV Nucleic Acid [Qualitative]) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.730 | HIV Infection (Tests for HIV Antibody) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.733 | Perinatal Hepatitis B Virus Infection (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.741 | Hepatitis B Immune Globulin (RXNORM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.744 | Coccidioidomycosis (Tests for Coccidioides species IgG Antibody) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.746 | Treponema pallidum (Tests by Microscopic Observation) | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.747 | Penicillin G [Benzathine] [Injectable] [Bicillin] (RXNORM) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.750 | Chest Pain (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.755 | Acute Upper Respiratory Illness (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.756 | Purpura (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.757 | Muscle Spasms (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.758 | Muscle Spasms (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.762 | Mumps (Test Panels for mumps virus IgM IgG Antibody) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.763 | Parotitis [Unspecified Cause] (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.764 | Mumps (Tests for mumps virus IgG Antibody) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.765 | Aseptic Meningitis (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.766 | Encephalitis (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.767 | Hearing Loss (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.770 | Invasive Pneumococcal Disease (Tests for Streptococcus pneumoniae Nucleic Acid in Specimen from Normally Sterile Site) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.773 | Invasive Haemophilus influenzae Disease (Tests for Haemophilus influenzae Nucleic Acid in Specimen from Normally Sterile Site) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.777 | Mastitis (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.779 | Pancreatitis (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.780 | Pancreatitis (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.782 | Rubella (Test Panels for rubella virus IgM IgG Antibody) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.785 | Opioid Overdose and Poisoning (Tests for Opioids [Qualitative]) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.789 | Purpura (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.79 | Campylobacteriosis (Disorders) (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.792 | Novel Influenza A Virus Infection (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.793 | Novel Influenza A Virus Infection (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.794 | Sore Throat (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.795 | Influenza (influenza A virus in Lab Results) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.796 | Influenza (Novel influenza A virus in Lab Results) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.797 | Influenza (Tests for influenza A or B virus by Culture and Identification Method) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.798 | Influenza (Tests for influenza A virus Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.799 | Influenza (Tests for influenza A virus Antigen) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.802 | Influenza (Tests for Novel influenza A virus Nucleic Acid) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.803 | Tests by Microscopic Observation in Tissue by H&E or PAS Stain | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.808 | Headache (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.809 | Headache (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.810 | Backache (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.811 | Backache (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.815 | NU_Anaplasmosis (Tests for Anaplasma species Antibody [Qualitative]) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.816 | Rubella (Tests for rubella virus IgG Antibody [Ratio] in Serum) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.818 | Measles (Tests for measles virus IgG Antibody [Ratio] in Serum) | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.820 | Rubella (Tests for rubella virus IgG Antibody [Quantitative] in Serum) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.822 | Pneumoconiosis (Unspecified) (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.823 | Pneumoconiosis (Unspecified) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.824 | Computerized Tomography of Chest (Imaging) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.830 | Poliovirus Infection (Tests for Poliovirus Antibody Titer in Serum Specimen) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.835 | Lead in Blood (Disorders) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.836 | Lead in Blood (Disorders) (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.839 | Acid Fast Bacilli (Organism or Substance in Lab Results) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.841 | Tuberculosis (Interferon Gamma Release Assays) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.842 | Tests by Microscopic Observation in Tissue | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.844 | Tuberculosis (Second Line Drugs for Treatment) (RXNORM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.846 | SARS (Tests for SARS_CoV by Culture and Identification Method) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.847 | SARS (Tests for SARS_CoV Nucleic Acid) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.86 | Hemolytic Uremic Syndrome (HUS) (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.864 | Nausea (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.865 | Confusion (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.867 | Dyspnea (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.869 | Loss of Consciousness (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.87 | Thrombotic Thrombocytopenic Purpura (TTP) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.875 | SARS (Organism or Substance in Lab Results) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.878 | MERS (Tests for MERS_CoV Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.88 | Hemolytic Uremic Syndrome (HUS) (Disorders) (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.881 | Difficulty Breathing (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.884 | Tests by Microscopic Observation in Blood | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.889 | Hantavirus Infection (Tests for Hantavirus IgM IgG Total Antibody) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.892 | Organisms (Tests by Microscopic Observation in Tissue by Acid Fast Stain) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.895 | Rhinorrhea (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.896 | Tests by Microscopic Observation in Blood Smear | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.897 | Dengue Virus Infection (Test Panels for dengue virus IgM IgG Antibody) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.9 | Xray of Chest (Imaging) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.90 | Cough (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.900 | Organisms (Tests by Microscopic Observation) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.902 | Acute Renal Failure [Unspecified Cause] (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.907 | Arthritis [Unspecified Cause] (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.91 | Cough (SNOMED) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.910 | Epididymitis [Unspecified Cause] (SNOMED) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.911 | Epididymitis [Unspecified Cause] (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.914 | Osteomyelitis [Unspecified Cause] (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.915 | Osteomyelitis [Unspecified Cause] (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.918 | Spondylitis [Unspecified Cause] (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.919 | Arthritis [Unspecified Cause] (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.92 | Thrombotic Thrombocytopenic Purpura (TTP) (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.927 | Thrombocytopenia [Unspecified Cause] (ICD10CM) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.928 | Bleeding [Unspecified Cause] (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.930 | ECG Abnormalities [Unspecified Cause] (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.931 | Hematemesis [Unspecified Cause] (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.932 | Hematemesis [Unspecified Cause] (ICD10CM) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.934 | Hematuria [Unspecified Cause] (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.935 | Hemoptysis (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.937 | Gastrointestinal Hemorrhage [Unspecified Cause] (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.942 | Petechiae [Non Traumatic] (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.952 | Thrombocytopenia [Unspecified Cause] (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.956 | Sepsis [Septicemia] [Bacterial] [Unspecified Organism] (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.957 | Regional Lymphadenitis [Including Bubo] (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.958 | Regional Lymphadenitis (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.96 | Salmonellosis [Salmonella Species and Subspecies] (Organism or Substance in Lab Results) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.963 | Arboviral Disease [Other] (Disorders) (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.965 | Proteinuria [Unspecified Cause] (ICD10CM) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.969 | Proteinuria [Unspecified Cause] (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.970 | Bulbar Weakness (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.971 | Bulbar Weakness (ICD10CM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.976 | Dysphagia (SNOMED) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.978 | Impaired Respiration [Unspecified Cause] (SNOMED) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.979 | Botulism (Organism or Substance in Lab Results) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.98 | Shigellosis (Disorders) (SNOMED) | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.989 | Tests for Mycobacterium species by Culture and Identification Method | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.991 | Rifampin (RXNORM) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.994 | Organisms (Tests for Nucleic Acid) | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.998 | Shigellosis (Tests for Enteroinvasive E. coli Nucleic Acid) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.999 | Chlamydia species (Organism or Substance in Lab Results) | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.109 | Pressure Injury Stage 2, 3, 4 or Unstageable | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.110 | Pressure Injury Stage 2, 3, 4 or Unstageable | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.112 | Pressure Injury Deep Tissue | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.113 | Pressure Injury Stage 2, 3, 4 or Unstageable | active | 2022-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.119 | Inpatient Falls | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.120 | Major Injuries | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.122 | Inpatient Falls | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.125 | Bleeding at Non Critical Site | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.130 | Anticoagulants for VTE Prophylaxis | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.131 | Anticoagulants for Indications Other than VTE Prophylaxis | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.135 | Bleeding at Critical Site | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.143 | Bleeding at Critical Site | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.144 | Bleeding at Critical Site | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.145 | Bleeding at Non Critical Site | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.146 | Bleeding at Non Critical Site | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.160 | Abdominal or Pelvic CT Scan with Contrast | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.163 | Ultrasound of Lower Extremities | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.164 | Ultrasound of Lower Extremities | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.165 | Ultrasound of Lower Extremities | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.171 | Inpatient Falls | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.183 | Anti Factor Xa Assay | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.187 | Extracorporeal Membrane Oxygenation (ECMO) | active | 2022-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.188 | Extracorporeal Membrane Oxygenation (ECMO) | active | 2022-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.190 | Intra Aortic Balloon Pump | active | 2022-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.191 | Intra Aortic Balloon Pump | active | 2022-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.193 | Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) | active | 2022-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.194 | Pressure Injury Deep Tissue Diagnoses | active | 2022-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.196 | Pressure Injury Stage 2, 3, 4, or Unstageable Diagnoses | active | 2022-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.197 | Present on Admission or Clinically Undetermined | active | 2022-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.198 | Not Present On Admission or Documentation Insufficient to Determine | active | 2022-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.1 | DEXA Dual Energy Xray Absorptiometry, Bone Density | active | 2016-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.11 | Bladder Cancer Staging Ta for Urology Care | active | 2016-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.12 | Bladder Cancer staging T1 for Urology Care | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.13 | Bladder Cancer staging Tis for Urology Care | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.15 | Carcinoma of urinary bladder, superficial | active | 2016-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.16 | Injection Leuprolide Acetate | active | 2017-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.17 | High grade bladder cancer Ta for Urology Care | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.18 | Immunocompromised state for Urology Care | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.19 | Systemic chemotherapy for urology care | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.2 | Bladder Cancer in Situ | active | 2016-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.20 | Corticosteroids for patients receiving Urology Care | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.21 | Calcineurin inhibitors for patients receiving Urology Care | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.23 | Immunomodulators for patients undergoing Urology Care | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.24 | Monoclonal antibody for patient undergoing Urology Care | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.28 | Radiotherapy for patients undergoing Urology Care | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.29 | Plasmacytoid cell, morphologic abnormality for urology care | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.3 | Bladder Cancer in Situ | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.30 | Sarcomatoid, morphologic abnormality for Urology Care | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.31 | Micropapillary, morphologic abnormality, for Urology Care | active | 2017-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.32 | Immunosuppressive Drugs for Urology Care | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.38 | DEXA Dual Energy Xray Absorptiometry, Bone Density for Urology Care | active | 2017-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.39 | Mixed histology urothelial cell carcinoma for Urology Care | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.4 | BCG Bacillus Calmette Guerin, Tice | active | 2016-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.40 | Cystectomy for Urology Care | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.44 | Unavailability of Bacillus Calmette Guerin for urology care | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.45 | Bladder Cancer for Urology Care | active | 2017-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.48 | Androgen deprivation therapy for Urology Care | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.5 | BCG Bacillus Calmette Guerin, Connaught | active | 2016-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.52 | BCG Bacillus Calmette Guerin for Urology Care | active | 2020-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.53 | Cystectomy for Urology Care | active | 2018-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.54 | Acute Tuberculosis for Urology Care | active | 2018-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.55 | Cystectomy for Urology Care | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.56 | Active Tuberculosis for Urology Care | active | 2018-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.57 | Bladder Cancer Staging Tis for Urology Care | active | 2019-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.58 | Bladder Cancer Staging Tis for Urology Care | active | 2019-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.59 | Hospital Services for Urology | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.6 | Peripheral DXA Scan | active | 2016-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.60 | Chemotherapy Agents for Advanced Cancer | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.8 | Tuberculosis Diagnosis Prior to Urology Care | active | 2016-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.9 | Leukemia Diagnosis Prior to Urology Care | active | 2016-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.13 | Preventative Clinical Encounters | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.14 | Intensive Lifestyle Interventions | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.15 | Intensive Lifestyle Interventions | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.16 | Intensive Lifestyle Interventions | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.17 | Intensive lifestyle interventions | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.21 | Outpatient Clinical Encounters | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.22 | Outpatient Clinical Encounters | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.23 | Outpatient Clinical Encounters | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.24 | Outpatient Clinical Encounters | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.25 | Reason for No Intensive Lifestyle Intervention | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.27 | Type 2 Diabetes Diagnoses | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.28 | Type 2 Diabetes Diagnoses | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.29 | Type 2 Diabetes Diagnoses | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.30 | Prediabetes HbA1c Tests | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.31 | Prediabetes HbA1c Tests | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.32 | Prediabetes HbA1c Tests | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.33 | Prediabetes Oral Glucose Tolerance Tests | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.34 | Prediabetes Oral Glucose Tolerance Tests | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.35 | Prediabetes Oral Glucose Tolerance Tests | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.36 | Prediabetes Fasting plasma glucose or Plasma Glucose Tests | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.37 | Prediabetes Fasting plasma glucose or Plasma Glucose Tests | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.38 | Prediabetes Fasting plasma glucose or Plasma Glucose Tests | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.4 | Glycemic Screening Tests | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.40 | Sickle Cell Disease with Vaso Occlusive Episode | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.41 | Sickle Cell Disease with Vaso Occlusive Episode | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.42 | Sickle Cell Disease with Vaso Occlusive Episode | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.43 | Analgesics for Acute Pain | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.49 | Medication Therapy Management Services for Essential Hypertension | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.5 | Glycemic Screening Tests | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.52 | Remote Physiologic Blood Pressure Monitoring | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.57 | Aldosterone Receptor Blocker for Hypertension | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.58 | Alpha Blocker for Hypertension | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.59 | Angiotensin Converting Enzyme Inhibitor for Hypertension | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.6 | Glycemic Screening Tests | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.60 | Angiotensin II Receptor Blocker for Hypertension | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.61 | Beta Blocker for Hypertension | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.62 | Calcium Channel Blocker Dihydropyridine for Hypertension | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.63 | Calcium Channel Blocker Non Dihydropyridine for Hypertension | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.64 | Central Acting for Hypertension | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.65 | Direct Renin Inhibitor for Hypertension | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.66 | Loop Diuretic for Hypertension | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.67 | Neuronal Blocking Agent for Hypertension | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.68 | Potassium Sparing Diuretic for Hypertension | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.69 | Thiazide Diuretic for Hypertension | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.7 | Preventative Clinical Encounters | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.70 | Vasodilator for Hypertension | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.73 | Analgesics for Acute Pain (Non Parenteral Route) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.74 | Analgesics for Acute Pain (Parenteral Route) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.75 | Analgesics for Acute Pain Non Oral Enteral/Mucosal Routes | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.77 | Antihypertensive Medication Classes | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.78 | Medication Therapy Management Services for Essential Hypertension | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.79 | Medication Therapy Management Services for Essential Hypertension | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.8 | Preventative Clinical Encounters | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.84 | Renal Colic | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.85 | Renal Colic | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.86 | Renal Colic | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.88 | Direct LDL Cholesterol | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.89 | Calculated LDL Cholesterol | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.9 | Preventative Clinical Encounters | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1164.50 | Urinary retention | active | 2017-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1164.51 | Urinary retention | active | 2017-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1164.52 | Urinary retention | active | 2017-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1164.65 | Morbid Obesity | active | 2018-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1164.66 | Morbid Obesity | active | 2018-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1164.67 | Morbid Obesity | active | 2018-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1164.68 | BMI greater than 40 | active | 2019-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1164.69 | Morbid Obesity | active | 2019-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.1 | Pregnancy Status | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.10 | Pap Smear Tests | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.103 | Female Sterilization HCPCS Devices | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.105 | Female Sterilization ICD10CM Provision Encounters | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.109 | Sterilization SNOMED Findings | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.11 | HIV Tests | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.110 | Pregnancy Bundle Visits | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.111 | Prenatal Care Specific Visits CPT | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.112 | Prenatal Care Specific Visits HCPCS | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.113 | Prenatal Care Specific Visits SNOMED | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.114 | Prenatal Care Specific Visits | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.115 | Self Identified Need for Contraception (SINC) | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.117 | Syphilis Tests | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.118 | Infecund Not for Contraceptive Reasons CPT Procedures | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.119 | Infecund Not for Contraceptive Reasons HCPCS Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.12 | Human Papilloma Virus Tests | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.120 | Prenatal Care Visits CPT | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.121 | Prenatal Care Visits HCPCS | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.122 | Prenatal Care Visits SNOMED | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.123 | Pregnancy Related Diagnoses ICD10CM | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.124 | Pregnancy Related Diagnoses SNOMED | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.125 | Non Live Birth Diagnoses ICD10CM | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.126 | Non Live Birth Diagnoses SNOMED | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.127 | Non Live Birth CPT Procedures | active | 2022-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.128 | Non Live Birth ICD10PCS Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.129 | Contraceptive Ring RXNORM Medications | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.13 | Chlamydia Trachomatis Tests | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.130 | Contraceptive Implants RXNORM Medications | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.131 | Injectable Contraceptive RXNORM Medications | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.132 | Oral Contraceptive Pills RXNORM Medications | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.133 | Pregnancy Related Diagnoses | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.134 | Female Sterilization SNOMED Provision Procedures | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.135 | General Prenatal Care Visits | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.136 | Non Live Birth Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.137 | Non Live Birth Diagnoses | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.138 | IUD Surveillance | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.139 | IUD Provision Procedures | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.14 | Neisseria Gonorrhoeae Tests | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.140 | IUD Devices | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.141 | Contraceptive Patch SNOMED Devices | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.142 | Female Sterilization Provision Procedures | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.143 | Live Birth Delivery CPT Procedures | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.144 | Contraceptive Patch SNOMED Provision Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.145 | Contraceptive Patch SNOMED Findings | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.146 | Contraceptive Patch ICD10CM Provision Encounters | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.147 | Contraceptive Patch ICD10CM Surveillance | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.148 | Live Birth Delivery ICD10PCS Procedures | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.149 | Contraceptive Patch HCPCS Devices | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.15 | Chlamydia trachomatis and Neisseria Gonorrhoeae combined Tests | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.150 | Contraceptive Patch LOINC | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.151 | Infecund Not for Contraceptive Reasons Procedures | active | 2022-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.152 | Live Birth Delivery Procedures SNOMED CT | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.153 | Contraceptive Ring SNOMED Surveillance Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.154 | Contraceptive Ring SNOMED Provision Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.155 | Contraceptive Ring SNOMED Findings | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.156 | Contraceptive Ring ICD10CM Provision Encounters | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.157 | Contraceptive Ring ICD10CM Surveillance | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.159 | Contraceptive Ring HCPCS Devices | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.160 | Contraceptive Ring LOINC | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.161 | Contraceptive Implant SNOMED Devices | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.162 | Contraceptive Implant ICD10PCS Provision Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.163 | Contraceptive Implant SNOMED Provision Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.164 | Contraceptive Implant SNOMED Findings | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.165 | Infecund Not for Contraceptive Reasons SNOMED Procedures | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.167 | Contraceptive Implant LOINC | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.168 | Pregnancy Bundle CPT | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.169 | Pregnancy Bundle HCPCS | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.17 | Contraceptive Type | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.170 | Contraceptive Implant ICD10CM Provision Encounters | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.171 | Contraceptive Implant ICD10CM Surveillance | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.173 | Contraceptive Implant HCPCS Devices | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.174 | Contraceptive Patch Devices | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.177 | Live Birth Delivery Procedures | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.178 | Contraceptive Ring Surveillance | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.18 | Contraception Not Used Reason | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.180 | Contraceptive Implant CPT Provision Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.181 | Injectable Contraceptive SNOMED Surveillance Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.182 | Injectable Contraceptive SNOMED Provision Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.183 | Injectable Contraceptive SNOMED Findings | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.185 | Injectable Contraceptive ICD10CM Provision Encounters | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.186 | Injectable Contraceptive ICD10CM Surveillance | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.187 | Injectable Contraceptive HCPCS Provision Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.188 | Injectable Contraceptive LOINC | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.189 | Oral Contraceptive Pill SNOMED Surveillance Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.190 | Oral Contraceptive Pill SNOMED Provision Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.191 | Oral Contraceptive Pill SNOMED Findings | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.192 | Contraceptive Implant SNOMED Surveillance Procedures | active | 2021-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.193 | Oral Contraceptive Pill ICD10CM Provision Encounters | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.194 | Oral Contraceptive Pill ICD10CM Surveillance | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.195 | Oral Contraceptive Pill HCPCS Provision Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.196 | Oral Contraceptive Pill LOINC | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.197 | Injectable Contraceptive Provision Procedures | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.198 | Injectable Contraceptive Surveillance | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.199 | Oral Contraceptive Pill Provision Procedures | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.200 | Oral Contraceptive Pill Surveillance | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.201 | Contraceptive Implant Devices | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.202 | Contraceptive Implant Provision Procedures | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.203 | Contraceptive Implant Surveillance | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.204 | Prenatal Care Bundle CPT | active | 2021-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.205 | Prenatal Care Bundle Visits | active | 2021-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.206 | Infecund Not for Contraceptive Reasons ICD10PCS Procedures | active | 2022-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.209 | Yes and No Answers | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.21 | Contraceptive Provision Method | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.210 | Pap Smear Results | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.211 | Contraceptive discussion | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.22 | Pregnancy Intention | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.24 | Clinical Provider Role | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.29 | Insurance Coverage Type | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.3 | Organism Detection | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.31 | English Proficiency | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.76 | Contraceptive Patch RXNORM Medications | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.78 | Intrauterine Devices CPT Provision Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.79 | Intrauterine Devices HCPCS Devices | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.80 | Intrauterine Devices LOINC | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.81 | Intrauterine Devices HCPCS Provision Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.83 | Intrauterine Devices ICD10CM Provision Encounters | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.84 | Intrauterine Devices ICD10CM Surveillance | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.85 | Intrauterine Devices RXNORM Medications | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.86 | Intrauterine Devices SNOMED Devices | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.87 | Intrauterine Devices SNOMED Findings | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.88 | Intrauterine Device SNOMED Provision Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.89 | Intrauterine Devices SNOMED Surveillance Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.91 | Intrauterine Devices ICD10PCS Provision Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.93 | Female Sterilization CPT Provision Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.96 | Infecund Not for Contraceptive Reasons SNOMED Findings | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.97 | Infecund Not for Contraceptive Reasons ICD10CM | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.98 | Female Sterilization LOINC | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.99 | Female Sterilization ICD10PCS Provision Procedures | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.10 | ASN Screening Declined | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.11 | Transportation Insecurity Diagnosis | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.12 | Food Insecurity Diagnosis | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.13 | Homelessness Diagnosis | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.14 | Housing Instability Diagnosis | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.15 | Intervention for Positive Transportation Insecurity Screen | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.16 | Intervention for Positive Food Insecurity Screen | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.17 | Intervention for Positive Food Insecurity Screen | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.18 | Intervention for Positive Food Insecurity Screen | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.19 | Intervention for Positive Food Insecurity Screen | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.2 | Intracranial or Intraspinal surgery | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.20 | Intervention for Positive Homelessness Screen | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.21 | Intervention for Positive Housing Instability Screen | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.22 | Emergency Department Observation | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.27 | Mental Health Diagnosis without Substance Use Disorders | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.28 | Mental Health Diagnosis without Substance Use Disorders | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.29 | Bed Assigned | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.3 | Malignant Intracranial Neoplasm Group | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.31 | Healthcare Agent & Power of Attorney Documentation | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.32 | Healthcare Agent and Power of Attorney Documentation | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.33 | Advance Directive Documentation | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.34 | Advance Directive Documentation | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.35 | Advance Directive Documentation | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.36 | Portable Medical Order(s) Documentation | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.37 | Portable Medical Order(s) Documentation | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.38 | Advance Care Planning Discussion Documentation | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.4 | Thrombolytic medications | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.40 | Advance Care Planning Documentation | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.41 | Advance Care Planning Documentation | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.42 | Healthcare Agent & Power of Attorney Documentation | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.43 | Advance Directive Documentation | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.45 | Advance Care Planning Documentation | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.46 | Advance Care Planning Documentation | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.47 | Portable Medical Order(s) Documentation | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.48 | Portable Medical Order(s) Documentation | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.49 | Intervention for Positive Utility Insecurity Screen | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.5 | Allergy to thrombolytics | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.50 | Intervention for Positive Utility Insecurity Screen | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.51 | Intervention for Positive Transportation Insecurity Screen | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.52 | Intervention for Positive Transportation Insecurity Screen | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.53 | Intervention for Positive Housing Instability Screen | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.54 | Intervention for Positive Housing Instability Screen | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.55 | Intervention for Positive Homelessness Screen | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.56 | Intervention for Positive Homelessness Screen | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.57 | Non Invasive Oxygen Therapy Device Codes | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.58 | Goals, preferences, and priorities for medical treatment | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.6 | Thrombolytics Adverse Event | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.7 | Intraspinal surgery | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.8 | Intervention for Positive Utility Insecurity Screen | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.9 | Utility Insecurity Diagnosis | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1176.58 | Food Insecurity Screening Positive | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.1 | Ezetimibe Therapy | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.10 | Antihypertensive Medications | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.100 | Allergy or Intolerance to ACE Medication | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.101 | Allergy or Intolerance to ARB Medication | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.102 | Chronic Kidney Disease Stage 1 | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.103 | Chronic Kidney Disease Stage 2 | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.104 | Chronic Kidney Disease Stage 3 | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.105 | Chronic Kidney Disease Stage 4 | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.106 | Chronic Kidney Disease Stage 5 | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.107 | ICD10 CM Chronic Kidney Disease Stage 1 | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.108 | ICD10 CM Chronic Kidney Disease Stage 2 | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.111 | AHA GWTG Chronic Kidney Disease Stage 2 | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.112 | ICD10 CM Chronic Kidney Disease Stage 3 | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.113 | ICD10 CM Chronic Kidney Disease Stage 4 | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.114 | ICD10 CM Chronic Kidney Disease Stage 5 | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.115 | AHA GWTG Chronic Kidney Disease Stage 1 | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.116 | AHA GWTG Chronic Kidney Disease Stage 3 | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.117 | AHA GWTG Chronic Kidney Disease Stage 4 | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.118 | SNOMED CT Atrial Fibrillation | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.119 | ICD10 CM Atrial Fibrillation | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.121 | AHA GWTG Atrial Fibrillation | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.123 | SNOMED CT Hyperlipidemia | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.124 | ICD10 CM Hyperlipidemia | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.125 | AHA GWTG Hyperlipidemia | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.126 | SNOMED CT Hypertriglyceridemia | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.127 | ICD10 CM Hypertriglyceridemia | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.129 | AHA GWTG Hypertriglyceridemia | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.130 | SNOMED CT Gestational Diabetes | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.131 | ICD10 CM Gestational Diabetes | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.132 | AHA GWTG Gestational Diabetes | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.133 | SNOMED CT Hyperglycemia | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.134 | ICD10 CM Hyperglycemia | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.135 | AHA GWTG Hyperglycemia | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.136 | SNOMED CT Nonobstructive CAD | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.137 | ICD10 CM Nonobstructive Coronary Artery Disease | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.138 | AHA GWTG Nonobstructive coronary artery disease | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.139 | AHA GWTG Anti Obesity Pharmacotherapy | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.15 | Non Tobacco Smoking Product User | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.16 | Antihypertensive Fixed Dose Combination Medications | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.2 | PCSK9 Inhibitors | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.20 | CCB and Thiazide and Thiazide Like Diuretics | active | 2021-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.21 | Referral to cardiac rehab | active | 2021-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.22 | Cardiac Rehabilitation | active | 2021-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.25 | 2 Hour Blood Glucose Test | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.26 | NYHA Functional Classification | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.27 | ARNI Therapy | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.29 | MRA Therapy | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.3 | Cholesterol non HDL Laboratory Test | active | 2021-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.30 | SGLT2 Inhibitors | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.31 | Heart Transplant | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.32 | Heart Transplant | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.33 | Heart Transplant | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.34 | Allergy to MRA Therapy | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.35 | Aspirin or Clopidogrel | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.39 | Cardiac Rehabilitation | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.4 | Hypothyroidism | active | 2021-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.40 | Cardiac Rehabilitation | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.43 | SGLT2 Ingredients | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.44 | MRA Ingredients | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.49 | Minnesota Living with Heart Failure Questionnaire | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.5 | Hypothyroidism | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.50 | Kansas City Cardiomyopathy Questionnaire | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.51 | Cardiac Pacer | active | 2021-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.52 | Cardiac Pacer | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.53 | Cardiac Pacer | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.54 | Heart Transplant Complications | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.55 | Heart Transplant Complications | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.56 | Heart Transplant Complications | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.57 | Left Ventricular Assist Device Complications | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.58 | Left Ventricular Assist Device Complications | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.59 | Left Ventricular Assist Device Placement | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.6 | Hypothyroidism | active | 2021-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.60 | Left Ventricular Assist Device Placement | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.61 | Left Ventricular Assist Device Placement | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.62 | Left Ventricular Assist Device Placement | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.63 | Heart Transplant | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.65 | Cardiac Pacer | active | 2022-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.66 | Diastolic Heart Failure | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.67 | Diastolic Heart Failure | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.68 | Diastolic Heart Failure | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.69 | Allergy to SGLT2 Inhibitors | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.7 | Anorexia Nervosa | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.70 | Intolerance to SGLT2 Inhibitors | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.71 | Intolerance to MRA Therapy | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.72 | ARNI Ingredient | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.73 | Mitral Stenosis | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.74 | Mitral Stenosis | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.75 | Mitral Stenosis | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.76 | Mechanical Prosthetic Heart Valve | active | 2022-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.77 | Mechanical Prosthetic Heart Valve | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.78 | Mechanical Prosthetic Heart Valve | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.79 | Mechanical Prosthetic Heart Valve in Situ | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.8 | Anorexia Nervosa | active | 2021-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.82 | Systolic Heart Failure | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.83 | Systolic Heart Failure | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.84 | Systolic Heart Failure | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.85 | Carotid Intervention | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.86 | Serum Creatinine | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.87 | Urine Creatinine | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.88 | Urine Albumin | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.9 | Anorexia Nervosa | active | 2021-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.90 | Non Steroidal Mineralcorticoid Receptor Antagonist | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.91 | Glucagon like peptide 1 medications | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.96 | AHA GWTG Long COVID19 | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.97 | AHA GWTG Long COVID19 SNOMEDCT | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.98 | AHA GWTG Long COVID19 ICD10CM | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.1 | Wound internal item and/or body structure visible value set (foundation metadata concept) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.11 | Wound exudate appearance value set (foundation metadata concept) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.12 | Wound exudate color value set (foundation metadata concept) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.13 | Exudate odor value set (foundation metadata concept) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.14 | Wound anatomic location value set (foundation metadata concept) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.16 | Skin temperature value set (foundation metadata concept) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.17 | Skin color enumerated value set (foundation metadata concept) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.18 | Skin turgor value set (foundation metadata concept) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.19 | Skin and mucous membrane integrity value set (foundation metadata concept) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.2 | Periwound condition value set (foundation metadata concept) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.20 | Skin moisture value set (foundation metadata concept) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.3 | Wound Type Etiology value set | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.4 | Wound episode value set (foundation metadata concept) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.6 | Wound bed appearance value set (foundation metadata concept) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.60 | Wound type reference set | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.7 | Wound bed color value set (foundation metadata concept) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.74 | Nonverbal pain indicators reference set | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.76 | Pain associated signs and symptoms reference set | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.77 | Pain body location reference set | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.8 | Wound edge description value set (foundation metadata concept) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.80 | Pain quality reference set | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.81 | Pain speed of onset reference set | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.9 | Presence absence value set (foundation metadata concept) | active | 2018-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.1 | Common drug substances for allergy and intolerance documentation | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.2 | Common drug classes for allergy and intolerance documentation | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.3 | Common dietary substances for allergy and intolerance documentation | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.4 | Common environmental substances for allergy and intolerance documentation | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.5 | Common refutations for substance causes for allergy and intolerance documentation | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.7 | Common substances for allergy and intolerance documentation | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.8 | Common substances for allergy and intolerance documentation including refutations | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.10 | NHSNCriterionOfDiagnosisCode(CDCNHSN) | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.11 | NHSNCriterionOfDiagnosisCode(SNOMEDCT) | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.12 | NHSNInfectionConditionCode(CDCNHSN) | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.13 | NHSNInfectionConditionCode(SNOMEDCT) | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.14 | NHSNInfectionTypeCode(CDCNHSN) | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.15 | NHSNInfectionTypeCode(SNOMEDCT) | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.16 | NHSNInfectionFirstReportedSource(CDCNHSN) | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.17 | NHSNInfectionFirstReportedSource(SNOMEDCT) | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.18 | NHSNLOS/MENDischargeDisposition(CDCNHSN) | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.19 | NHSNLOS/MENDischargeDisposition(SNOMEDCT) | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.20 | NHSNPopulationSummaryReportTypeCode(CDCNHSN) | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.21 | NHSNPopulationSummaryReportTypeCode(LOINC) | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.22 | NHSNSameDayOutcomeMeasure(CDCNHSN) | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.23 | NHSNSameDayOutcomeMeasure(SNOMEDCT) | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.24 | NHSNSignificantPathogenCode(CDCNHSN) | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.25 | NHSNSignificantPathogenCode(SNOMEDCT) | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.26 | NHSNSpinalFusionApproachCode(CDCNHSN) | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.27 | NHSNSpinalFusionApproachCode(SNOMEDCT) | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.28 | NHSNVascularAccessTypeCode(CDCNHSN) | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.29 | NHSNVascularAccessTypeCode(SNOMEDCT) | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.30 | NHSNVascularSpecimenCollectionSite(CDCNHSN) | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.31 | NHSNVascularSpecimenCollectionSite(SNOMEDCT) | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.38 | Blood Glucose Laboratory and Point of Care Tests | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.58 | Diabetes Medications | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.6 | NHSNPathogenCodeARO | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.62 | Lab Tests for Clostridioides difficile | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.63 | Bacterial and Fungal Blood Culture Tests | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.7 | NHSNRoleOfPerformerCode(CDCNHSN) | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.74 | Enteral Medication Route | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.75 | Intravenous Medication Route | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.76 | Fidaxomicin | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.77 | Vancomycin | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.78 | Metronidazole | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.79 | Fidaxomicin, Vancomycin, and Metronidazole | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.8 | NHSNRoleOfPerformerCode(SNOMEDCT) | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.85 | Baloxavir | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.86 | Peramivir | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.87 | Zanamivir | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.88 | Digestive, Intramuscular, Intravenous Route of Administration | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.89 | Maternal Diagnoses | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.9 | NHSNRoleOfPerformerCode(HealthCareProviderTaxonomy) | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.90 | NHSN LTC AU Antimicrobial Agents | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.91 | Long Term Care Discharge Disposition | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.94 | NHSNNeurogenicBladder | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.95 | NHSNSpinalCordInjury | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1139 | S4G Hyperlipidemia | active | 2022-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1291 | S4G Cardiomyopathy | active | 2022-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1292 | S4G Tricuspid valve disorder | active | 2022-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1293 | S4G Pompe disease | active | 2022-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1294 | S4G Malignant hyperthermia | active | 2022-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1295 | S4G Malignancy | active | 2022-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1297 | S4G Intestinal polyp | active | 2022-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1298 | S4G Hamartoma | active | 2022-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1299 | S4G Diabetes mellitus | active | 2022-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1300 | S4G Muscular dystrophy and weakness | active | 2022-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1325 | S4G Hamartoma and S4G Intestinal Polyp | active | 2022-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1326 | S4G Malignancy and S4G Intestinal Polyp | active | 2022-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1344 | Tests for Neisseria gonorrhoeae of unspecified site reported by presence | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1352 | Body weight | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1354 | Cefixime preparations for oral administration | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1358 | Beta lactam medicinal product SNOMED | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1370 | Beta lactam ingredients for allergy determination RXNORM | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.147 | SCIP Major Surgical Procedure | active | 2019-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.158 | Multiple Myeloma Regimen Drugs | active | 2019-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.226 | Opioids, All | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3483 | Financial Insecurity Screening Assessments Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3484 | Food Insecurity Screening Assessments Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3485 | Health Literacy Screening Assessments Questions | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3486 | Homelessness Screening Assessments Questions | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3487 | Housing Instability Screening Assessments Questions | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3488 | Less Than High School Education Screening Assessments Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3519 | Health Insurance Coverage Status Screening Assessments And Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3520 | Inadequate Housing Screening Assessments And Questions | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.393 | Hypoglycemics Severe Hypoglycemia | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.394 | Hypoglycemics Treatment Medications | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4436 | Gentamicin medications | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4437 | Azithromycin medications | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4448 | Lidocaine | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4466 | Pharyngeal specimens | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4467 | Urogenital & Anorectal Specimens | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4469 | Cabotegravir Injectable Products | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4470 | Emtricitabine oral for HIV PrEP | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4474 | HIV Laboratory Based Tests | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4502 | Ceftriaxone all code types | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.491 | Medium Dose ICS Formoterol Preparations | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.495 | ICS LABA LAMA Preparations | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.788 | Social Determinants of Health Conditions | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.789 | Social Determinants of Health Procedures | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.790 | Social Determinants of Health Service Requests | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.93 | CPIC RxNORM abacavir SCDG | active | 2019-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.94 | CPIC RxNORM allopurinol SCDG | active | 2019-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.95 | CPIC RxNORM amitriptyline SCDG | active | 2019-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.96 | CPIC RxNORM atazanavir SCDG | active | 2019-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.97 | CPIC RxNORM atomoxetine SCDG | active | 2019-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.99 | CPIC RxNORM capecitabine SCDG | active | 2019-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.1 | Mechanical Complications Related To Hip and Knee Procedures | active | 2019-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.10 | Surgical Site Bleeding and Other Surgical Site Complications | active | 2019-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.11 | Procedures Resulted From Surgical Site Bleeding and Other Surgical Site Complications | active | 2019-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.12 | Opioid (Oral Tablets and Patches only) | active | 2019-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.13 | Comorbidity Risk Factors | active | 2020-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.14 | Treatment of Hemorrhage or Hematoma | active | 2020-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.15 | General Surgery | active | 2020-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.17 | Coagulation Disorder Conditions | active | 2020-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.18 | Acute Respiratory Failure | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.19 | Anticoagulant Medications | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.2 | Fracture Exclusions For Hip And Knee Procedures | active | 2019-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.20 | Anticoagulant Medications, Oral | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.21 | Anticoagulant Medications, Injection | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.28 | Active Bleeding | active | 2020-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.29 | Fall Risk Increasing Drugs (FRIDs) | active | 2021-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.3 | Pulmonary Embolism Complications Related To Hip and Knee Procedures | active | 2019-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.30 | Fall Risk Factors | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.32 | Total Hip Arthroplasty Surgery | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.33 | Total Knee Arthroplasty Surgery | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.34 | AbnormalityOfGaitAndMobility | active | 2021-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.35 | Assymetry Symptoms | active | 2021-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.36 | Hemiplegia Symptoms | active | 2021-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.37 | Leg Weakness Symptoms | active | 2021-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.38 | Osteopenia Symptoms | active | 2021-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.39 | Stroke Symptoms | active | 2021-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.4 | Sepsis Complications Related To Hip and Knee Procedures | active | 2019-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.40 | Vestibular Symptoms | active | 2021-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.41 | TricyclicAntidepressants | active | 2021-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.42 | Benzodiazepines | active | 2021-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.43 | LoopDiuretics | active | 2021-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.44 | Antiepileptics | active | 2021-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.45 | Antipsychotics | active | 2021-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.46 | Opioid Medications | active | 2021-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.47 | Imaging Related to VTE | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.48 | Anticoagulant Medication | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.49 | VTE Diagnoses | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.5 | Nonprimary Total Hip, Total Knee Replacement | active | 2019-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.50 | Bisphosphonate Therapy | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.51 | VTE Symptoms | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.52 | Oncology Critical Care Units | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.53 | Provider Types | active | 2022-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.56 | FOBT_Lab | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.57 | Colorectal Screening | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.58 | Screening Mammogram (CPT) | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.59 | Screening Mammogram (LOINC) | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.6 | Pneumonia Complications Related To Hip and Knee Procedures | active | 2019-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.60 | Screening Mammogram (SNOMEDCT) | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.61 | Screening Mammogram (Grouping) | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.62 | Diagnostic Mammography (CPT) | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.63 | Diagnostic Mammography (LOINC) | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.64 | Diagnostic Mammography (SNOMEDCT) | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.65 | Diagnostic Mammography | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.66 | Breast Cancer Biopsy and Surgical Excision | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.67 | BI_RADS Categories 0, 4, and 5 | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.68 | BI_RADS Categories 1, 2, and 3 | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.7 | Malignant Neoplasm Complications Related To Hip and Knee Procedures | active | 2019-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.8 | Periprosthetic Joint Infection/Wound Infection and Other Wound Complications | active | 2019-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.9 | Procedures Resulted From Periprosthetic Joint Infection/Wound Infections | active | 2019-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.101 | Local Anesthetics | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.102 | Ophthalmic Epinephrines | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.103 | Inhaled Epinephrines | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.104 | Clopidogrels | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.105 | Cytochrome P450 2C19 inhibitors | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.106 | Cytochrome P450 2C9 inhibitors | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.107 | Aspirin Ingredient and Risk of GI Bleeding | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.109 | Oral Anticoagulant Ingredients and Risk of GI Bleeding | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.110 | Corticosteroid Ingredients and Risk of GI Bleeding | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.111 | Antidepressant Ingredients and Risk of GI Bleeding | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.112 | PPI and Risk of GI Bleeding | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.113 | Antiplatelet Ingredients and Risk of GI Bleeding | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.114 | NSAIDs Ingredients and Risk of GI Bleeding | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.115 | Kratom containing compounds | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.117 | Clopidogrel Ingredients and Risk of GI Bleeding | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.121 | Gastrointestinal bleeding episode and Risk of GI Bleeding 1 | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.122 | Gastrointestinal bleeding episode and Risk of GI Bleeding 2 | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.123 | Gastrointestinal bleeding episode and Risk of GI Bleeding | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.24 | Oxycodones | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1217.2 | TESTSemanticBitsValueSet | active | 2020-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.1 | Bronchiectasis Disorder SNOMED | active | 2020-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.10 | Interstitial Lung Disease ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.100 | Occupational Therapy Procedure HCPCS | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.101 | Occupational Therapy Procedure | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.102 | Speech Language Therapy Procedure HCPCS | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.103 | Speech Language Therapy Procedure | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.104 | Home Health Procedure | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.105 | Intermittent Skilled Nursing Home Health Procedure | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.106 | pH, Hematocrit, Partial Pressure Carbon Dioxide, Partial Pressure Oxygen or Bicarbonate Laboratory Test for Breathing Assistance Device Evaluation Excluding Oxygen Saturation | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.107 | Breathing Test Procedure During Sleep | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.108 | Ambulance Transport Procedure | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.109 | Prefabricated Spinal Orthotic Device | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.11 | Interstitial Lung Disease SNOMEDCT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.110 | Custom Fitted Spinal Orthotic Device | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.111 | Custom Fabricated Spinal Orthotic Device | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.112 | Orthotic Device Supply | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.113 | Spinal Orthotic Device or Supply | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.115 | Spine or Neck Disorder SNOMED CT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.116 | Spine or Neck Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.117 | Spine or Neck Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.118 | Total Electric Hospital Bed Supply | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.119 | Hypoventilation Disorder SNOMEDCT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.12 | Interstitial Lung Disease | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.120 | Hypoventilation Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.121 | Hypoventilation Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.122 | Respiratory Assist Device Qualifying Condition | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.123 | Apnea Hypopnea Index Rate Measurement | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.124 | Forced Expiratory Volume in One Second (FEV1)/Forced Vital Capacity (FVC) Measurement | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.125 | Maximal Inspiratory Pressure Measurement | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.126 | Forced Vital Capacity (FVC) Measurement by Spirometry | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.127 | Oxygen Saturation Measurement At Rest | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.128 | Respiratory Assist Device | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.129 | Respiratory Assist Device Supply | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.13 | Cystic Fibrosis Lung Disease ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.130 | Home Oxygen Therapy Accessory | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.131 | Forced Vital Capacity (FVC) Measurement Prediction | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.132 | Oxygen Saturation Laboratory Test and Setting for Breathing Assistance Device Evaluation | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.133 | Respiratory Disturbance Index | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.134 | Sleep Related Symptom for Positive Airway Pressure Device Use Evaluation | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.135 | Past Medical History Condition Related to Need for Positive Airway Pressure Device | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.136 | Home or Facility Care Location | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.137 | Fracture of Bone Disorder SNOMED CT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.138 | Fracture of Bone Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.139 | Fracture of Bone Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.14 | Cystic Fibrosis Lung Disease SNOMEDCT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.140 | Severe Obesity Disorder SNOMED CT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.141 | Severe Obesity Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.142 | Severe Obesity Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.143 | Transfer from Bed Impairment SNOMED CT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.144 | Bed Confinement Impairment | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.145 | Transfer from Bed Impairment | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.146 | Ability to Safely Sit in Chair or Wheelchair Impairment SNOMED CT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.147 | Mobility Impairment or Fall From Chair ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.148 | Ability to Safely Sit in Chair or Wheelchair Impairment | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.149 | Fall or Fall Risk from Wheelchair or Stretcher SNOMED CT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.15 | Cystic Fibrosis Lung Disease | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.150 | Fall or Fall Risk from Wheelchair or Scooter ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.152 | Muscle, Tendon or Joint Contracture Disorder SNOMED CT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.153 | Muscle, Tendon or Joint Contracture Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.154 | Muscle, Tendon or Joint Contracture Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.155 | Muscle Weakness or Myasthenia Gravis Disorder SNOMED CT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.156 | Muscle Weakness or Myasthenia Gravis Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.158 | Myocardial Infarction Disorder SNOMED CT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.159 | Myocardial Infarction Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.16 | Neoplasm of Lung or Trachea Disorder SNOMEDCT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.160 | Myocardial Infarction Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.161 | Amputation Disorder SNOMED CT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.162 | Amputation Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.164 | Lower Extremity Deep Vein Thrombosis Disorder SNOMED CT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.165 | Lower Extremity Deep Vein Thrombosis Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.167 | Spinal Cord Injury or Paralysis Disorder SNOMED CT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.168 | Spinal Cord Injury or Paralysis Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.169 | Spinal Cord Injury or Paralysis Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.17 | Neoplasm of Lung or Trachea Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.170 | Demyelinating Disorder SNOMED CT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.171 | Demyelinating Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.172 | Demyelinating Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.173 | Grade 2, 3 or 4 Decubitus Ulcer on Buttock Disorder SNOMED CT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.174 | Grade 2, 3 or 4 Decubitus Ulcer on Buttock Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.176 | Wound Disorder SNOMED CT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.177 | Wound Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.178 | Wound Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.179 | Danger to Self or Others Disorder SNOMED CT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.18 | Neoplasm of Lung or Trachea Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.180 | Danger to Self or Others Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.181 | Danger to Self or Others Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.182 | Behavioral Disorder Related to Need for Non Emergency Ambulance Transfer SNOMED CT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.183 | Behavioral Disorder Related to Need for Non Emergency Ambulance Transfer ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.184 | Behavioral Disorder Related to Need for Non Emergency Ambulance Transfer | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.185 | Pain on Movement or Joint Pain Disorder SNOMED CT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.186 | Pain in Joint Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.187 | Pain on Movement or Joint Pain Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.188 | Non Emergency Ambulance Transport Reason | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.189 | Osteoarthritis Disorder SNOMED CT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.19 | Secondary Erythrocytosis Disorder SNOMEDCT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.190 | Osteoarthritis Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.191 | Osteoarthritis Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.192 | Immunosuppressive Medication RxNorm | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.193 | Medication Supporting Immunosupressive Medication RxNorm | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.194 | Non Emergency Ambulance Transport Qualifying Procedure | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.197 | Turalio | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.198 | Hepatic Medical History | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.2 | Bronchiectasis Disorder ICD10CM | active | 2020-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.20 | Secondary Erythrocytosis Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.21 | Secondary Erythrocytosis Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.22 | Acute or Chronic Heart Failure Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.23 | Acute or Chronic Heart Failure Disorder SNOMEDCT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.24 | Acute or Chronic Heart Failure Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.25 | Home Oxygen Therapy Qualifying Condition | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.26 | Device Use Patient Activity Level | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.27 | Portable Liquid Oxygen Therapy Device | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.28 | Stationary Liquid Oxygen Therapy Device | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.29 | Sleep Apnea or Breathing Related Sleep Disorder SNOMEDCT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.3 | Bronchiectasis Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.30 | Sleep Apnea or Breathing Related Sleep Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.31 | Sleep Apnea or Breathing Related Sleep Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.32 | Positive Airway Pressure Device | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.33 | Diabetes Mellitus Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.34 | Diabetes Mellitus Disorder SNOMEDCT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.35 | Diabetes Mellitus Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.36 | Restrictive Lung Disease SNOMEDCT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.37 | Restrictive Lung Disease ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.38 | Restrictive Lung Disease | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.39 | Chest Wall Deformity Disorder SNOMEDCT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.4 | Chronic Obstructive Lung Disease (COPD) ICD10CM | active | 2020-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.40 | Chest Wall Deformity Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.41 | Chest Wall Deformity Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.42 | Motor Neuron Disease or Spinal Muscular Atrophy Disorder SNOMEDCT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.43 | Motor Neuron Disease or Spinal Muscular Atrophy Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.44 | Motor Neuron Disease or Spinal Muscular Atrophy Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.45 | Chronic Respiratory Failure Disorder SNOMEDCT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.46 | Chronic Respiratory Failure Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.47 | Chronic Respiratory Failure Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.48 | Ventilator Therapy Qualifying Condition | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.49 | Ventilator Device | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.5 | Chronic Obstructive Lung Disease SNOMEDCT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.50 | Fixed Height Hospital Bed Supply | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.51 | Variable Height Hospital Bed Supply | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.52 | Semi electric Hospital Bed Supply | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.53 | Heavy Duty Extra Wide Hospital Bed Supply | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.54 | Extra Heavy Duty Hospital Bed Supply | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.55 | Hospital Bed Trapeze Accessory Supply | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.56 | Hospital Bed Cradle Accessory Supply | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.57 | Hospital Bed Side Rail or Safety Enclosure Supply | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.58 | Hospital Bed Supply | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.59 | Intermittent Urinary Catheter or Urological Supply for Intermittent Urinary Catheter Supply | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.6 | Chronic Obstructive Lung Disease (COPD) | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.60 | Indwelling Urinary Catheter Supply or Urological Supply for Indwelling Urinary Catheter Supply | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.61 | Urinary Collection and Irrigation System Device or Supply | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.62 | External Catheter or Urinary Collection Device | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.63 | Miscellaneous Urinary Catheter Supply | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.64 | Urinary Incontinence Disorder SNOMEDCT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.65 | Urinary Incontinence ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.66 | Urinary Incontinence Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.67 | Chronic Urinary Retention Disorder SNOMEDCT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.68 | Urinary Retention Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.69 | Chronic Urinary Retention Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.7 | Hypoxemia Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.70 | Urinary Incontinence or Chronic Urinary Retention Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.72 | Portable Compressed Gas Oxygen Therapy Device | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.73 | Stationary Oxygen Concentrator Therapy Device | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.74 | Compressed Gas Oxygen Therapy Device | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.75 | Stationary Compressed Gas Oxygen Therapy Device | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.76 | Portable Oxygen Concentrator Therapy Device | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.77 | Liquid Oxygen Therapy Device | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.78 | Oxygen Concentrator Therapy Device | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.79 | Portable Oxygen Therapy Device | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.8 | Hypoxemia Disorder SNOMEDCT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.80 | Stationary Oxygen Therapy Device | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.81 | Organ Transplant History Significant to Immunosuppressive Therapy | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.82 | Immunosuppressive Medication HCPCS | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.83 | Medication Supporting Immunosuppressive Medication HCPCS | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.84 | Home Blood Glucose Monitor Device | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.85 | Insulin Medication | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.86 | Hyperglycemia or Hypoglycemia Disorder SNOMEDCT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.87 | Hyperglycemia or Hypoglycemia Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.88 | Hyperglycemia or Hypoglycemia Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.89 | Diabetic Test Strip or Lancet Supply | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.9 | Hypoxemia Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.90 | Organ Transplant Procedure Significant to Immunosuppressive Therapy | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.91 | Pulmonary Hypertension Disorder SNOMEDCT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.92 | Pulmonary Hypertension Disorder ICD10CM | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.93 | Pulmonary Hypertension Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.94 | Laboratory Test for Home Glucose Monitor Evaluation | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.95 | Physical Therapy Procedure SNOMED CT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.96 | Occupational Therapy Procedure SNOMED CT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.97 | Speech Language Therapy Procedure SNOMED CT | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.98 | Physical Therapy Procedure HCPCS | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.99 | Physical Therapy Procedure | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.135 | Last Menstrual Period (LMP) | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.146 | Abortion, All (ICD 10 CM) | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.149 | Abortion, All (SNOMED CT) | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.150 | Abortion, All | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.151 | Abortion, All (CPT) | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.152 | Abortion, 1st Trimester | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.153 | Abortion, 2nd Trimester | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.154 | Abortion, 2nd Trimester | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.155 | Abortion, 3rd Trimester | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.156 | Abortion, Elective | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.157 | Abortion, Elective | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.158 | Abortion, Failed Attempt | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.159 | Abortion, Induced | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.160 | Abortion, Induced | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.161 | Abortion, Induced | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.162 | Abortion, Medical Management | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.163 | Abortion, Medical Management | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.164 | Abortion, Medical Management | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.165 | Abortion, Elective | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.166 | Abortion, Surgical Management | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.167 | Abortion, Surgical Management | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.168 | Abortion, Surgical Management | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.169 | Abortion, Spontaneous / Miscarriage | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.170 | Abortion, Spontaneous / Miscarriage | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.171 | Abortion, Spontaneous / Miscarriage | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.172 | Contraception, Counseling | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.173 | Contraception, Counseling | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.174 | Contraception, Counseling | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.175 | Contraception, Counseling | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.176 | Methotrexate Injection | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.177 | Mifepristone | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.178 | Misoprostol | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.179 | Abortion Medications | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.180 | Contraception, Surveillance | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.181 | Contraception, Surveillance | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.182 | Contraception, Surveillance | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.183 | Clomiphene (Selective Estrogen Receptor Modulator / SERM) | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.184 | Letrozole (Aromatase inhibitor) | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.185 | Infertility, Female Medications | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.186 | Infertility, Female | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.187 | Infertility, Female | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.188 | Infertility, Female | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.189 | Infertility, Male | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.190 | Infertility, Male | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.191 | Infertility, Male | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.192 | Infertility, All | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.193 | Gender Dysphoria | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.194 | Gender Identity | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.195 | Intersex Surgery, History | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.196 | Intersex Surgery, Non specific | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.197 | Intersex Surgery, Female to Male | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.198 | Intersex Surgery, Female to Male | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.199 | Intersex Surgery, Female to Male | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.200 | Intersex Surgery, Male to Female Sex | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.201 | Intersex Surgery, Male to Female Sex | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.202 | Intersex Surgery, Male to Female Sex | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.203 | Intersex Surgery, All | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.204 | Pregnancy Labs, Blood/Serum/Plasma/Urine | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.205 | Stillbirth | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.206 | Stillbirth | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.208 | Sexual Orientation | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.209 | Transfeminine Regimens, Antiandrogens | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.210 | Transfeminine Regimens, Estrogens | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.211 | Transfeminine Regimens, GnRH Agonists | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.212 | Transfeminine Regimens, All | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.213 | Transmasculine Regimens, Testosterone, Transdermal | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.214 | Transmasculine Regimens, Testosterone, Parenteral | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.215 | Transmasculine Regimens, All | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1221.216 | Abortion, 1st Trimester | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.100 | Sleep Apnea Disorders SCT | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1005 | Sexual Satisfaction | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.101 | Sleep Apnea Disorders ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1015 | Substance Use | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1016 | Tobacco Use | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.102 | Sleep Apnea Disorders | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1020 | Screen Time | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1022 | Fluid Management | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1023 | Fat Intake | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1024 | Unsaturated Fat Intake | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1025 | Saturated Fat Intake | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1026 | Carbohydrate Intake | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1027 | Salt Intake | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1028 | Vegetable Intake | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1029 | Fruit Intake | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.103 | PostTraumatic Stress Disorder PTSD | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1030 | English Proficiency | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.104 | PostTraumatic Stress Disorder PTSD ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1042 | Neglect | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1048 | Current or Former Occupation | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.105 | PostTraumatic Stress Disorder PTSD SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1050 | Work Productivity | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1053 | Income Level | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1057 | Caregiver Characteristics | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1058 | Caregiver Availability | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1060 | Living Situation | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1064 | Marital or Spousal Status | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1065 | Dependents in Home | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1068 | Physical Activity Level | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1069 | Leisure Activity Engagement | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1075 | Exposure to Environmental Hazards | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1076 | Neighborhood Safety | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1080 | Experiences of Discrimination | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1082 | Criminal Justice Involvement or Incarceration | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1083 | Immigration Status | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.111 | Creatinine in blood, serum or plasma | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.113 | Blood Urea Nitrogen | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.114 | Hemoglobin | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.118 | Iron Saturation (Transferrin Saturation/TSAT) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.119 | Hemoglobin A1C | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1197 | Sleep Behavior | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.120 | Potassium in blood, serum or plasma | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1203 | Medication Literacy | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1213 | Elder and Child Abuse SCT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.122 | Corrected Calcium | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1229 | Education Level SCT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.123 | Phosphorus in blood, serum or plasma | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.126 | Vitamin D Levels | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.128 | KT/V Hemodialysis Ratio | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1281 | Elder and Child Abuse | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.129 | Intact Parathyroid Hormone | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.130 | Bicarbonate in blood, serum or plasma | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.131 | Sodium in blood, serum or plasma | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.132 | Chloride in blood, serum or plasma | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1336 | Elder and Child Abuse ICD10 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.135 | High Density Lipoprotein | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.137 | Triglyceride in blood, serum or plasma | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1375 | Tinnitus | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1377 | Brain Fog | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1378 | Depression Symptoms | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1379 | Mood Swings | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.138 | Cystatin C | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1380 | Anxiety | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1381 | Lightheadedness | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1382 | Stress | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1383 | Grief and Suffering | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1384 | Insomnia and Other Sleep Difficulties | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1385 | Impaired Sense of Taste | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1386 | Pink Eye Diagnosis SCT | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1387 | Pink Eye Diagnosis ICD10 | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1388 | Pink Eye Diagnosis | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.139 | Total Cholesterol | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1392 | Lymphadenopathy Diagnosis SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1393 | Lymphadenopathy Diagnosis ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1394 | Lymphadenopathy Diagnosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1395 | Visual Changes | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1396 | Impaired Sense of Smell | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1398 | Fatigue | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1399 | Chills | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.140 | Ferritin | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1400 | Fever | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1401 | Functional and Mobility Impairment | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1403 | Orthostatic Intolerance | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1405 | Cough | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1406 | Dyspnea | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1409 | Wheezing | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.141 | Red Blood Cell Count (Erythrocytes) | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1413 | Sinonasal Congestion | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1414 | Respiratory Distress | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1415 | Edema | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1419 | Weight Changes | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.142 | White Blood Cell (Leukocytes) Count | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1422 | Immunologic Changes | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1424 | Pain | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1425 | Arthralgia | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1426 | Chest Pain | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1427 | Headache | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1428 | Myalgia | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1429 | Back Pain | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.143 | Hematocrit | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1430 | Pain in Extremities | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1431 | Pain in Throat | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1432 | Palpitations | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1433 | Tachycardia | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1434 | Bleeding | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1435 | Abdominal Pain | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1436 | Diarrhea | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1437 | Gastroesophageal Reflux | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1438 | Nausea | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1439 | Vomiting | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.144 | Mean Corpuscular Volume | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1440 | Constipation | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1441 | Difficulty Swallowing | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1442 | Bronchiectasis Diagnosis ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1443 | Loss of Appetite | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1444 | Paresthesia | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1445 | Rash | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1446 | Covid Toes (Toes and/or Fingers) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1447 | Itching | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1448 | Menstrual Cycle Irregularities | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1449 | Lower Urinary Tract Symptoms | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.145 | Mean Corpuscular Hemoglobin Concentration | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1450 | Urinary Incontinence | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1451 | Dizziness | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1453 | Hair Loss | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1455 | Disability Severity | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1456 | Hypercoagulability | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1457 | Post Exertional Malaise | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1458 | Chronic Pain | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1459 | Neurogenic Pain | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.146 | Platelet Count | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1460 | Impaired Hearing | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1461 | Parkinsonia Like Symptoms | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1462 | Bronchiectasis Diagnosis SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1463 | Bronchiectasis Diagnosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1464 | Chronic obstructive pulmonary disease (COPD) Diagnosis SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1465 | Chronic obstructive pulmonary disease (COPD) Diagnosis ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1466 | Chronic obstructive pulmonary disease (COPD) Diagnosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1467 | Interstitial lung disease Diagnosis SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1468 | Interstitial lung disease Diagnosis ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1469 | Interstitial lung disease Diagnosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.147 | Erythrocyte Distribution Width | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1470 | Asthma Diagnosis SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1471 | Asthma Diagnosis ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1472 | Asthma Diagnosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1473 | Fibromyalgia Diagnosis SCT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1474 | Fibromyalgia Diagnosis ICD10 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1475 | Fibromyalgia Diagnosis | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1476 | Herpes zoster Diagnosis ICD10 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1477 | Herpes zoster Diagnosis SCT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1478 | Herpes zoster | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1479 | Pulmonary embolism Diagnosis SCT | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.148 | Platelet Distribution Width | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1480 | Pulmonary embolism Diagnosis ICD10 | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1481 | Pulmonary embolism Diagnosis | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1482 | Hypertension, Pulmonary Hypertension SCT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1483 | Hypertension, Pulmonary Hypertension Diagnosis ICD10 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1484 | Hypertension, Pulmonary Hypertension | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1485 | Language and Speech Problems | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1486 | Postural tachycardia syndrome (POTS) Diagnosis SCT | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1487 | Postural tachycardia syndrome (POTS) Diagnosis ICD10 | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1488 | Postural tachycardia syndrome (POTS) Diagnosis | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1489 | Functional disorder of gastrointestinal tract Diagnosis SCT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.149 | Platelet Mean Volume | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1490 | Functional disorder of gastrointestinal tract Diagnosis ICD10 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1491 | Functional disorder of gastrointestinal tract Diagnosis | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1492 | Autonomic dysfunction | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1496 | Mast Cell Activation Syndrome (MCAS) Diagnosis SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1497 | Mast Cell Activation Syndrome (MCAS) Diagnosis ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1498 | Mast Cell Activation Syndrome (MCAS) Diagnosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.150 | Estimated Average Glucose | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1500 | Debility or Frailty SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1501 | Debility or Frailty ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1502 | Debility or Frailty | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1503 | Ehlers Danlos syndrome (EDS) Diagnosis SCT | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1504 | Ehlers Danlos syndrome (EDS) Diagnosis ICD10 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1505 | Ehlers Danlos syndrome (EDS) Diagnosis | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1506 | Malnutrition Diagnosis SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1507 | Malnutrition Diagnosis ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1508 | Narcolepsy Diagnosis SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1509 | Narcolepsy Diagnosis ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.151 | Albumin in Blood, Plasma, or Serum | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1510 | Narcolepsy | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1514 | Small Fiber Neuropathy Diagnosis SCT | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1515 | Small Fiber Neuropathy Diagnosis ICD10 | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1516 | Small Fiber Neuropathy Diagnosis | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1517 | Malnutrition Diagnosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1518 | Neuropathy Diagnosis | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1519 | Multisystem Inflammatory Syndrome in Adults (MIS A) Diagnosis SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1520 | Multisystem Inflammatory Syndrome in Adults (MIS A) ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1521 | Multisystem Inflammatory Syndrome in Adults (MIS A) Diagnosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1522 | Congestive heart failure Diagnosis SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1523 | Congestive heart failure Diagnosis ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1524 | Congestive heart failure Diagnosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1525 | Cognitive disorder Diagnosis ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1526 | Cognitive disorder SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1527 | Post Acute Sequelae of Sars Cov 2 infection (PASC) SCT | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1529 | Post Acute Sequelae of Sars Cov 2 infection (PASC) ICD10 | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.153 | Anion Gap | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1530 | Post Acute Sequelae of Sars Cov 2 infection (PASC) Diagnosis | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1531 | Hypertension, Persistent SCT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1532 | Acute Renal Failure Diagnosis SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1533 | Acute Renal Failure Diagnosis ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1534 | Acute Renal Failure Diagnosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1535 | Complication due to Diabetes Mellitus Diagnosis SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1536 | Complication due to Diabetes Mellitus Diagnosis ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1537 | Complication due to Diabetes Mellitus Diagnosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1538 | Coronary Revascularization History SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1539 | Coronary Revascularization History ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.154 | Urine Urea Nitrogen | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1540 | Coronary Revascularization History | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1541 | Heart Failure Diagnosis SCT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1542 | Heart Failure Diagnosis ICD10 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1543 | Heart Failure Diagnosis | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1547 | Hypertension, Primary and Secondary Diagnosis | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1548 | Cerebrovascular Disease Diagnosis SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1549 | Cerebrovascular Disease Diagnosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.155 | Bone Density | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1550 | Migraine Diagnosis SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1551 | Migraine Diagnosis ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1552 | Migraine Diagnosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1553 | Chronic Tension type Headache Diagnosis SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1554 | Chronic Tension type Headache Diagnosis ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1555 | Chronic Tension type Headache Diagnosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1556 | Low Back Pain SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1557 | Low Back Pain ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1558 | Low Back Pain | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1559 | Metabolic Syndrome Diagnosis SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.156 | Bone Survey X Rays | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1560 | Metabolic Syndrome Diagnosis ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1561 | Metabolic Syndrome Diagnosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1562 | Hypertension, Persistent ICD10 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1563 | Hypertension, Persistent | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1564 | Pregnancy SCT | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1565 | Pregnancy ICD10 | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1566 | Pregnancy | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1568 | Low Density Lipoprotein | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1569 | Physical findings of the abdomen | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.157 | Chronic Kidney Disease All Stages (1 through 5) SNOMED | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1571 | Chest US | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1572 | Sleep Disorder Assessment | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1573 | Cerebral Spinal Fluid (CSF) Analysis | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1574 | Comprehensive Metabolic Panel (CMP) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1575 | Arterial Blood Gas (ABG) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1576 | Coagulation Assay (PT, aPTT, Fibrinogen) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1577 | D Dimer Test | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1578 | Procalcitonin in Blood, Serum, or Plasma | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1579 | Creatine Kinase (CK, CK MB) in Blood, Serum, or Plasma | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.158 | Chronic Kidney Disease All Stages (1 through 5) ICD10CM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1580 | COVID 19 (SARS CoV 2), SARS CoV, Influenza virus A and B Tests | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1581 | Microorganisms Detection by Blood Culture | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1582 | Microorganisms Detection by Sputum Culture | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1583 | Cystography | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1584 | Cognitive Health Related Questionnaire Panel Codes | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1585 | Alcohol Use Related Questionnaire Panel Codes | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1586 | Functional Status Related Questionnaire Panel Codes | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1587 | Kidney Disease Related Questionnaire Panel Codes | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1588 | Long Covid Related Questionnaire Panel Codes | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1589 | Nutrition Status Related Questionnaire Panel Codes | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.159 | Chronic Kidney Disease All Stages (1 through 5) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1590 | Pain Perception Related Questionnaire Panel Codes | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1591 | Patient Goal Related Questionnaire Panel Codes | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1592 | Social Determinant of Health Related Questionnaire Panel Codes | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1593 | Covid 19 Related Health Questionnaire Panel Codes | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1594 | Caregiver Considerations Related Questionnaire Panel Codes | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1595 | Acute COVID 19 Diagnosis SCT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1597 | Drugs of Abuse Screen | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1598 | Criminal Justice Involvement or Incarceration History | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1599 | Cardiomyopathy Diagnosis SCT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1600 | Cardiomyopathy Diagnosis ICD10 | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1601 | Atherosclerotic Cardiovascular Disease SCT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1602 | Neuropathy Diagnosis ICD10 | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1603 | Neuropathy Diagnosis SCT | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1605 | Left Ventricular Hypertrophy ICD10 | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1606 | Left Ventricular Hypertrophy | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1607 | Alanine Aminotransferase (ALT) in Blood, Plasma, or Serum | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1608 | Aspartate Aminotransferase (AST) in Blood, Plasma, or Serum | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1609 | Erythrocyte Sedimentation Rate (ESR) in Blood | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.1610 | Oxygen Saturation in Blood | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.176 | Urine Sediment | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.179 | Estimated Glomerular Filtration Rate (eGFR) | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.22 | Alcohol Use Disorder SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.23 | Alcohol Use Disorder ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.24 | Alcohol Use Disorder | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.25 | Peripheral Vascular Disease SCT | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.26 | Peripheral Vascular Disease ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.27 | Peripheral Vascular Disease | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.28 | Hepatitis C Condition SCT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.30 | Hepatitis C Conditions | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.31 | Diabetic Neuropathy SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.32 | Diabetic Neuropathy ICD10CM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.33 | Diabetic Neuropathy Conditions | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.35 | Obesity ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.36 | Obesity Conditions | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.37 | Obesity SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.4 | Chronic Kidney Disease Type or Cause SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.41 | Tuberculosis (Disorders) SCT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.417 | Prediabetes (Borderline Diabetes) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.418 | Prediabetes (Borderline Diabetes) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.419 | Prediabetes (Borderline Diabetes) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.420 | Maturity Onset Diabetes of the Young (MODY) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.43 | Tuberculosis Disorders | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.44 | Tuberculosis (Disorders) Ext | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.45 | Hypoalbuminemia Conditions SCT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.450 | CKD Progression Risk | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.46 | Hypoalbuminemia Conditions ICD10 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.47 | Hypoalbuminemia Conditions | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.48 | Hyperkalemia Conditions SCT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.480 | Diabetic Coma | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.481 | Diabetic Coma | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.482 | Diabetic Coma | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.49 | Hyperkalemia Conditions ICD10 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.490 | Diabetic Peripheral Angiopathy | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.491 | Diabetic Peripheral Angiopathy | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.492 | Diabetic Peripheral Angiopathy | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.496 | Cataract of the Eye | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.497 | Cataract of the Eye | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.498 | Cataract of the Eye | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.499 | Rubeosis Iridis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.5 | Chronic Kidney Disease Type or Cause ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.50 | Hyperkalemia Conditions | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.500 | Rubeosis Iridis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.501 | Rubeosis Iridis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.502 | Rubeosis Iridis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.506 | Emotional Distress caused by Chronic Condition | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.507 | Emotional Distress caused by Chronic Condition | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.508 | Emotional Distress caused by Chronic Condition | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.51 | Anemia Conditions SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.510 | Hypoglycemic Event | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.512 | Hypoglycemic Event | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.513 | Hypoglycemic Event | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.514 | Hypoglycemia Unawareness | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.515 | Hyperglycemic Hyperosmolar Nonketotic Syndrome HHNS | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.516 | Hyperglycemic Hyperosmolar Nonketotic Syndrome HHNS | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.517 | Hyperglycemic Hyperosmolar Nonketotic Syndrome HHNS | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.518 | Ketoacidosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.519 | Ketoacidosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.52 | Anemia Conditions ICD10 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.520 | Ketoacidosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.521 | Diabetic Foot | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.522 | Diabetic Foot | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.523 | Diabetic Foot | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.524 | Diabetic Foot Ulcer | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.525 | Diabetic Foot Ulcer | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.526 | Diabetic Foot Ulcer | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.529 | Charcot Foot | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.53 | Anemia Conditions | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.530 | Charcot Foot | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.531 | Charcot Foot | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.533 | Cellulitis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.535 | Diabetic Hand or Diabetic Cheiroarthropathy | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.538 | Necrobiosis Lipoidica (Skin Lesions) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.539 | Necrobiosis Lipoidica (Skin Lesions) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.540 | Necrobiosis Lipoidica (Skin Lesions) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.541 | Gangrene | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.542 | Gangrene | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.543 | Gangrene | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.544 | Dupuytren's Contracture | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.545 | Dupuytren's Contracture | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.546 | Dupuytren's Contracture | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.547 | Scleroderma or Thick Skin Syndrome | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.548 | Scleroderma or Thick Skin Syndrome | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.549 | Scleroderma or Thick Skin Syndrome | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.554 | Acanthosis Nigricans | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.555 | Acanthosis Nigricans | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.556 | Acanthosis Nigricans | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.557 | Eruptive Xanthomatosis | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.558 | Periodontitis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.559 | Periodontitis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.560 | Periodontitis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.561 | Amputated Limb (Not Traumatic) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.562 | Amputated Limb (Not Traumatic) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.563 | Amputated Limb (Not Traumatic) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.564 | Hypertension, Essential or Primary ICD10 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.565 | Hypertension, Essential or Primary SCT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.567 | Hypertension, Secondary ICD10 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.568 | Hypertension, Secondary SCT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.571 | Hypertension Stage | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.579 | Cardiomyopathy | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.58 | Hypercalcemia Conditions SCT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.580 | NYHA Heart Failure Functional Classifications | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.581 | American Heart Association Heart Failure Stage | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.582 | Framingham Risk Assessments | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.583 | American College of Cardiology or American Heart Association Ascvd Risk Score (acc/aha Ascvd Risk) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.584 | Atherosclerotic Cardiovascular Disease | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.586 | Gout | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.587 | Psoriatic Arthritis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.588 | Reactive Arthritis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.59 | Hypercalcemia Conditions ICD10 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.590 | Experience of Traumatic Events | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.591 | Cannabis Use | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.592 | Hearing Impairment | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.6 | Chronic Kidney Disease Type or Cause | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.60 | Hypercalcemia Conditions | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.606 | Angina | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.607 | Angina | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.608 | Angina | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.609 | Unstable Angina | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.61 | Hypocalcemia Conditions | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.610 | Unstable Angina | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.611 | Unstable Angina | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.613 | Ischemic Heart Disease | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.614 | Ischemic Heart Disease | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.615 | Left Ventricular Hypertrophy SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.616 | Stroke History | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.618 | Stroke | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.619 | Transient Ischemic Attack | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.62 | Hypocalcemia Conditions ICD10 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.620 | Transient Ischemic Attack | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.621 | Transient Ischemic Attack | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.625 | Aneurysm | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.626 | Aneurysm | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.627 | Aneurysm | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.63 | Hypocalcemia Conditions SCT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.634 | Aortic Disease | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.635 | Aortic Disease | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.636 | Aortic Disease | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.637 | Carotid Stenosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.638 | Carotid Stenosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.639 | Carotid Stenosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.64 | Hyperphosphatemia Conditions SCT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.640 | Intracranial Stenosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.641 | Intracranial Stenosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.642 | Intracranial Stenosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.643 | Pulmonary Edema | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.644 | Pulmonary Edema | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.645 | Pulmonary Edema | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.646 | Osteoarthritis (Oa) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.647 | Osteoarthritis (Oa) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.648 | Osteoarthritis (Oa) | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.649 | Rheumatoid Arthritis (Ra) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.65 | Hyperphosphatemia Conditions ICD10 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.650 | Rheumatoid Arthritis (Ra) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.651 | Rheumatoid Arthritis (Ra) | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.652 | Infectious Arthritis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.653 | Infectious Arthritis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.654 | Infectious Arthritis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.656 | Temporomandibular Disorder Diagnosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.658 | Irritable Bowel Syndrome | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.659 | Irritable Bowel Syndrome | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.66 | Hyperphosphatemia Conditions | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.660 | Irritable Bowel Syndrome | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.661 | Neuropathic Pain (Neuralgia) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.662 | Neuropathic Pain (Neuralgia) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.663 | Neuropathic Pain (Neuralgia) | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.664 | Neuromas | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.665 | Neuromas | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.666 | Neuromas | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.667 | Phantom Pain | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.668 | Phantom Pain | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.669 | Phantom Pain | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.67 | Hematuria Conditions | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.670 | Entrapment Neuropathy | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.671 | Entrapment Neuropathy | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.672 | Entrapment Neuropathy | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.673 | Myalgic Encephalomyelitis or Chronic Fatigue Syndrome | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.674 | Myalgic Encephalomyelitis or Chronic Fatigue Syndrome | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.675 | Myalgic Encephalomyelitis or Chronic Fatigue Syndrome | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.676 | Psychotic Depression | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.677 | Psychotic Depression | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.678 | Psychotic Depression | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.679 | Post Partum Depression | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.68 | Hematuria Conditions ICD10 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.680 | Post Partum Depression | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.681 | Post Partum Depression | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.682 | Seasonal Affective Disorder | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.683 | Seasonal Affective Disorder | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.684 | Seasonal Affective Disorder | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.685 | Psychological Trauma | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.686 | Psychological Trauma | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.687 | Psychological Trauma | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.688 | Grief or Loss | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.689 | Grief or Loss | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.69 | Hematuria Conditions SCT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.690 | Grief or Loss | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.691 | Suicide Risk | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.692 | Suicide Risk | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.693 | Suicide Risk | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.694 | Vaping | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.695 | Vaping | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.696 | Vaping | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.697 | Tobacco Use or Exposure | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.699 | Tobacco Use or Exposure | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.70 | Metabolic Acidosis Conditions | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.701 | Binge Drinking | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.702 | Binge Drinking | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.703 | Binge Drinking | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.704 | Drug Misuse | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.705 | Drug Misuse | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.706 | Drug Misuse | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.707 | Drug Misuse | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.708 | Sensory Status | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.709 | Sensory Status | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.71 | Metabolic Acidosis Conditions ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.711 | Fall Risk | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.713 | Lower Urinary Tract Symptoms (LUTS) From Benign Prostatic Hyperplasia | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.714 | Lower Urinary Tract Symptoms (LUTS) From Benign Prostatic Hyperplasia | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.715 | Lower Urinary Tract Symptoms (LUTS) From Benign Prostatic Hyperplasia | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.716 | Urinary Incontinence | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.717 | Urinary Incontinence | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.718 | Urinary Incontinence | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.719 | Urinary Urgency | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.72 | Metabolic Acidosis Conditions SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.720 | Urinary Urgency | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.721 | Urinary Urgency | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.722 | Urinary Frequency | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.723 | Urinary Frequency | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.724 | Urinary Frequency | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.725 | Nocturia | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.726 | Nocturia | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.727 | Nocturia | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.728 | Pelvic Organ Prolapse | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.729 | Pelvic Organ Prolapse | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.73 | Hyperlipidemia Conditions | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.730 | Pelvic Organ Prolapse | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.731 | Erectile Dysfunction | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.732 | Erectile Dysfunction | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.733 | Erectile Dysfunction | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.734 | Interstitial Cystitis or Bladder Pain Syndrome | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.735 | Interstitial Cystitis or Bladder Pain Syndrome | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.736 | Interstitial Cystitis or Bladder Pain Syndrome | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.737 | Recurrent Urinary Tract Infections | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.738 | Recurrent Urinary Tract Infections | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.739 | Recurrent Urinary Tract Infections | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.74 | Hyperlipidemia Conditions ICD10 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.740 | Hypertriglyceridemia | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.741 | Hypertriglyceridemia | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.742 | Hypertriglyceridemia | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.743 | Hypothyroidism | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.744 | Hypothyroidism | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.745 | Hypothyroidism | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.746 | Menopause | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.747 | Menopause | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.748 | Menopause | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.749 | Testicular Hypofunction | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.75 | Hyperlipidemia Conditions SCT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.750 | Testicular Hypofunction | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.751 | Testicular Hypofunction | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.752 | Primary Aldosteronism | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.753 | Primary Aldosteronism | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.754 | Primary Aldosteronism | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.755 | Restless Leg Syndrome | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.756 | Restless Leg Syndrome | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.757 | Restless Leg Syndrome | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.759 | Claudication | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.76 | Chronic Pain Conditions | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.760 | Claudication | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.761 | Claudication | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.762 | Angioedema | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.763 | Angioedema | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.764 | Angioedema | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.768 | Nonalcoholic Fatty Liver Disease | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.769 | Nonalcoholic Fatty Liver Disease | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.77 | Chronic Pain ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.770 | Nonalcoholic Fatty Liver Disease | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.771 | Thalassemia | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.772 | Thalassemia | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.773 | Thalassemia | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.78 | Chronic Pain SCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.79 | Arthritis Disorders SCT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.790 | Urine Protein to Creatinine Ratio (UPCR) | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.791 | 24 Hour Urine Volume | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.792 | 24 Hour Urine Protein Excretion | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.793 | Total Carbon Dioxide or Bicarbonate in blood, serum or plasma | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.794 | Calcium (Not Corrected for Serum Albumin) in Blood, Plasms, or Serum | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.795 | B Type Natriuretic Peptide [Bnp] in Blood, Serum or Plasma | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.797 | N Terminal Pro_B_Type Natriuretic Peptide [Nt_Probnp] in blood, serum or plasma | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.799 | Temporomandibular Disorder Diagnosis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.80 | Arthritis Disorders ICD10 | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.800 | Temporomandibular Disorder Diagnosis | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.801 | High Sensitivity Troponin | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.804 | Aspartate Transaminase or Alanine Aminotransferase Ratio | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.805 | Alkaline Phosphatase (Alp) in Blood, Serum or Plasma | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.806 | Gamma Glutamyl Transpeptidase (Ggt) in blood, serum or plasma | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.807 | Triiodothyronine in serum or plasma | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.808 | Fasting Blood Glucose | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.809 | Random Blood Glucose Test | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.81 | Arthritis Disorders | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.261 | Incarceration Status Service Requests | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.262 | Language Access Diagnoses | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.263 | Language Access Diagnoses ICD10CM | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.264 | Language Access Diagnoses SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.265 | Language Access Goals SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.266 | Language Access Goals | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.267 | Language Access Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.268 | Language Access Procedures | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.269 | Language Access Service Requests | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.27 | Transportation Insecurity Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.270 | Language Access Screening Assessments | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.271 | Language Access Screening Assessments Answers | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.272 | Language Access Screening Assessments Questions | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.273 | Language Access Screening Assessments And Questions | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.28 | Transportation Insecurity Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.29 | Financial Insecurity Goals SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.3 | Food Insecurity Diagnoses ICD10CM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.30 | Financial Insecurity Goals | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.31 | Financial Insecurity Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.32 | Financial Insecurity Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.33 | Material Hardship Diagnoses ICD10CM | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.34 | Material Hardship Diagnoses SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.35 | Material Hardship Diagnoses | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.36 | Material Hardship Goals SNOMED CT | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.37 | Material Hardship Goals | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.38 | Material Hardship Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.39 | Material Hardship Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.4 | Food Insecurity Goals SNOMED CT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.40 | Unemployment Diagnoses ICD10CM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.41 | Unemployment Diagnoses SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.42 | Unemployment Diagnoses | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.43 | Housing Instability Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.44 | Housing Instability Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.45 | Housing Instability Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.46 | Inadequate Housing Diagnoses SNOMED CT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.47 | Inadequate Housing Diagnoses ICD10CM | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.48 | Inadequate Housing Diagnoses | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.49 | Inadequate Housing Goals SNOMED CT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.5 | Social Determinants of Health General Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.50 | Inadequate Housing Goals | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.51 | Inadequate Housing Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.52 | Inadequate Housing Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.53 | Inadequate Housing Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.54 | Less Than High School Education Goals SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.55 | Less Than High School Education Goals | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.56 | Less Than High School Education Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.57 | Less Than High School Education Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.58 | Unemployment Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.59 | Unemployment Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.6 | Food Insecurity Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.60 | Unemployment Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.61 | Elder Abuse Diagnoses ICD10CM | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.62 | Elder Abuse Diagnoses SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.63 | Elder Abuse Diagnoses | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.64 | Elder Abuse Goals SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.65 | Elder Abuse Goals | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.66 | Elder Abuse Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.67 | Elder Abuse Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.68 | Elder Abuse Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.69 | Unemployment Goals SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.7 | Food Insecurity Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.70 | Unemployment Goals | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.71 | Social Determinants of Health Goals | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.72 | Stress Diagnoses SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.73 | Stress Interventions SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.74 | Stress Diagnoses ICD10CM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.75 | Stress Diagnoses | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.76 | Veteran Status Diagnoses SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.77 | Veteran Status Diagnoses ICD10CM | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.78 | Veteran Status Diagnoses | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.79 | Social Connection Diagnoses SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.8 | Social Determinants of Health General Interventions CPT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.80 | Social Connection Diagnoses ICD10CM | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.81 | Social Connection Diagnoses | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.82 | Intimate Partner Violence Diagnoses SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.83 | Intimate Partner Violence Diagnoses ICD10CM | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.84 | Intimate Partner Violence Diagnoses | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.85 | Stress Goals SNOMED CT | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.86 | Stress Goals | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.87 | Stress Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.88 | Social Connection Goals SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.89 | Social Connection Goals | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.9 | Food Insecurity Interventions HCPCS | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.90 | Veteran Status Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.91 | Veteran Status Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.92 | Stress Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.93 | Social Connection Interventions SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.94 | Social Connection Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.95 | Social Connection Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.96 | Intimate Partner Violence Interventions SNOMED CT | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.97 | Intimate Partner Violence Procedures | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.98 | Intimate Partner Violence Service Requests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.99 | Intimate Partner Violence Goals SNOMED CT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.105 | Mechanical Ventilation Procedures | active | 2022-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.106 | Mechanical Ventilation | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.107 | Mechanical Ventilation | active | 2022-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.109 | aPTT Tests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.119 | Opioid Antagonist | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.12 | High Risk Diagnosis for AKI | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.120 | Opioids | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.124 | Immune Modulators | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.130 | Suicide Attempt | active | 2023-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.134 | Central Nervous System Depressants | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.136 | Leukemia or Lymphoma | active | 2022-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.137 | Liver Disease Moderate to Severe | active | 2022-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.138 | COVID19 | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.139 | COVID 19 | active | 2022-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.14 | Hemolytic Uremic Syndrome (HUS) | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.140 | COVID 19 | active | 2022-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.162 | Obesity | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.163 | Antidepressants | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.164 | Antihypertensives | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.165 | Delirium | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.166 | Dementia | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.167 | Psychosis | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.168 | Delirium or Dementia and Other Psychoses | active | 2022-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.169 | Depression | active | 2022-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.170 | Diuretics | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.171 | Epilepsy | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.172 | Neurologic Movement Disorders | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.173 | Neurologic Disorders, Other | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.174 | Neurologic Movement and Related Disorders | active | 2022-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.175 | Peripheral Neuropathy | active | 2022-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.176 | Stroke | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.177 | Abnormal Weight Loss and Malnutrition | active | 2022-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.178 | Intubation | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.179 | Intubation | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.180 | Tracheostomy Procedures | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.181 | Tracheostomy Procedures | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.182 | Head and Neck Surgeries with High Risk Airway Compromise | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.185 | Spinal Surgery | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.187 | Routes of Administration for Opioid Antagonists | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.19 | High Risk Procedures for AKI | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.197 | Hospital Based Dialysis Services | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.198 | Hospital Based Dialysis Services | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.199 | Hospital Based Dialysis Services | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.200 | Nephrectomy | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.201 | Thrombotic Thrombocytopenic Purpura | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.204 | VTE Prophylaxis | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.205 | Moderate Injuries | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.206 | General and Neuraxial Anesthesia | active | 2023-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.207 | General and Neuraxial Anesthesia | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.208 | General and Neuraxial Anesthesia | active | 2023-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.209 | Non Invasive Oxygen Therapy by Nasal Cannula or Mask | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.21 | Creatinine Mass Per Volume | active | 2022-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.210 | Continuous and Bilevel Positive Airway Pressure | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.211 | Continuous and Bilevel Positive Airway Pressure | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.213 | Non Invasive Oxygen Therapy | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.214 | Non Invasive Oxygen Therapy Devices | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.216 | Procedural Hospital Locations | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.217 | ASA physical status class | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.218 | Blood urea nitrogen lab test | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.219 | Hemoglobin lab test | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.22 | Anticoagulants for All Indications | active | 2022-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.220 | Smoking status | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.221 | Albumin lab test | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.222 | Leukocyte count lab test | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.223 | Bilirubin lab test | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.224 | Aspartate transaminase lab test | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.226 | Cardiac Arrest | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.23 | Coagulation Disorders | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.230 | PO Antibacterials | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.231 | Injectable Antifungals | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.238 | Neuromuscular Disorder | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.239 | Neuromuscular Disorder | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.24 | Malignant Bone Disease | active | 2022-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.240 | Degenerative Neurological Disorder | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.241 | Degenerative Neurological Disorder | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.242 | Heart and Lung Transplants | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.243 | Heart and Lung Transplants | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.245 | Lung Resections and Excisions | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.246 | Lung Resections and Excisions | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.247 | Chest Wall Procedures | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.248 | Chest Wall Procedures | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.249 | Maxillary Procedures | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.250 | Maxillary Procedures | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.251 | Head, Neck, and Thoracic Surgeries with High Risk Airway Compromise | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.252 | Anesthesia Requiring Monitored Care | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.253 | Anesthesia Requiring Monitored Care | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.255 | Anesthesia Requiring Monitored Care | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.256 | Osteoporosis | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.260 | Rivaroxaban Anticoagulant | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.262 | Fondaparinux Anticoagulant | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.263 | Dalteparin Anticoagulant | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.264 | Heparin | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.268 | Enoxaparin Anticoagulant | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.271 | Undetectable Lab Result Value | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.272 | Undetectable Lab Result Value | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.274 | Dietary Recommendations | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.275 | Bariatric Procedures | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.276 | Telemedicine Services | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.277 | Prostate Cancer Treatment | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.28 | Traumatic Avulsion of Kidney | active | 2022-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.29 | Rapidly Progressive Nephritic Syndrome | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.301 | LDL Cholesterol | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.33 | Obstetrics and VTE Obstetrics | active | 2022-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.34 | Glucose Lab Test Mass Per Volume | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.349 | Tuberculosis for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.350 | Tuberculosis for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.351 | Tuberculosis for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.352 | Androgen Deprivation Therapy for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.353 | Bacillus Calmette Guerin for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.354 | Bladder Cancer for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.355 | Chemotherapy Agents for Advanced Cancer | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.356 | Cystectomy for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.357 | Cystectomy for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.358 | Cystectomy for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.359 | DEXA Bone Density for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.360 | Hospital Services for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.361 | Immunocompromised Conditions | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.362 | Immunocompromised Conditions | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.363 | Immunocompromised Conditions | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.364 | Immunosuppressive Drugs for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.365 | Mixed Histology Urothelial Cell Carcinoma for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.366 | Morbid Obesity | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.367 | Morbid Obesity | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.368 | Morbid Obesity | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.369 | Unavailability of Bacillus Calmette Guerin for Urology Care | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.370 | Urinary Retention | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.371 | Urinary Retention | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.372 | Urinary Retention | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.374 | Face to Face Interaction | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.375 | Face to Face Interaction | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.376 | HIV Viral Load Tests | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.377 | HIV Viral Load Tests | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.389 | Syphilis Tests | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.4 | Nephrectomy | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.79 | Acute Brain or Spinal Injury or Hemorrhage | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.8 | Large Body Surface Area (BSA) Burns | active | 2022-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.80 | Pulmonary Arterial Thrombectomy | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.81 | Extracorporeal Membrane Oxygenation | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.85 | Elective Inpatient Encounter | active | 2023-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.86 | Intubation | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.88 | Acute Respiratory Failure | active | 2023-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.89 | Tracheostomy Diagnoses | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.90 | Tracheostomy Procedures | active | 2023-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.91 | Neuromuscular Disorder | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.92 | Degenerative Neurological Disorder | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.93 | Head and Neck Surgeries with High Risk Airway Compromise | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.94 | Oxygen Partial Pressure in Arterial Blood | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.95 | Carbon Dioxide Partial Pressure in Arterial Blood | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.96 | Arterial Blood pH | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1250.2 | Psychological Neuropsychological or Neurobehavioral Testing | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1250.3 | Psychological or Neuropsychological Testing | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.10 | Tricuspid Valve Regurgitation | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.12 | Hypertension | active | 2022-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.2 | Valvular Heart Disease | active | 2022-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.22 | Acute Kidney Injury | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.23 | Anemia | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.24 | Cardiac Arrhythmias | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.25 | Attention Deficit and Hyperactivity Disorder | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.26 | Cerebrovascular Disease | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.27 | Seizure Disorder | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.28 | Proteinuria | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.29 | Thyroid Hormone Disorder | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.30 | Thromboembolic Disease | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.31 | Parkinson's Disease and Parkinsonism | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.32 | Upper GI Diseases | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.33 | Failure to Thrive | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.34 | Osteoporosis | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.35 | Mood Disorders | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.36 | Dyslipidemia | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.37 | Heart Failure | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.38 | Coronary Artery Disease | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.39 | Chronic Kidney Disease | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.40 | Chronic Obstructive Pulmonary Disease | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.41 | Diabetes Mellitus | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1254.1 | EventTiming-TimingEvent | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1254.2 | EventTiming-EventTiming | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1258.1 | Gonorrhea Screening | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1258.2 | Abnormal Weight Loss | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.2 | Prescribable brand and generic non insulin drugs for hyperglycemia in Type 2 Diabetes | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.3 | Prescribable brand and generic insulins and analogues | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.4 | eGFR Using 2021 Race Free Formulas | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.5 | Fructosamine in Serum or Plasma | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.6 | Glucose tests in venous blood, capillary blood, serum/plasma for Diabetes | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.7 | Creatinine in serum/plasma | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.9 | IgE Agonists, prescribable | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.10 | Estrogen Receptor Testing for Orserdu | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.100 | MMR Proficient | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.101 | Systemic Cancer Directed Therapy | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.102 | Face To Face Interaction | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.104 | Erdafitinib | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.107 | Chemotherapy Encounter | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.108 | Urothelial Cancers ICD9 | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.109 | Urothelial Cancer ICD10 | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.11 | Estrogen Receptor Test for Orserdu | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.110 | Urothelial Cancers | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.111 | Prior Therapies for Erdafitinib | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.112 | Urothelial Cancer Histologies | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.113 | Malignant Tumor Behavior | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.114 | Localized Bladder Cancer Stage SNOMED | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.116 | Localized Bladder Cancer Staging | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.117 | Advanced Bladder Cancer Stage | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.118 | Localized Bladder Cancer T Stage | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.119 | Localized Bladder Cancer T Stage | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.12 | Negative | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.120 | Localized Bladder Cancer N Stage | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.121 | Localized Bladder Cancer M Stage | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.122 | Advanced Bladder Cancer M Stage | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.124 | Locoregional Urothelial Cancer ICD9 | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.125 | Locoregional Urothelial Cancer ICD10 | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.126 | Locoregional Urothelial Cancer SNOMED | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.127 | Locoregional Urothelial Cancer | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.128 | FGFR3 Gene | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.129 | FGFR3 Gene Interpretation Positive SNOMED | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.13 | HER2 Negative | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.130 | FGFR3 Gene Interpretation Positive LOINC | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.131 | FGFR3 Gene Interpretation Positive NCI | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.133 | FGFR3 Gene Interpretation Positive | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.134 | FGFR3 Gene Interpretation Negative SNOMED | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.135 | FGFR3 Gene Interpretation Negative NCI | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.137 | FGFR3 Gene Interpretation Negative | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.138 | FGFR3 Molecular Variants | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.139 | Tumor Behavior | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.14 | Endocrine Therapy | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.140 | Physcological Support for Cancer | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.141 | Referral For Pain From Cancer | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.142 | Cancer Pain Education | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.143 | Telehealth Encounters | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.144 | Pain Assessment Score | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.146 | Telehealth Encounters SNOMEDCT | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.147 | Telehealth Encounters CPT | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.148 | Telehealth Encounters HCPCS | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.149 | Telehealth Encounters All | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.15 | All Metastatic Sites | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.150 | Chemo Admin SNOMEDCT | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.151 | Chemo Admin CPT | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.152 | Chemo Admin HCPCS | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.153 | Chemotherapy Administration All | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.154 | Radiation Treatment CPT | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.155 | Radiation Treatment HCPCS | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.156 | Radiation Treatment SNOMEDCT | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.157 | Radiation Treatment All | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.158 | Bipolar Diagnosis Codes | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.159 | Telephone Visits SNOMED | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.16 | All Metastatic Sites | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.160 | Telephone Visit CPT | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.161 | Telephone Visits All | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.162 | Adolescent depression screening assessment | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.163 | Adult depression screening assessment LOINC | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.165 | Referral for Depression Adult | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.166 | Referrals for Adolescent Depression | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.167 | Follow Ups for Adolescent Depression | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.168 | FollowUps for Adult Depression | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.169 | Depression Screen Declined for Medical Reason | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.17 | Metastatic Breast Cancer | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.170 | Physical Therapy Evaluations SNOMEDCT | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.171 | Physical Therapy Evaluation CPT | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.172 | Physical Therapies Evaluations | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.173 | Non Opioid Analgesics | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.174 | Adjuvant Analgesics | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.176 | Lung Cancer ICD9 | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.177 | Lung Cancer ICD10 | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.178 | Lung Cancer | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.179 | Prior Therapies for Osimertinib | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.18 | Stage IA | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.181 | Plan of Care for Pain | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.182 | All Antineoplastic Agents | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.183 | Locally Advanced NSCLC Stage Group | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.185 | Localized NSCLC Stage Group SNOMED | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.186 | Radiation Treatment Management | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.187 | Plan of Care | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.188 | Documentation of Plan of Care | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.189 | Pain Present | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.19 | Stage IB | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.190 | Localized NSCLC Stage Group NCIM | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.192 | Localized NSCLC Stage Group | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.193 | Advanced NSCLC Stage Group | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.194 | NSCLC M Stage (metastatic) | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.195 | NSCLC T Stage | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.196 | NSCLC N Stage | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.197 | SCLC and rarer lung cancer histology | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.198 | EGFR Gene | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.199 | EGFR Gene Interpretation Positive SNOMED | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.20 | Stage IIA | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.200 | EGFR Gene Interpretation Positive LOINC | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.201 | EGFR Gene Interpretation Positive | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.202 | EGFR Osimertinib Molecular Variants | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.203 | EGFR Generic Molecular Variant NCIM | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.204 | EGFR Generic Molecular Variant SNOMED | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.205 | EGFR Generic Molecular Variant LOINC | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.206 | EGFR Molecular Variants Osimertinib PM | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.207 | Osimertinib | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.208 | Pemetrexed | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.209 | Radiation Treatment Management SNOMEDCT | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.21 | Stage IIB | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.210 | Radiation Treatment Management Codes | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.211 | Radiation Treatment Delivery CPT | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.212 | 77427 Management Code | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.213 | Radiation Treatment Delivery HCPCS | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.214 | Radiation Treatment Delivery NCIM | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.215 | Radiation Treatment Delivery SNOMED | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.216 | Radiation Treatment Delivery | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.217 | MET Gene Test | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.219 | Tepotinib | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.22 | Stage IIIA | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.220 | MET Positive gene interpretation | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.227 | MET Exon 14 skipping molecular variant | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.23 | Stage IIIB | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.230 | All Cancer Directed therapies | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.231 | EGFR Amivantamab Molecular Variants | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.232 | EGFR Molecular Variants Amivantamab PM | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.233 | test43 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.234 | ROS1 Molecular Variants Repotrectinib PM | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.235 | ROS1 Repotrectinib Molecular Variants | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.236 | ROS1 Negative (geneinterpretation) SNOMEDCT | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.237 | ROS1 Negative (geneinterpretation) NCI | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.238 | ROS1 Negative (geneinterpretation) SNOMEDCT,NCI | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.239 | ROS1 Positive (geneinterpretation) | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.24 | Stage IIIC | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.240 | ROS1 results (HGNC) | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.241 | ROS1 Gene Rearrangement | active | 2024-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.242 | RET Test (HGNC) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.243 | RET Positive (Genei interpretation ) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.244 | RET Gene Rearrangement | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.245 | RET Negative (geneinterpretaion) SNOMED | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.246 | RET Negative (geneinterpretaion) NCI | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.247 | RET Negative (geneinterpretaion) SNOMEDCT,NCI | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.248 | RET Fusion Molecular Variants | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.249 | pralsetinib | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.25 | ESR1 Gene Test | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.250 | Repotrectinib Value set | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.251 | Amivantamab | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.252 | Alectinib Drug | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.253 | Gemcitabine Drug Value set | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.254 | vinorelbine Drug | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.255 | NSCLC_Tumor_resection SNOMEDCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.256 | NSCLC_Tumor_resection CPT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.257 | NSCLC_Tumor_resection SNOMEDCT CPT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.258 | ALK results (HGNC) | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.259 | ALK Positive (geneinterpretation) SNOMED | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.26 | ESR1 Genetic Mutation | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.260 | ALK Positive (geneinterpretation) NCI | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.261 | ALK Positive (geneinterpretation) SNOMEDCT NCI | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.262 | ALK Negative (geneinterpretation) SNOMEDCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.263 | ALK Negative (geneinterpretation) NCI | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.264 | ALK Negative (geneinterpretation) SNOMEDCT NCI | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.265 | Locoregional Sites | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.266 | NSCLC N2 Stage | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.267 | NSCLC N1 Stage | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.268 | NSCLC N0 Stage | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.269 | NSCLC T3_T4 Stage | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.27 | Genetic Test Finding | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.270 | NSCLC T2 Stage | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.271 | NSCLC T1 Stage | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.272 | Locally_Advanced_Metastatic_NSCLC Stage Group | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.273 | Localized_Inclusion_NSCLC Stage Group | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.274 | Localized_Exclusion_NSCLC Stage Group | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.275 | tarlatamab dlle | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.276 | Extensive SCLC Stage Group SNOMEDCT | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.277 | Extensive SCLC Stage Group NCIM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.278 | Extensive SCLC Stage Group | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.279 | Localized SCLC Stage Group | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.28 | Her2 Negative | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.280 | SCLC M Stage (metastatic) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.281 | SCLC T Stage | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.282 | SCLC N Stage | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.283 | SCLC histology (to include those patients) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.284 | Binimetinib | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.285 | Encorafenib | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.286 | Encorafenib PM Molecular variant | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.288 | BRAF Positive (geneinterpretation) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.289 | BRAF test (HGNC) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.29 | HER2 Positive | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.292 | Prior therapy for Amivantamab | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.293 | ENHERTU Drug | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.294 | Metastatic_Solid_Cancer_Stage Group SNOMED CT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.295 | Locally_Advanced_Solid_Cancer_Stage Group SNOMED CT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.296 | Localized_Solid_Cancer_Stage Group SNOMED CT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.297 | Solid cancer M Stage (metastatic) | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.298 | Solid Cancer T Stage | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.299 | Solid Cancer N Stage | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.30 | HER2 Positive | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.302 | HER2_IHC_Positive | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.303 | HER2 Negative (geneinterpretation/Labtestvalue) SNOMED | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.304 | HER2 Negative (geneinterpretation/Labtestvalue) LOINC | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.305 | HER2 Negative (geneinterpretation/Labtestvalue) NCI | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.307 | HER2 Negative (geneinterpretation/Labtestvalue) | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.308 | Solid Cancer Diagnosis ICD 9 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.309 | Solid Cancer Diagnosis SNOMED CT | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.31 | HER2 Positive | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.310 | Solid Cancer Diagnosis | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.311 | Localized_Solid_Cancer_Stage Group NCIM | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.313 | Localized_Solid_Cancer_Stage Group | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.314 | Locally_Advanced_Solid_Cancer_Stage Group NCIM | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.315 | Locally_Advanced_Solid_Cancer_Stage Group | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.316 | Metastatic_Solid_Cancer_Stage Group NCIM | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.317 | Metastatic_Solid_Cancer_Stage Group | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.318 | Solid Cancer T Stage LOINC | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.319 | Solid Cancer T Stage NCI | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.32 | HER2 Positive | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.320 | Solid Cancer T Stage codes | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.321 | Prior_Systemic_therapy_Enhertu | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.322 | RET test_Solid_cancer (HGNC) | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.323 | RET Positive_Solid_Cancer (geneinterpretation) | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.324 | RET Negative_Solid_Cancer (geneinterpretation) | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.325 | RET fusion Molecular Variants_Solid_Cancer | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.326 | Prior_systemic_therapy_Retevmo | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.327 | Selpercatinib (Retevmo) Drug | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.328 | Breast Cancer Diagnosis ICD9 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.329 | Breast Cancer Diagnosis ICD10 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.33 | Metastatic Breast Cancer | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.330 | Breast Cancer Diagnosis | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.331 | Metastatic_Breast_Cancer_Stage Group | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.332 | Locally_Advanced_Breast_Cancer_Stage Group | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.333 | Localized_Breast_Cancer_Stage Group | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.334 | Breast cancer M Stage (metastatic) | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.335 | Breast Cancer T Stage | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.336 | Breast Cancer N Stage | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.337 | Metastatic Sites All Breast SNOMEDCT | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.338 | Metastatic Sites All Breast ICD9 | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.339 | Metastatic Sites All Breast ICD10 | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.340 | Metastatic Sites All Breast (grouped, SNOMEDCT/ICD9/ICD10) | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.341 | Aromatase_Inhibitor therapy | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.342 | Capivasertib_therapy | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.343 | Fulvestrant_therapy | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.344 | PTEN_gene | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.345 | PTEN_geneinterpretation | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.346 | PIK3CA_gene | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.347 | PI3KCA_geneinterpretation | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.348 | AKTI_gene | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.349 | AKTI_geneinterpretation | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.35 | All Metastatic Sites | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.350 | Progesterone_receptor_gene | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.351 | Progesterone_receptor_geneinterpretation | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.352 | Estrogen_receptor_gene | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.353 | Estrogen_receptor_geneinterpretation | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.354 | Progesterone_receptor_labtest | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.355 | Progesterone_receptor_labinterpretation | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.356 | Estrogen_receptor_labtest | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.357 | Estrogen_receptor_labinterpretation | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.358 | NSCLC M0 Stage | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.359 | HER2_IHC_test_Gene | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.36 | All Metastatic Sites | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.360 | HER2_IHC_test_Lab | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.361 | HER2_Fish_test | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.362 | HER2_IHC_Negative | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.363 | Trodelvy | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.364 | Chemotherapy_breast_cancer | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.365 | Cyclin_dependent_kinase | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.366 | Taxane_Trodelvy | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.367 | Endocrine_therapy | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.368 | HER2_Fish_test_Negative | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.369 | HER2_IHC_Equivocal | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.37 | Locoregional Breast Cancer | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.370 | HER2 Positive_PM_results | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.371 | HER2 test_Lab | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.372 | HER2 test_gene | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.374 | Thyroid Cancer Diagnosis | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.375 | Metastatic_Thyroid_Stage Group | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.376 | RET mutation_Molecular Variants | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.377 | RET Gene mutation | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.378 | Locally_Advanced_Localized_Thyroid_Cancer_Stage Group | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.379 | Thyroid cancer M1_Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.38 | Locoregional Breast Cancer | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.380 | Thyroid_cancer_M0_Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.381 | Thyroid_cancer_T_Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.382 | Thyroid_cancer_T1_T2_T3_Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.383 | Thyroid_cancer_T4_Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.384 | Thyroid_cancer_N1b_Stage&Above | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.385 | Thyroid_cancer_N_Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.386 | Medullary_thyroid_histology | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.387 | RET test_Thyroid_cancer (HGNC) | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.388 | RET Positive | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.389 | NSCLC N3 Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.39 | Locoregional Breast Cancer | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.390 | CRC Cancer Diagnosis ICD9 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.391 | CRC Cancer Diagnosis ICD10 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.392 | CRC Cancer Diagnosis ICD9/ICD10 | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.393 | Metastatic_CRC_Cancer_Stage Group | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.394 | Locally_Advanced_Localized_CRC_Stage Group | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.395 | CRC cancer M Stage (metastatic) | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.396 | CRC Cancer T Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.397 | CRC Cancer N Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.398 | KRAS_gene | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.399 | KRAS_negative | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.40 | Locoregional Breast Cancer | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.400 | Fluoropyrimidine_CRC | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.401 | Oxaliplatin | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.402 | Irinotecan_based_therapy | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.403 | anti_VEGF_therapy_CRC | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.404 | anti_EGFR_therapy_CRC | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.405 | fruquitinib | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.406 | Locally_Advanced_CRC_Stage Group | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.407 | Localized_CRC_Stage Group | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.408 | CRC cancer M0_Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.409 | CRC_Cancer_T1_Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.41 | All Metastatic Sites ICD910 | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.410 | CRC_Cancer_T2_Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.411 | CRC_Cancer_T3_Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.412 | CRC_Cancer_T4_Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.413 | CRC Cancer N1 Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.414 | CRC Cancer N2 Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.415 | CRC Cancer N2b Stage | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.416 | KRAS_G12C_MV | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.417 | KRAS_G12C_PM | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.418 | KRAS_positive | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.419 | Adagrasib | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.42 | Breast Cancer | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.420 | cetuximab_therapy | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.421 | Tamoxifen_therapy | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.423 | Endometrial Cancer Diagnosis ICD 10 | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.425 | Endometrial Cancer Diagnosis ICD9CM | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.426 | Endometrial Cancer Diagnosis | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.428 | Localized_Endometerial_Stage Group SNOMED | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.429 | Localized_Endometerial_Stage Group NCIM | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.43 | Breast Cancer | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.431 | Endometrial_Sarcoma_Tumor_Histology_exc | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.432 | Endometrial cancer M Stage (metastatic) | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.433 | Endometrial_M0_Stage | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.436 | Prior_therapy_Endometrial | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.437 | Paclitaxel_therapy | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.44 | Breast Cancer | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.441 | Carboplatin_therapy | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.442 | Durvalumab_therapy | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.444 | MMR_Gene_Lab_LOINC | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.447 | MMR_Gene_HGNC | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.449 | Endometrial_ Cancer N Stage | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.45 | Endometrial Cancer ICD9 | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.451 | Endometrial_N0_Stage | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.453 | Endometrial_N1_N2_Stage | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.455 | Endometrial_T1_T3_Stage | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.456 | Endometrial_T3_Stage | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.458 | Endometrial_T4_Stage | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.459 | Endometrial Cancer T Stage | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.46 | Endometrial Cancer ICD10 | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.460 | Localized_Endometerial_Stage Group_SNOMED/NCIM | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.461 | Metastatic Sites All CRC | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.462 | Metastatic Sites All CRC ICD 10 | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.463 | Metastatic Sites All CRC ICD 9 | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.464 | Metastatic Sites All CRC (grouped, SNOMEDCT/ICD9/ICD10) | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.465 | NTRK Repotrectinib Molecular Variants | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.466 | NTRK_Gene_rearrangment | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.467 | Prior_Systemic_therapy_Repotrectinib | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.468 | NTRK_Positive | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.469 | NTRK_test_gene | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.47 | Systemic treatment for endometrial cancer | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.470 | Tamoxifen_Trodelvy | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.471 | Toremifene_trodelvy | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.472 | Fulvestrant_Trodelvy | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.473 | Elacestrant | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.474 | Anastrozole_Trodelvy | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.475 | Leuprolide_Trodelvy | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.476 | Abemaciclib | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.477 | Palbociclib | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.478 | Ribociclib | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.479 | Carboplatin_Trodelvy | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.48 | Endometrial Cancers | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.480 | Cisplatin_Trodelvy | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.481 | Cyclophosphamide | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.482 | Methotrexate | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.483 | Gemcitabine | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.484 | Capecitabine | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.485 | Eribulin | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.486 | Doxorubicin | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.487 | Vinorelbine | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.488 | Epirubicin | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.489 | Ixabepilone | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.49 | MSI Testing | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.490 | Olaparib | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.491 | Talazoparib | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.492 | Entrectinib | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.493 | larotrectinib | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.494 | Alpelisib | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.495 | Capivasertib | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.496 | Pembrolizumab | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.497 | Dostarlimab | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.498 | Selpercatinib | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.499 | Everolimus | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.50 | MSI High | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.500 | Trastuzumab_deruxtecan | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.501 | Test 23 | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.502 | All Metastatic sites Endometrial SNOMED | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.503 | All Metastatic sites Endometrial ICD9 | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.504 | All Metastatic sites Endometrial ICD10 | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.505 | All Metastatic sites Endometrial | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.506 | Create CRC_Cancer_T4a_Stage | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.507 | Create CRC_Cancer_T4b_Stage | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.508 | High Emetogenic Risk Chemotherapy | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.510 | InactiveFollowup | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.53 | MMR Gene Testing | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.54 | MSI High | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.55 | MSI High | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.56 | Early and Limited Stage | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.57 | Early Stage IIB or lower | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.58 | MMR Deficient | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.59 | MMR Deficient | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.6 | Orserdu | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.60 | MMR Deficient | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.61 | Stage IIB or lower and limited | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.62 | Stage III or higher | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.63 | Stage III or higher | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.64 | Stage III or higher | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.65 | Staging Unknown | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.66 | Staging Unknown | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.67 | Staging Unknown | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.68 | Jemperli | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.69 | Uterine Sarcoma | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.7 | Her2 Test For Orserdu | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.70 | Tumor Histology | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.71 | Platinum based therapy | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.72 | Prior Therapies for Tucatinib | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.73 | Tucatinib | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.74 | Colorectal Cancer ICD10 | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.75 | Colorectal Cancer ICD9 | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.76 | Colorectal Cancer ICD9 and ICD10 | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.78 | Advanced or Unresectable Colorectal Cancer Staging | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.79 | 0 to IIIB Colorectal Cancer Staging | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.80 | Colorectal Cancer M1 Stage | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.81 | RAS Genes | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.82 | RAS Gene Interpretation Negative LOINC | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.83 | RAS Gene Interpretation Negative SNOMED | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.84 | RAS Gene Interpretation Negative NCM | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.85 | RAS Gene Negative | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.86 | RAS Gene Interpretation Positive SNOMED | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.87 | RAS Gene Interpretation Positive LOINC | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.88 | RAS Gene Positive | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.89 | Her2 Testing | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.9 | ER Test for Orserdu | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.90 | Patient Reason | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.91 | MSI High NCI | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.92 | MSI Low SNOMED | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.93 | MSI Low LOINC | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.94 | MSI Low NCI | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.95 | MSI Low | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.96 | MMR Deficient NCI | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.97 | MMR Proficient SNOMED | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.98 | MMR Proficient LOINC | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.99 | MMR Proficient NCI | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1262.3 | ICD9 Codes for HIV Diagnosis | active | 2023-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.1 | Inpatient Pneumonia Diagnosis | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.11 | Chest Imaging for Pneumonia, HCPCS | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.12 | Chest Imaging for Pneumonia Grouping Definition | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.18 | ICD9 Abnormal Finding on Chest Imaging | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.19 | ICD10 Abnormal Finding on Chest Imaging | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.2 | ICD9 Pneumonia Definition | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.20 | SNOMEDCT Abnormal Finding on Chest Imaging | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.21 | Abnormal Finding on Chest Imaging | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.22 | SNOMEDCT Pneumonia Definition | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.23 | CAP Concurrent Infections | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.24 | CAP Pneumonia Diagnostic | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.25 | Antibiotic Usage for CAP Diagnosis | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.27 | Legionella Presence by Urine Antigen or DNA | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.29 | Broad Spectrum Antibiotics for MDRO | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.3 | ICD10 Pneumonia Definition | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.32 | CPT Transplants, Stem Cell and Solid | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.33 | HCPCS Transplant, Stem Cell and Solid | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.34 | ICD10CM Transplant, Stem Cell and Solid | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.35 | ICD10PCS Transplant, Stem Cell and Solid | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.37 | SNOMEDCT Transplant, Stem Cell and Solid | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.38 | Transplant, Stem Cell and Solid | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.39 | Antibiotic Usage for CAP Duration | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.40 | CAP Sepsis Diagnostic | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.41 | CAP Respiratory Failure Diagnostic | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.42 | MRSA Organism or Substance in Lab Results | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.8 | Systemic Antimicrobials | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.9 | Chest Imaging for Pneumonia, CPT | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.1 | Problem Type | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.10 | Information Source for Medication Adherence HSLOC | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.11 | Information Source for Medication Adherence | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.13 | Screening and Assessment Survey Codes | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.14 | Unknown and Asked but Unknown (DAR) | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.15 | Yes or No SCT | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.16 | Answer Set with Yes No and Unknowns | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.17 | Common LOINC Lab Codes | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.18 | Radiology Procedures (LOINC) | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.19 | Clinical Tests | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.21 | Universal Common LOINC Lab Orders | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.22 | Route of Administration of Therapeutic Agents | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.23 | Encounter Type | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.24 | Specimen Condition SCT | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.25 | Detailed race including absence reasons. | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.26 | Healthcare Facility type (SCT) | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.27 | Social History Type (LOINC) | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.28 | Social History Type | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.29 | Encounter Type CPT | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.3 | Smoking status comprehensive | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.31 | Healthcare Service Location Type Combined | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.4 | Smoking Status Type LOINC | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.5 | Smoking Status Pack Years SCT | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.6 | Smoking Status Type | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.7 | Information Source for Medication Adherence HL7 Role Code | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.8 | Information Source for Medication Adherence ParticpationFunction | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.9 | Information Source for Medication Adherence SCT | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.1 | Malnutrition | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.10 | Fracture | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.11 | Transplant Diagnoses | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.13 | Transplant Diagnoses ICD10CM | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.14 | Transplant Diagnoses SNOMED CT | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.15 | Respiratory Procedures | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.2 | Moderate Injuries (SNOMEDCT) | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.3 | Diabetes | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.4 | Diabetes | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.5 | Diabetes | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.6 | Immobility | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.7 | Smoking status | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.8 | Obesity | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.9 | Hormone Therapy | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1282.1 | Drug Intervention Not Indicated/Contraindicated | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1282.10 | Endotracheal Intubation | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1282.2 | Procedure Not Indicated/Contraindicated | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1282.9 | Mechanical Circulatory Assist Device | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1289.1 | RXNormSBD0305 | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1289.2 | RXNormSCD0305 | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1290.4 | Sequential Organ Failure Assessment SOFA | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1290.5 | Septic Shock | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1290.6 | Septic Shock | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.1 | Administrative Gender (HL7 V3) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.10267 | ParticipationFunction | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.10416 | Financially Responsible Party Type Value Set | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.10612 | Unknown Null | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.10637 | PostalAddressUse | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.10901 | ParticipationType | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.11610 | x_ActRelationshipDocument | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.12199 | LanguageAbilityProficiency | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.12212 | Marital Status | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.12249 | LanguageAbilityMode | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.14914 | Race Value Set | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.15913 | EntityNameUse | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.16926 | HL7 BasicConfidentialityKind | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.18877 | Coverage Role Type Value Set | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19185 | Religious Affiliation | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19563 | Personal Relationship Role Type | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19579 | Family Member Value | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19601 | x_ServiceEventPerformer | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19717 | No Immunization Reason | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.12 | HealthStatus | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.3 | ReferralDocumentType | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.4 | TransferDocumentType | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.5 | Wound Measurements | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.6 | Wound Type | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.7 | Nutritional Status | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.9 | Nutrition Recommendations | active | 2018-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2 | Advance Directive Type Code | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.22 | HPDocumentType | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20275 | HealthcareServiceLocation | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20549 | Criticality Observation | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.78 | Observation Interpretation (HL7) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.15.2.5.1 | Initial Case Report Trigger Code Result Status | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.15.2.5.12 | Therapeutic Response to Medication | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.22.5.300 | Transmission Based Precaution Types | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.22.5.304 | Organism | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.22.5.305 | Microbiology and Antimicrobial Susceptibility Tests | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.22.5.306 | Infectious Disease | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.1.5.9.2 | Codes for MDRO and CDI Summary Data LTCF | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.1.5.9.3 | NHSNPrimaryResidentServiceType | active | 2020-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.1.5.9.4 | Codes for Denominators for Long Term Care Locations LTCF | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.1.5.9.5 | Codes for Prevention Process Measures LTCF | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.1.9.1 | NHSNReportNoEventsMDROLTCF | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.10 | Codes for Healthcare Personnel Influenza Vaccination (HP FLU) Summary Data | active | 2019-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.11 | Codes for Hemovigilance (HV) Summary Data | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.12 | Codes for Intensive Care Unit (ICU) Summary Data | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.13 | Codes for Neonatal Intensive Care Unit (NICU) Summary Data | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.15 | Codes for Prevention Process and Outcome Measures (POM) Summary Data | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.16 | Codes for Specialty Care Area (SCA) Summary Data | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.17 | Codes for Vascular Access Type (Dialysis) Summary Data | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.18 | NHSNReportNoEventsICU | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.19 | NHSNReportNoEventsNICU | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.20 | NHSNReportNoEventsSCA | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.21 | NHSNReportNoEventsMDRO | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.22 | NHSNReportNoEventsDialysis | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.24 | NHSNVascularSpecimenCollectionSite | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.29 | NHSNSSIDetectionMethod | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.3 | NHSNLastLocationEncounterTypeCode | active | 2020-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.30 | NHSNLOS/MENDischargeDisposition | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.31 | NHSNSSIDetectionMethodType | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.32 | Codes for Outpatient Procedure Component Same Day Outcome Measures Summary Data | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.33 | NHSNReportNoEventsOPCSameDayOutcomeMeasures | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.34 | NHSNOPCProcedureCategoryCode | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.35 | NHSNReportNoEventsAR | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.4 | NHSNDrugSusceptibilityTestMethod | active | 2020-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.40 | NHSN COVID19 Case Classification | active | 2021-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.5 | NHSN Pathogen Reduced Apheresis Platelet Usage | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.50 | NHSNGenotypicTestInterpretation | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.6 | HealthcarePersonnelType | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.7 | NHSNInfluenzaVaccinationSetting | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.8 | Codes for Antimicrobial Resistance Option (ARO) Summary Data | active | 2020-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.9 | Codes for Antimicrobial Usage, Pharmacy (AUP) Summary Data | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.1.1 | SurgicalOperationNoteDocumentTypeCode | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.12.1 | Personal And Legal Relationship Role Type | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.4.1 | DischargeSummaryDocumentTypeCode | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.6.1 | ProcedureNoteDocumentTypeCodes | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.7.1 | SupportedFileFormats | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.8.1 | ProgressNoteDocumentTypeCode | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.18 | MoodCodeEvnInt | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.19 | ProblemAct statusCode | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.20 | Telecom Use (US Realm Header) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.21 | AgePQ_UCUM | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.22 | ProcedureAct statusCode | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.23 | Planned moodCode (Act/Encounter/Procedure) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.24 | Planned moodCode (SubstanceAdministration/Supply) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.25 | Planned moodCode (Observation) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.26 | EntityPersonNamePartQualifier | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.29 | DIRQuantityMeasurementTypeCodes | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.31 | ConsultDocumentType | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.32 | DIRDocumentTypeCodes | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.33 | INDRoleclassCodes | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.34 | Patient Education | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.35 | Pressure Ulcer Stage | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.36 | Pressure Point | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.37 | TargetSite Qualifiers | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.38 | Smoking Status | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.39 | Result Status | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.41 | Tobacco Use | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.44 | Mental and Functional Status Response | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.46 | Ability | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.47 | ADL Result Type | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.49 | Residence and Accommodation Type | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.50 | Sensory Status Problem Type | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.51 | Healthcare Agent Qualifier | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.52 | Encounter SCT | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.54 | Planned Intervention moodCode | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.55 | Goal Achievement | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.56 | Referral Types | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.58 | Wound Characteristic | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.59 | DIRSectionTypeCodes | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.60 | Priority Level | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.61 | Care Model | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.62 | Related Document (append/replace) | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.65 | Physical Exam Type | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.66 | Patient Referral Act moodCode | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.68 | Note Types | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.1.1 | Advance Care Planning Services CPT | active | 2018-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.1.2 | Advance Care Planning Services SCT | active | 2018-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.1.3 | Advance Care Planning Services Grouping | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.17 | Obligation or Prohibition Instruction Type | active | 2018-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.4 | Advance Healthcare Directive Categories LOINC | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.5 | Advance Directives Content Types | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.6 | Planned or Completed moodCode | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.7 | Obligation or Prohibition Instruction Type | active | 2017-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.80 | Pregnancy Status Determination Method | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.81 | Estimated Date of Delivery Including Method | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.82 | Estimated Gestational Age Code Including Method | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.84 | Other Pregnancy Outcome | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.86 | Pregnancy Outcome | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.87 | Postpartum Status | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.88 | Pregnancy Related Findings | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.89 | D(Rh) Type | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.90 | D(Rh) Sensitized | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.91 | Rho(D) Immune Globulin | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.1 | NHSNEncounterTypeCode | active | 2019-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.10 | NHSNASAClassCode | active | 2019-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.11 | NHSNSpinalFusionLevelCode | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.12 | NHSNOccasionOfDetectionCode | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.13 | NHSNDrugSusceptibilityFindingCode | active | 2020-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.15 | NHSNDrugSusceptibilityTestsCode | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.16 | NHSNPathogenCode | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.17 | NHSNProcedureCategoryCode | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.19 | NHSNHealthcareServiceLocationCode | active | 2019-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.2 | NHSNSpinalFusionApproachCode | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.20 | NHSNInfectionTypeCode | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.3 | NHSNHipReplacementCode | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.4 | NHSNKneeReplacementCode | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.6 | NHSNInfectionRiskFactorsCode | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.7 | NHSNBloodStreamInfectionEvidenceTypeCode | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.9 | NHSNWoundClassCode | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.17.4077.2.1017 | Closed Head and Facial Trauma | active | 2020-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.17.4077.2.1018 | Closed Head and Facial Trauma | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.1 | Major Surgical Procedure | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.134 | Oral Factor Xa Inhibitor for VTE Prophylaxis or VTE Treatment | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.136 | Perforation of Uterus | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.137 | Uterine Window | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.138 | Uterine Rupture | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.200 | Anticoagulant Therapy | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.201 | Antithrombotic Therapy Anticoagulant | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.202 | Atrial Fibrillation or Flutter | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.203 | Atrial Ablation | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.204 | Carotid Intervention | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.205 | Direct Thrombin Inhibitor | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.207 | Discharged to Health Care Facility for Hospice Care | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.209 | Discharged to Home for Hospice Care | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.211 | Injectable Factor Xa Inhibitor for VTE Prophylaxis | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.212 | Hemorrhagic Stroke | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.213 | INR | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.214 | Intermittent pneumatic compression devices | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.215 | LDLc | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.218 | Unfractionated Heparin | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.219 | Low Molecular Weight Heparin for VTE Prophylaxis | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.222 | Intravenous route | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.223 | Subcutaneous route | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.226 | Thrombolytic tPA Therapy | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.230 | Venous foot pumps | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.232 | Warfarin | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.234 | Hemorrhagic Stroke | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.235 | Hemorrhagic Stroke | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.238 | Carotid Intervention | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.239 | Carotid Intervention | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.242 | Atrial Ablation | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.243 | Atrial Ablation | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.244 | Atrial Fibrillation or Flutter | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.245 | Atrial Fibrillation or Flutter | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.246 | Atrial Fibrillation or Flutter | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.247 | Ischemic Stroke | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.25 | Single Live Birth | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.251 | Ischemic Stroke Embolism | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.252 | Ischemic Stroke Embolism | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.255 | General Surgery | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.256 | Graduated compression stockings | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.257 | Gynecological Surgery | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.258 | Hip Fracture Surgery | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.259 | Hip Replacement Surgery | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.26 | Single Live Born Newborn Born in Hospital | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.260 | Intracranial Neurosurgery | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.261 | Knee Replacement Surgery | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.263 | Obstetrical or Pregnancy Related Conditions | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.264 | Obstetrics VTE | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.27 | Dietary Intake Other than Human Milk | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.270 | Acute or Persistent Asthma | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.271 | Acute or Persistent Asthma | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.272 | Urological Surgery | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.279 | Venous Thromboembolism | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.281 | Labor | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.282 | Cesarean Birth | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.286 | Conditions Possibly Justifying Elective Delivery Prior to 39 Weeks Gestation | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.288 | Medical Induction of Labor | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.292 | Emergency Department Visit | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.294 | Decision to Admit to Hospital Inpatient | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.295 | Decision to Admit to Hospital Inpatient | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.296 | Psychiatric/Mental Health Diagnosis | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.298 | Psychiatric/Mental Health Diagnosis | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.299 | Psychiatric/Mental Health Diagnosis | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.30 | Human Milk | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.308 | Left Against Medical Advice | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.309 | Patient Expired | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.310 | Gynecological Surgery | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.313 | Gynecological Surgery | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.315 | Knee Replacement Surgery | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.317 | Knee Replacement Surgery | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.319 | Hip Replacement Surgery | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.321 | Hip Replacement Surgery | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.323 | Hip Fracture Surgery | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.325 | Hip Fracture Surgery | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.328 | Venous Thromboembolism | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.33 | Galactosemia | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.330 | Venous Thromboembolism | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.331 | Urological Surgery | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.333 | Urological Surgery | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.335 | Obstetrical or Pregnancy Related Conditions | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.337 | Obstetrical or Pregnancy Related Conditions | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.338 | Obstetrics VTE | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.340 | Obstetrics VTE | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.344 | Intracranial Neurosurgery | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.346 | Intracranial Neurosurgery | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.348 | General or Neuraxial Anesthesia | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.35 | Galactosemia | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.361 | General Surgery | active | 2021-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.365 | General Surgery | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.367 | Cesarean Birth | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.369 | Cesarean Birth | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.37 | Parenteral Nutrition | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.38 | Parenteral Nutrition | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.384 | Medical Induction of Labor | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.393 | Conditions Possibly Justifying Elective Delivery Prior to 39 Weeks Gestation | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.395 | Conditions Possibly Justifying Elective Delivery Prior to 39 Weeks Gestation | active | 2025-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.400 | Low Risk | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.401 | Delivery Procedures | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.418 | Classical Cesarean Birth | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.419 | Classical Cesarean Birth | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.421 | Classical Cesarean Birth | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.422 | Myomectomy | active | 2024-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.423 | Statin Allergen | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.424 | Nonelective Inpatient Encounter | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.473 | Medical Reason For Not Providing Treatment | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.75 | Neonatal Intensive Care Unit | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.76 | Single Live born Newborn | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.78 | Galactosemia | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.79 | Parenteral Nutrition | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.87 | Discharge To Acute Care Facility | active | 2021-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.93 | Patient Refusal | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1434.1047 | Skin Melanoma pT1 | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.100 | Injectable Fluorouracil | active | 2020-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.101 | Trastuzumab and Biosimilars | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.102 | Breast Cancer | active | 2020-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.103 | HER2 Presence in Tissue | active | 2020-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.104 | Depression Screening for Adult | active | 2020-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.105 | Long Acting Opioids | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.106 | High Fiber Supplement or Diet Education | active | 2020-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.107 | Standardized Assessment Tools for Dyspnea | active | 2020-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.108 | Nausea or Vomiting Assessment | active | 2020-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.109 | Pancreatic Cancer | active | 2020-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.110 | Pancreatic Cancer | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.111 | Audio Visual Telehealth Encounter | active | 2020-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.112 | Telephone Encounter | active | 2020-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.113 | Telehealth Emergency Department or Initial Inpatient | active | 2020-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.114 | Karnofsky Performance Status | active | 2020-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.115 | Referral to Hospice Care | active | 2020-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.116 | Referral to Palliative Care | active | 2020-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.117 | Assessment Scale for Dyspnea | active | 2020-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.118 | Nausea or Vomiting Assessment | active | 2020-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.119 | Enrollment in Hospice Care | active | 2020-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.120 | Palliative Care | active | 2020-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.121 | Advance Directive Including Durable Power of Attorney or Instructional | active | 2020-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.122 | Carmustine Injectable | active | 2022-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.123 | Dacarbazine Injectable | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.124 | Streptozocin Injectable | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.126 | Alemtuzumab Injectable | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.127 | Azacitidine Injectable | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.128 | Bendamustine Injectable | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.129 | Busulfan Injectable | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.130 | Temozolomide Injectable | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.131 | Thiotepa Injectable | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.132 | Oxaliplatin Injectable | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.133 | Romidepsin Injectable | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.134 | Trabectedin Injectable | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.135 | Dolasetron Oral | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.136 | Dolasetron Injectable | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.137 | Granisetron Oral | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.138 | Granisetron Transdermal | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.139 | Granisetron Injectable | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.140 | Ondansetron Oral | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.141 | Ondansetron Injectable | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.142 | Ifosfamide Injectable | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.143 | Arsenic Trioxide Injectable | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.144 | Netupitant Palonosetron Oral | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.145 | Fosnetupitant Palonosetron Injectable | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.146 | Aprepitant Injectable | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.147 | Rolapitant Injectable | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.148 | Dexamethasone Oral | active | 2022-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.149 | Dexamethasone Injectable | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.150 | Dexamethasone Drug Implant | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.151 | Olanzapine Oral | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.152 | Olanzapine Injectable | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.153 | Idarubicin Injectable | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.154 | Neurokinin 1 Receptor Antagonist Ingredient | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.155 | Serotonin Receptor Antagonist Ingredient | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.156 | Clofarabine Injectable | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.157 | Belinostat Injectable | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.158 | Bortezomib Injectable | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.159 | Cabazitaxel Injectable | active | 2021-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.160 | Carfilzomib Injectable | active | 2021-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.161 | Decitabine Injectable | active | 2021-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.162 | Elotuzumab Injectable | active | 2021-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.163 | Enfortumab Injectable | active | 2021-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.164 | Eribulin Injectable | active | 2021-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.165 | Etoposide Injectable | active | 2021-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.166 | Inotuzumab Ozogamicin Injectable | active | 2021-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.167 | Mitoxantrone Injectable | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.168 | Moxetumomab Injectable | active | 2021-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.169 | Necitumumab Injectable | active | 2021-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.170 | Nelarabine Injectable | active | 2021-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.171 | Temsirolimus Injectable | active | 2021-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.172 | Tisagenlecleucel Injectable | active | 2021-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.173 | Topotecan Injectable | active | 2021-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.178 | Atezolizumab Injectable | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.179 | Avelumab Injectable | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.180 | Bleomycin Injectable | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.181 | Cemiplimab Injectable | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.182 | Cladribine Injectable | active | 2021-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.183 | Daratumumab Injectable | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.184 | Durvalumab Injectable | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.185 | Emapalumab Injectable | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.186 | Fludarabine Injectable | active | 2021-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.187 | Ipilimumab Injectable | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.188 | Nivolumab Injectable | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.189 | Pembrolizumab Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.190 | Polatuzumab Vedotin Injectable | active | 2021-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.191 | Pralatrexate Injectable | active | 2021-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.192 | Vincristine Injectable | active | 2021-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.193 | Methotrexate Injectable | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.194 | Trastuzumab Injectable | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.195 | Mitomycin Injectable | active | 2021-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.196 | Brentuximab Vedotin Injectable | active | 2021-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.197 | Doxorubicin Pegylated Liposomal Injectable | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.198 | Blinatumomab Injectable | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.199 | Trastuzumab Emtansine Injectable | active | 2021-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.200 | Gemtuzumab Ozogamicin Injectable | active | 2021-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.201 | Tagraxofusp Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.202 | Axicabtagene Ciloleucel Injectable | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.203 | BRCA1 | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.204 | BRCA2 | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.205 | BRCA1 Testing | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.207 | Epithelial Ovarian Cancer | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.208 | Primary Peritoneal Cancer | active | 2022-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.209 | Fallopian Tube Cancer | active | 2022-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.210 | Multigene Panel | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.211 | BRCA1 and BRCA2 | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.212 | BRCA1 and BRCA2 Testing | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.213 | BRAF V600 | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.214 | BRAF V600 Testing | active | 2023-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.215 | Colorectal Cancer | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.216 | BRAF V600 Mutation Status | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.217 | Cancer Stage I | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.218 | Head and Neck Cancer | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.219 | Malignant Melanoma of Skin | active | 2022-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.220 | Brain Cancer | active | 2022-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.221 | Waldenstrom Macroglobulinemia | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.222 | High Emetic Risk Intravenous Antineoplastic Agent | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.223 | Moderate Emetic Risk Intravenous Antineoplastic Agent | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.224 | Docetaxel Injectable | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.225 | Cyclophosphamide Injectable | active | 2022-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.226 | LAG 3 Inhibitor | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.227 | Neoplasm of Brain | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.233 | Chemotherapy Administration | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.240 | Pathological N Stage N3c | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.241 | Audio Visual Telehealth Encounter | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.242 | Moderate or High Emetic Risk Oral Antineoplastic Agent | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.243 | Minimal to Low Emetic Risk Oral Antineoplastic Agent | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.244 | Copanlisib Injectable | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.245 | Isatuximab Injectable | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.246 | Loncastuximab tesirine Injectable | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.247 | Margetuximab Injectable | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.248 | Mirvetuximab soravtansine Injectable | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.249 | Tafasitamab Injectable | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.250 | Teclistamab Injectable | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.251 | Tisotumab Injectable | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.252 | Asparaginase Injectable | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.254 | Belantamab Injectable | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.255 | Dostarlimab Injectable | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.256 | Mosunetuzumab Injectable | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.257 | Tremelimumab Injectable | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.258 | Indication for Dexamethasone | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.260 | Indication for Olanzapine | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.261 | Indication for Dexamethasone | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.263 | Indication for Olanzapine | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.264 | Prednisone | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.265 | As Needed PRN | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.266 | Amivantamab Injectable | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.200 | Doxorubicin | active | 2020-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.201 | Epirubicin | active | 2020-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.202 | Capecitabine | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.203 | Cyclophosphamide | active | 2020-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.204 | Injectable Fluorouracil | active | 2020-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.205 | Methotrexate | active | 2020-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.206 | Trastuzumab and Biosimilars | active | 2020-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.207 | HER2 Presence in Tissue | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.208 | Carboplatin | active | 2020-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.209 | Depression Screening for Adult | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.210 | Long Acting Opioids | active | 2020-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.211 | High Fiber Supplement or Diet Education | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.212 | Dexamethasone | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.213 | Olanzapine | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.214 | Pancreatic Cancer | active | 2020-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.215 | Audio Visual Telehealth Encounter | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.216 | Telephone Encounter | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.217 | Telehealth Emergency Department or Initial Inpatient | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.218 | Dyspnea Assessment | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.219 | Nausea or Vomiting Assessment | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.220 | Karnofsky Performance Status | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.221 | Referral to Hospice Care | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.222 | Referral to Palliative Care | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.223 | Palliative Care | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.224 | Enrollment in Hospice Care | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.225 | Advance Directive Including Durable Power of Attorney or Instructional | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.228 | Low Emetic Risk Intravenous Antineoplastic Agent | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.229 | Minimal Emetic Risk Intravenous Antineoplastic Agent | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.232 | Epithelial Ovarian Cancer | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.233 | Primary Peritoneal Cancer | active | 2022-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.235 | BRCA2 Testing | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.236 | Multigene Panel | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.237 | BRCA1 Testing | active | 2023-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.238 | First Line Drug Therapy for Metastatic Colorectal Cancer | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.239 | BRAF V600 Testing | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.240 | Cancer Stage 4 | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.241 | Cancer Stage M1 | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.242 | High Emetic Risk Intravenous Antineoplastic Agent | active | 2022-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.243 | Moderate Emetic Risk Intravenous Antineoplastic Agent | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.244 | Anthracycline Injectable | active | 2024-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.245 | Antiemetic Agent | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.247 | Indication for Dexamethasone | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.249 | Indication for Olanzapine | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.2074.1.1.3 | Race Category Excluding Nulls | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1 | Abdomen CT without contrast | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.11 | Oxycodone | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.12 | Oxymorphone | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.70 | Morphine | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.71 | Methadone Medications | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.72 | Meperidine | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.73 | Levorphanol | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.74 | Hydromorphone | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.75 | Hydrocodone | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.76 | Fentanyl | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1002.77 | Codeine | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.12 | Butorphanol | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.13 | Dihydrocodeine | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.14 | Nalbuphine | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.15 | Opium Combinations | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.16 | Pentazocine | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.17 | Tapentadol | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1004.18 | Tramadol | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1017 | Adrenal Mass | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1019 | Diseases of Urinary System | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1020 | Hematuria | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1021 | Infections of Kidney | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1022 | Jaundice | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1023 | Liver Lesion (Mass or Neoplasm) | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1024 | Malignant Neoplasm of Bladder | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1025 | Malignant Neoplasm of Pancreas | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1026 | Non Traumatic Aortic Disease | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1028 | Unspecified Disorder of Kidney and Ureter | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1301 | Surgery Integumentary System Breast | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1302 | Surgery Respiratory System Accessory Sinuses | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1303 | Surgery Respiratory System Larynx | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1304 | Surgery Respiratory System Trachea and Bronchi | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1305 | Surgery Respiratory System Lungs and Pleura | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.13064 | Surgery Digestive System Esophagus | active | 2020-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1307 | Surgery Digestive System Intestines (Except Rectum) | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1308 | Surgery Digestive System Rectum | active | 2019-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1309 | Surgery Digestive System Anus | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1310 | Surgery Digestive System Biliary Tract | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1311 | Surgery Digestive System Abdomen Peritoneum Omentum | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1312 | Surgery Digestive System Kidney | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.13133 | Surgery Digestive System Ureter | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1314 | Surgery Digestive System Bladder | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1315 | Surgery Female Genital System Cervix Uteri | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1316 | Surgery Female Genital System Corpus Uteri | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1317 | Surgery Female Genital System Oviduct Ovary | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1318 | Surgery Eye and Ocular Adnexa Anterior Segment | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.13193 | Other Surgeries | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.13202 | SPECT MPI | active | 2020-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.13213 | Stress Echocardiography | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.13222 | Stress MRI | active | 2020-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1323 | CCTA | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1329 | Diabetes Mellitus | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1330 | Renal insufficiency | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1331 | Stroke transient ischemic attack | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1332 | Prior heart failure | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1333 | Ischemic heart disease | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1802 | Physical Therapy | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1803 | Chiropractic Evaluation | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1804 | Claim(s) for evaluation and management > 28 days and <60 days preceding the lumbar spine MRI | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1805 | MRI Lumbar Spine Procedures | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1809 | Other Deforming Dorsopathies | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1810 | Spondylopathies | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1811 | Other Dorsopathies | active | 2021-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1812 | Biomechanical Lesions (not Elsewhere Classified) | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1813 | Dislocation or Sprain of those Joints and Ligaments Located in the Lumbar Spine or Pelvis | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.18143 | Patients with lumbar spine surgery in the 90 days prior to MRI | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1832 | Cancer | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1833 | Congenital spine and spinal cord malformations | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1834 | Inflammatory and autoimmune disorders | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1835 | Infectious conditions | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1836 | Spinal vascular malformations and/or the cause of occult subarachnoid hemorrhage | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1837 | Spinal cord infarction | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1838 | Neoplastic abnormalities | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1839 | Treatment fields for radiation therapy | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1840 | Spinal abnormalities associated with scoliosis | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1841 | Syringohydromyelia | active | 2020-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1842 | Postoperative fluid collections and soft tissue changes | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1843 | Trauma | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1844 | IV Drug Abuse | active | 2022-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1845 | Neurological Impairment | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1846 | Human Immunodeficiency Virus | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1847 | Unspecified Immune Deficiencies | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.190123 | Diagnostic Mammography Study | active | 2018-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.1902 | Ultrasound of the Breast | active | 2019-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.190412 | Screening Mammography and DBT Studies | active | 2018-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.2 | Abdomen CT with contrast | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.2000.1 | Percutaneous Coronary Intervention ICD10 | active | 2018-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.2000.2 | Percutaneous Coronary Intervention SNOMEDCT | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.2000.3 | Percutaneous Coronary Intervention CPT | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.2000.4 | Percutaneous Coronary Intervention HCPCS | active | 2018-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.2000.5 | Percutaneous Coronary Intervention | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.21 | Abdomen CT Without then With Contrast | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4009 | Malignant Intracranial Neoplasm | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4010 | Malignant Intracranial Neoplasm | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4015 | STEMI | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4016 | STEMI | active | 2019-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4017 | STEMI | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4019 | Fibrinolytic Therapy | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4023 | Cerebral Vascular Lesion | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4024 | Cerebral Vascular Lesion | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4025 | Cerebral Vascular Lesion | active | 2019-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4026 | Closed Head and Facial Trauma | active | 2019-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4028 | Aortic Dissection or Ruptured Aortic Aneurysm | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4029 | Acute Peptic Ulcer | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4030 | Acute Peptic Ulcer | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4031 | Acute Peptic Ulcer | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4032 | Dementia and Related Intracranial Pathologies | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4033 | Dementia and Related Intracranial Pathologies | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4034 | Active Bleeding or Bleeding Diathesis, Excluding Menses | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4035 | Active Bleeding or Bleeding Diathesis, Excluding Menses | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4036 | Active Bleeding or Bleeding Diathesis, Excluding Menses | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4043 | Dementia and Related Intracranial Pathologies | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4044 | Aortic Dissection or Ruptured Aortic Aneurysm | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4045 | Oral Anticoagulant Medications | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4046 | Cardiopulmonary Emergency | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4047 | Cardiopulmonary Emergency | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4048 | Cardiopulmonary Emergency | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4049 | Mechanical Circulatory Assist Device | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4050 | Mechanical Circulatory Assist Device | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4052 | Mechanical Circulatory Assist Device | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4053 | Pregnant State | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4054 | Pregnant State | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4055 | Pregnant State | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4056 | Major Surgical Procedure | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4057 | Emergency Department Encounter | active | 2020-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3157.4066 | Diagnostic DBT Study | active | 2022-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3566.2.1005 | Chronic Stable Angina | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3566.2.1006 | Chronic Stable Angina | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3566.3.1002 | Chronic Stable Angina | active | 2021-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1001 | Hospice Encounter | active | 2021-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1002 | Hospice Encounter | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1003 | Hospice Encounter | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1004 | Nutrition Services | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1005 | Nutrition Services | active | 2021-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1006 | Nutrition Services | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1007 | Hospice Care Ambulatory | active | 2021-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1008 | Hospice Care Ambulatory | active | 2021-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1005 | Office Visit | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1020 | Initial Hospital Inpatient Visit | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1030 | Discharge Services Hospital Inpatient Same Day Discharge | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1035 | Discharge Services Hospital Inpatient | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1040 | Outpatient Consultation | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1050 | Emergency Department Evaluation and Management Visit | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1060 | Nursing Facility Visit | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1065 | Discharge Services Nursing Facility | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1080 | Home Healthcare Services | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1110 | Preventive Care, Initial Office Visit, 0 to 17 | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1115 | Preventive Care Services Initial Office Visit, 18 and Up | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1120 | Preventive Care, Established Office Visit, 0 to 17 | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1125 | Preventive Care Services Established Office Visit, 18 and Up | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1130 | Preventive Care Services Individual Counseling | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1135 | Preventive Care Services Group Counseling | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1215 | Referral | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1216 | Face-to-Face Interaction | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1221 | Behavioral Health Follow up Visit | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1222 | Psychotherapy and Pharmacologic Management | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1228 | Detoxification Visit | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1232 | Audiology Visit | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1233 | Medical Disability Exam | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1260 | Telephone Visits | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1261 | Nursing Facility Visit | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1262 | Care Services in Long Term Residential Facility | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1264 | Office Visit | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1265 | Home Healthcare Services | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1266 | Outpatient Consultation | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1276 | Frailty Encounter | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1277 | Outpatient Encounter | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1278 | Outpatient Encounter | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1279 | Frailty Encounter | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1281 | Virtual Encounter | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1282 | Virtual Encounter | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1284 | Outpatient Encounter | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1285 | Palliative Encounter | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1286 | Palliative Encounter | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.11.1287 | Telephone Visits | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1001 | Office Visit | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1004 | Initial Hospital Inpatient Visit | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1006 | Discharge Services Hospital Inpatient Same Day Discharge | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1007 | Discharge Services Hospital Inpatient | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1008 | Outpatient Consultation | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1010 | Emergency Department Evaluation and Management Visit | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1012 | Nursing Facility Visit | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1013 | Discharge Services Nursing Facility | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1014 | Care Services in Long Term Residential Facility | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1016 | Home Healthcare Services | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1022 | Preventive Care Services, Initial Office Visit, 0 to 17 | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1023 | Preventive Care Services Initial Office Visit, 18 and Up | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1024 | Preventive Care, Established Office Visit, 0 to 17 | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1025 | Preventive Care Services Established Office Visit, 18 and Up | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1026 | Preventive Care Services Individual Counseling | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1027 | Preventive Care Services Group Counseling | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1046 | Referral | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1048 | Face-to-Face Interaction | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1054 | Behavioral Health Follow up Visit | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1055 | Psychotherapy and Pharmacologic Management | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1059 | Detoxification Visit | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1066 | Audiology Visit | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1073 | Medical Disability Exam | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1080 | Telephone Visits | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1087 | Outpatient Encounter | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1088 | Frailty Encounter | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1089 | Virtual Encounter | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.101.12.1090 | Palliative Care Encounter | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1010 | Multiple Myeloma | active | 2021-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1011 | Multiple Myeloma | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1012 | Premature Menopause | active | 2021-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1013 | Premature Menopause | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1014 | Multiple Myeloma | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1015 | Premature Menopause | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1019 | Amenorrhea | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.11.1031 | Acute Pharyngitis | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.11.1033 | Acute Pharyngitis | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.11.1034 | Acute Tonsillitis | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.11.1036 | Acute Tonsillitis | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.11.1058 | Upper Respiratory Infection | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.11.1059 | Upper Respiratory Infection | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.11.1066 | Comorbid Conditions for Respiratory Conditions | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.11.1067 | Comorbid Conditions for Respiratory Conditions | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.12.1011 | Acute Pharyngitis | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.12.1012 | Acute Tonsillitis | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.12.1017 | Competing Conditions for Respiratory Conditions | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.12.1022 | Upper Respiratory Infection | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.102.12.1025 | Comorbid Conditions for Respiratory Conditions | active | 2022-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1021 | Amenorrhea | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1022 | Amenorrhea | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1025 | Bilateral Oophorectomy | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1026 | Unilateral Oophorectomy Left | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1028 | Unilateral Oophorectomy Left | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1029 | Unilateral Oophorectomy Left | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.103.12.1001 | Diabetes | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.103.12.1020 | Type 1 Diabetes | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1030 | Unilateral Oophorectomy Right | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1031 | Unilateral Oophorectomy Right | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1032 | Unilateral Oophorectomy Right | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1034 | Unilateral Oophorectomy, Unspecified Laterality | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1035 | Unilateral Oophorectomy, Unspecified Laterality | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1036 | Eating Disorders | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1038 | Eating Disorders | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1039 | Eating Disorders | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.104.11.1029 | Essential Hypertension | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.104.11.1031 | Essential Hypertension | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.104.12.1011 | Essential Hypertension | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1040 | Major Transplant | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1042 | Major Transplant | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1043 | Potentially Harmful Antihistamines for Older Adults | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1046 | Evidence of Bilateral Oophorectomy | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1048 | Evidence of Bilateral Oophorectomy | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1049 | Potentially Harmful Antiparkinsonian Agents for Older Adults | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1010 | Mental Health Diagnoses | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1012 | Mental Health Diagnoses | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1017 | Major Depression | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1019 | Major Depression | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1060 | Major Depression In Remission | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1062 | Major Depression In Remission | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1161 | Schizophrenia or Psychotic Disorder | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1162 | Schizophrenia or Psychotic Disorder | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1163 | Schizophrenia or Psychotic Disorder | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1178 | Pervasive Developmental Disorder | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1180 | Pervasive Developmental Disorder | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1206 | Mental Behavioral and Neurodevelopmental Disorders | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1207 | Mental Behavioral and Neurodevelopmental Disorders | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1210 | Schizophrenia | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1211 | Schizophrenia | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1212 | Seizure Disorder | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1213 | Seizure Disorder | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1214 | REM | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1215 | REM | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1216 | Benzodiazepine Withdrawal | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1217 | Benzodiazepine Withdrawal | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1218 | Alcohol Withdrawal | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1219 | Alcohol Withdrawal | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1220 | General Anxiety | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.11.1221 | General Anxiety | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1004 | Mental Health Diagnoses | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1007 | Major Depression | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1104 | Schizophrenia or Psychotic Disorder | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1152 | Pervasive Developmental Disorder | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1203 | Mental Behavioral and Neurodevelopmental Disorders | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1205 | Schizophrenia | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1206 | Seizure Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1207 | REM Sleep Behavior Disorder | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1208 | Benzodiazepine Withdrawal | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1209 | Alcohol Withdrawal | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.105.12.1210 | Generalized Anxiety Disorder | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1050 | Potentially Harmful Gastrointestinal Antispasmodics for Older Adults | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1051 | Dipyridamole Medications | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1053 | Nifedipine Medications | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1054 | Potentially Harmful Antidepressants for Older Adults | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1055 | Potentially Harmful Barbiturates for Older Adults | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1057 | Meprobamate Medications | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1058 | Potentially Harmful Estrogens for Older Adults | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1059 | Potentially Harmful Sulfonylureas for Older Adults | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.106.11.1001 | Substance Use Disorder | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.106.11.1003 | Substance Use Disorder | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.106.11.1012 | Substance Use Disorder Treatment | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.106.11.1036 | Substance Use Disorder Treatment | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.106.12.1001 | Substance Use Disorder | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.106.12.1005 | Substance Use Disorder Treatment | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1060 | Desiccated Thyroid Medications | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1062 | Potentially Harmful Skeletal Muscle Relaxants for Older Adults | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1063 | Potentially Harmful Pain Medications for Older Adults | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1065 | Digoxin Medications | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1066 | Digoxin Medications | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1067 | Doxepin Medications | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1068 | Doxepin Medications | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1001 | Malignant Neoplasm of Colon | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1003 | Malignant Neoplasm of Colon | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1025 | Malignant Neoplasm of Lymphatic and Hematopoietic Tissue | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1027 | Malignant Neoplasm of Lymphatic and Hematopoietic Tissue | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1044 | Pap Test | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1047 | Mammography | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1051 | Colonoscopy | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1052 | Colonoscopy | active | 2017-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1053 | Colonoscopy | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.11.1145 | sDNA FIT Test | active | 2017-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.12.1001 | Malignant Neoplasm of Colon | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.12.1009 | Malignant Neoplasm of Lymphatic and Hematopoietic Tissue | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.12.1017 | Pap Test | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.12.1018 | Mammography | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.12.1020 | Colonoscopy | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.12.1038 | CT Colonography | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.108.12.1039 | sDNA FIT Test | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1024 | Kidney Transplant | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1025 | Kidney Transplant | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1026 | Dialysis Services | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1027 | Dialysis Services | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1028 | Dialysis Services | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1029 | ESRD Monthly Outpatient Services | active | 2017-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1052 | Kidney Transplant | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1060 | Kidney Transplant Recipient | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.11.1067 | Kidney Transplant | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.12.1012 | Kidney Transplant | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.12.1013 | Dialysis Services | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.12.1014 | ESRD Monthly Outpatient Services | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.109.12.1029 | Kidney Transplant Recipient | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1065 | DTaP Vaccine Administered | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1066 | DTaP Vaccine Administered | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1068 | Hepatitis A | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1070 | Hepatitis A | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1078 | Measles | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1080 | Measles | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1085 | Measles, Mumps and Rubella (MMR) Vaccine Administered | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1086 | Measles, Mumps and Rubella (MMR) Vaccine Administered | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1087 | Mumps | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1089 | Mumps | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1098 | Rubella | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.110 | Rubella | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1104 | Varicella Zoster | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1105 | Varicella Zoster | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1106 | Varicella Zoster Vaccine (VZV) Administered | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1107 | Varicella Zoster Vaccine (VZV) Administered | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1109 | Hepatitis A Vaccine Administered | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1110 | Hepatitis A Vaccine Administered | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1111 | Hepatitis B Vaccine Administered | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1112 | Hepatitis B Vaccine Administered | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1115 | Child Influenza Vaccine Administered | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1116 | Child Influenza Vaccine Administered | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1117 | Inactivated Polio Vaccine (IPV) Administered | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1118 | Inactivated Polio Vaccine (IPV) Administered | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1119 | Pneumococcal Conjugate Vaccine Administered | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1120 | Rotavirus Vaccine (3 dose schedule) Administered | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1121 | Rotavirus Vaccine (2 dose schedule) Administered | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1123 | Genital Herpes | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1124 | Genital Herpes | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1128 | Lab Tests for Sexually Transmitted Infections | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1129 | Chlamydia Screening | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1133 | Pneumococcal Conjugate Vaccine Administered | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1135 | HPV Test | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1148 | Rotavirus Vaccine (2 Dose Schedule) Administered | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1149 | Rotavirus Vaccine (3 Dose Schedule) Administered | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1150 | Advanced Illness | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1151 | Advanced Illness | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1152 | HiB Vaccine (3 dose schedule) | active | 2021-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1153 | HiB Vaccine (3 dose schedule) Administered | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1154 | HiB Vaccine (4 dose schedule) | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1155 | HiB Vaccine (4 dose schedule) Administered | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1156 | HiB Vaccine (3 dose schedule) Administered | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1157 | HiB Vaccine (4 dose schedule) Administered | active | 2024-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1158 | Competing Conditions for Respiratory Conditions | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.11.1159 | Competing Conditions for Respiratory Conditions | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1022 | DTaP Vaccine Administered | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1024 | Hepatitis A | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1031 | Measles, Mumps and Rubella (MMR) Vaccine Administered | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1032 | Mumps | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1037 | Rubella | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1039 | Varicella Zoster | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1040 | Varicella Zoster Vaccine (VZV) Administered | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1041 | Hepatitis A Vaccine Administered | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1042 | Hepatitis B Vaccine Administered | active | 2022-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1044 | Child Influenza Vaccine Administered | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1045 | Inactivated Polio Vaccine (IPV) Administered | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1046 | Pneumococcal Conjugate Vaccine Administered | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1047 | Rotavirus Vaccine (3 dose schedule) Administered | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1048 | Rotavirus Vaccine (2 dose schedule) Administered | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1049 | Genital Herpes | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1051 | Lab Tests for Sexually Transmitted Infections | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1052 | Chlamydia Screening | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1053 | Measles | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1059 | HPV Test | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1082 | Advanced Illness | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1083 | Hib Vaccine (3 dose schedule) | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1084 | Hib Vaccine (3 dose schedule) Administered | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1085 | Hib Vaccine (4 dose schedule) | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1086 | Hib Vaccine (4 dose schedule) Administered | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1087 | Influenza Virus LAIV Vaccine | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.110.12.1088 | Influenza Virus LAIV Vaccine Administered | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1012 | Lab Tests During Pregnancy | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1013 | Diagnostic Studies During Pregnancy | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1019 | Pregnancy Test | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1022 | Complications of Pregnancy, Childbirth and the Puerperium | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1023 | Complications of Pregnancy, Childbirth and the Puerperium | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1028 | Procedures for Sexual Activity | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1030 | Procedures for Sexual Activity | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1031 | Diagnosis for Sexual Activity | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1032 | Diagnosis for Sexual Activity | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.11.1033 | Procedures for Sexual Activity | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.12.1007 | Lab Tests During Pregnancy | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.12.1008 | Diagnostic Studies During Pregnancy | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.12.1011 | Pregnancy Test | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.12.1012 | Complications of Pregnancy, Childbirth and the Puerperium | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.12.1016 | Congenital or Acquired Absence of Cervix | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.12.1017 | Procedures Used to Indicate Sexual Activity | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.111.12.1018 | Diagnoses Used to Indicate Sexual Activity | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.112.11.1024 | Absence of Cervix | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.112.11.1025 | Absence of Cervix | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.112.11.1026 | Absence of Cervix | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1073 | Osteoporosis Without Current Fracture | active | 2017-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1074 | Osteoporosis Without Current Fracture | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1078 | History of hip fracture in parent | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1080 | Rheumatoid Arthritis | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1081 | Rheumatoid Arthritis | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1083 | Central DXA of Hip or Spine | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1085 | Osteogenesis Imperfecta | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1087 | Osteogenesis Imperfecta | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1088 | Ankylosing Spondylitis | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1090 | Ankylosing Spondylitis | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1091 | Psoriatic Arthritis | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1093 | Psoriatic Arthritis | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1094 | Ehlers Danlos Syndrome | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1096 | Ehlers Danlos Syndrome | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1097 | Marfan's Syndrome | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1099 | Marfan's Syndrome | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1100 | Osteopenia | active | 2018-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1102 | Osteopenia | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1200 | Osteoporosis With Current Fracture | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1201 | Osteoporosis With Current Fracture | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1202 | DXA (Dual energy Xray Absorptiometry) Scan Non Hip or Spine | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1308 | Frailty Diagnosis | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1309 | Frailty Diagnosis | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1310 | Frailty Symptom | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.11.1311 | Frailty Symptom | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1005 | Rheumatoid Arthritis | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1038 | Osteoporosis Without Current Fracture | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1040 | History of hip fracture in parent | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1044 | Osteogenesis Imperfecta | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1045 | Ankylosing Spondylitis | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1046 | Psoriatic Arthritis | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1047 | Ehlers Danlos Syndrome | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1048 | Marfan's Syndrome | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1049 | Osteopenia | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1050 | Osteoporosis With Current Fracture | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1051 | DXA (Dual energy Xray Absorptiometry) Scan | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1074 | Frailty Diagnosis | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.113.12.1075 | Frailty Symptom | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.114.11.1021 | Narcolepsy | active | 2018-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.114.11.1023 | Narcolepsy | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.114.11.1024 | Neurologic impairment | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.114.11.1025 | Neurologic impairment | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.114.11.1026 | Neurologic impairment | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.114.12.1011 | Narcolepsy | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.114.12.1012 | Neurologic impairment | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1149 | Substance Use Disorder Long Acting Medication | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.115.11.1248 | Retinal or Dilated Eye Exam | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.115.12.1088 | Retinal or Dilated Eye Exam | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1150 | Substance Use Disorder Short Acting Medication | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1151 | Substance Use Disorder Long Acting Medication Administration | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1152 | Substance Use Disorder Short Acting Medication Administration | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1155 | Substance Use Disorder Short Acting Medication Administration | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1156 | Substance Use Disorder Long Acting Medication Administration | active | 2021-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1157 | Substance Use Disorder Short Acting Medication Administration | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1163 | Encephalitis Due to Diphtheria, Tetanus or Pertussis Vaccine | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1164 | Encephalitis Due to Diphtheria, Tetanus or Pertussis Vaccine | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1165 | Hospice Diagnosis | active | 2022-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1166 | Hospice Diagnosis | active | 2022-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1167 | Palliative Care Diagnosis | active | 2022-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1168 | Palliative Care Diagnosis | active | 2022-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1169 | Palliative Care Diagnosis | active | 2022-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.11.1023 | Cushings Syndrome | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.11.1025 | Cushings Syndrome | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.11.1026 | Lupus | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.11.1028 | Lupus | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.11.1031 | Hyperthyroidism | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.11.1033 | Hyperthyroidism | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.11.1034 | Hyperparathyroidism | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.11.1036 | Hyperparathyroidism | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.12.1009 | Cushings Syndrome | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.12.1010 | Lupus | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.12.1015 | Hyperthyroidism | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.117.12.1016 | Hyperparathyroidism | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1170 | Atomoxetine | active | 2022-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1171 | Clonidine | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1172 | Dexmethylphenidate | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1173 | Dextroamphetamine | active | 2022-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1174 | Lisdexamfetamine | active | 2022-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1176 | Methylphenidate | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1177 | Lower Body Fractures Excluding Ankle and Foot | active | 2022-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1178 | Lower Body Fractures Excluding Ankle and Foot | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1179 | Malignant Neoplasms of Lower and Unspecified Limbs | active | 2022-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.118.11.1042 | Counseling for Physical Activity | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.118.11.1077 | Falls Screening | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.118.11.1097 | CT Colonography | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.118.11.1220 | Frailty Device SNOMED | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.118.12.1028 | Falls Screening | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.118.12.1035 | Counseling for Physical Activity | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.118.12.1300 | Frailty Device | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1180 | Malignant Neoplasms of Lower and Unspecified Limbs | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1181 | Mechanical Complications Excluding Upper Body | active | 2022-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1182 | Mechanical Complications Excluding Upper Body | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1183 | Partial Arthroplasty of Hip | active | 2022-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1184 | Partial Arthroplasty of Hip | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1188 | Removal, Revision and Supplement Procedures of the Lower Body and Spine | active | 2022-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1189 | Removal, Revision and Supplement Procedures of the Lower Body and Spine | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1190 | Antibiotic Medications for Upper Respiratory Infection | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1193 | Malignant Neoplasms | active | 2022-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1194 | Malignant Neoplasms | active | 2022-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1196 | Atherosclerosis of the Extremities | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1197 | Atherosclerosis of the Extremities | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1198 | Atherosclerosis of the Extremities | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1199 | Lower Extremity Neurological Assessment Result or Finding | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1001 | Disorders of the Immune System | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1003 | Disorders of the Immune System | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1004 | HIV Viral Load | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1005 | HIV 1 | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1007 | HIV 1 | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1008 | HIV 2 | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1010 | HIV 2 | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1011 | Severe Combined Immunodeficiency | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.11.1012 | Severe Combined Immunodeficiency | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.12.1001 | Disorders of the Immune System | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.12.1002 | HIV Viral Load | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.12.1003 | HIV | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.120.12.1007 | Severe Combined Immunodeficiency | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1200 | Lower Extremity Neurological Tests | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1201 | Lower Extremity Visual Inspection Result or Finding | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1202 | Lower Extremity Visual Inspection Test | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1203 | Monofilament Test Result or Finding | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1204 | Monofilament Tests | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1205 | Pedal Pulse Result or Finding | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1206 | Peripheral Neuropathy | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1207 | Peripheral Neuropathy | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1208 | Peripheral Neuropathy | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1209 | Amputation of Bilateral Feet | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.121.11.1011 | Consultant Report | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.121.11.1028 | BMI percentile | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.121.11.1030 | Height | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.121.11.1031 | Weight | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.121.12.1006 | Consultant Report | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.121.12.1012 | BMI percentile | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.121.12.1014 | Height | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.121.12.1015 | Weight | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1210 | Amputation of Bilateral Feet | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1211 | Amputation of Bilateral Feet | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1212 | Amputation of Left Foot | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1213 | Amputation of Left Foot | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1214 | Amputation of Left Foot | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1215 | Amputation of Right Foot | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1216 | Amputation of Right Foot | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1217 | Amputation of Right Foot | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1218 | Amputation of Unspecified Foot | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1219 | Amputation of Unspecified Foot | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.122.11.1003 | Ambulatory | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.122.12.1003 | Ambulatory | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1220 | Foot Assessment With Abnormal Result or Finding | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1221 | Foot Assessment With Abnormal Result or Finding | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1222 | Acquired Absence of Bilateral feet | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1223 | Acquired Absence of Bilateral feet | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1224 | Acquired Absence of Left Foot | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1225 | Acquired Absence of Left Foot | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1226 | Acquired Absence of Left Foot | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1227 | Acquired Absence of Right Foot | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1228 | Acquired Absence of Right Foot | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1229 | Acquired Absence of Right Foot | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1230 | Lower Body Fractures Excluding Ankle and Foot | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1231 | Malignant Neoplasms of Lower and Unspecified Limbs | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1232 | Mechanical Complications Excluding Upper Body | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1233 | Partial Arthroplasty of Hip | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1234 | Partial Arthroplasty of Hip | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1235 | Removal, Revision and Supplement Procedures of the Lower Body and Spine | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1236 | Removal, Revision and Supplement Procedures of the Lower Body and Spine | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1237 | Removal, Revision and Supplement Procedures of the Lower Body and Spine | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1238 | Primary THA Procedure | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1239 | Foot Ulcer | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1240 | Foot Ulcer | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1241 | Foot Ulcer | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1242 | Referral for Foot Care | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1243 | Therapeutic Footwear | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1244 | Foot Deformity | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1245 | Foot Deformity | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1246 | Foot Deformity | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1247 | Megestrol Medications | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1248 | Meperidine Medications | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1249 | Potentially Harmful Antidepressants for Older Adults | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.11.1004 | Fluoride Varnish Application for Children | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.11.1007 | Dental Caries | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.11.1009 | Dental Caries | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.11.1010 | Clinical Oral Evaluation | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.11.1011 | Fluoride Varnish Application for Children | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.12.1002 | Fluoride Varnish Application for Children | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.12.1003 | Clinical Oral Evaluation | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.125.12.1004 | Dental Caries | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1250 | Potentially Harmful Antihistamines for Older Adults | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1251 | Potentially Harmful Antiparkinsonian Agents for Older Adults | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1252 | Potentially Harmful Barbiturates for Older Adults | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1253 | Potentially Harmful Estrogens for Older Adults | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1254 | Potentially Harmful Gastrointestinal Antispasmodics for Older Adults | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1255 | Potentially Harmful Pain Medications for Older Adults | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1256 | Potentially Harmful Skeletal Muscle Relaxants for Older Adults | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1257 | Potentially Harmful Sulfonylureas for Older Adults | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1258 | Substance Use Disorder Long Acting Medication | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1259 | Substance Use Disorder Short Acting Medication | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1260 | Viloxazine | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1266 | Diabetic Retinopathy Severity Level | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1272 | Diabetes | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1273 | Diabetes | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.195.11.1003 | Counseling for Nutrition | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.195.11.1004 | Counseling for Nutrition | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.195.12.1003 | Counseling for Nutrition | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1001 | Antibiotic Medications for Pharyngitis | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1078 | Nifedipine Medications | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1080 | Contraceptive Medications | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1109 | Meperidine Medications | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1129 | Desiccated Thyroid Medications | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1143 | Isotretinoin | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1167 | Dipyridamole Medications | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1205 | Leucovorin | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1211 | Aspirin and Other Antiplatelets | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1212 | DTaP Vaccine | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1214 | Hepatitis A Vaccine | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1216 | Hepatitis B Vaccine | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1220 | Child Influenza Vaccine | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1222 | Inactivated Polio Vaccine (IPV) | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1228 | Pneumococcal Conjugate Vaccine | active | 2023-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1232 | Rotavirus Vaccine (3 dose schedule) | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1234 | Varicella Zoster Vaccine (VZV) | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1235 | Measles, Mumps and Rubella (MMR) Vaccine | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1252 | Guanfacine Medications | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1255 | Megestrol Medications | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1256 | Meprobamate Medications | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1266 | Aromatase Inhibitors | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1267 | Glucocorticoids (oral only) | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1481 | Potentially Harmful Nonbenzodiazepine Hypnotics for Older Adults | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1482 | Potentially Harmful Antiinfectives for Older Adults | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1517 | Dementia Medications | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1530 | Antidepressant Medication | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1531 | Potentially Harmful Benzodiazepines for Older Adults | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.11.1532 | Potentially Harmful Antipsychotics for Older Adults | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1001 | Antibiotic Medications for Pharyngitis | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1080 | Contraceptive Medications | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1143 | Isotretinoin | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1170 | Varicella Zoster Vaccine (VZV) | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1205 | Leucovorin | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1211 | Aspirin and Other Antiplatelets | active | 2024-06 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1213 | Antidepressant Medication | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1214 | DTaP Vaccine | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1215 | Hepatitis A Vaccine | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1216 | Hepatitis B Vaccine | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1218 | Child Influenza Vaccine | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1219 | Inactivated Polio Vaccine (IPV) | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1221 | Pneumococcal Conjugate Vaccine | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1223 | Rotavirus Vaccine (3 dose schedule) | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1224 | Measles, Mumps and Rubella (MMR) Vaccine | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1265 | Aromatase Inhibitors | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1266 | Glucocorticoids (oral only) | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1480 | Potentially Harmful Nonbenzodiazepine Hypnotics for Older Adults | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1481 | Potentially Harmful Antiinfectives for Older Adults | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1510 | Dementia Medications | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1522 | Potentially Harmful Benzodiazepines for Older Adults | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.196.12.1523 | Potentially Harmful Antipsychotics for Older Adults | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1005 | Bilateral Mastectomy | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1009 | Primary THA Procedure | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1015 | Flexible Sigmoidoscopy | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1016 | Flexible Sigmoidoscopy | active | 2017-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1017 | Flexible Sigmoidoscopy | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1020 | Fecal Occult Blood Test (FOBT) | active | 2017-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1023 | Group A Streptococcus Test | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1024 | HbA1c Laboratory Test | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1026 | Hysterectomy with No Residual Cervix | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1027 | Hysterectomy with No Residual Cervix | active | 2024-11 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1035 | Total Colectomy | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1036 | Total Colectomy | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1055 | XRay Study | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1061 | Gastric Bypass Surgery | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1062 | Gastric Bypass Surgery | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1080 | Primary THA Procedure | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1084 | History of bilateral mastectomy | active | 2017-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1085 | History of bilateral mastectomy | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1086 | Status Post Left Mastectomy | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1087 | Status Post Right Mastectomy | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1089 | Unilateral Mastectomy, Unspecified Laterality | active | 2017-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1090 | Unilateral Mastectomy, Unspecified Laterality | active | 2017-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1091 | Status Post Left Mastectomy | active | 2017-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1092 | Status Post Right Mastectomy | active | 2017-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1096 | Major Transplant | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1097 | Major Transplant | active | 2021-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1132 | Unilateral Mastectomy Left | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1133 | Unilateral Mastectomy Right | active | 2021-10 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1134 | Hysterectomy with No Residual Cervix | active | 2023-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1135 | Hysterectomy with No Residual Cervix | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1140 | Bilateral Mastectomy | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1143 | Total Colectomy | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1144 | Unilateral Mastectomy Left | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1145 | Unilateral Mastectomy Right | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1148 | Palliative Intervention | active | 2023-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1005 | Bilateral Mastectomy | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1006 | Primary THA Procedure | active | 2023-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1010 | Flexible Sigmoidoscopy | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1011 | Fecal Occult Blood Test (FOBT) | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1012 | Group A Streptococcus Test | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1013 | HbA1c Laboratory Test | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1014 | Hysterectomy with No Residual Cervix | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1019 | Total Colectomy | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1034 | XRay Study | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1050 | Gastric Bypass Surgery | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1068 | History of bilateral mastectomy | active | 2017-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1069 | Status Post Left Mastectomy | active | 2017-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1070 | Status Post Right Mastectomy | active | 2017-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1071 | Unilateral Mastectomy, Unspecified Laterality | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1075 | Major Transplant | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1133 | Unilateral Mastectomy Left | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1134 | Unilateral Mastectomy Right | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.12.1135 | Palliative Care Intervention | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1064 | Anaphylactic Reaction to DTaP Vaccine | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1065 | Chronic Liver Disease | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1067 | Chronic Liver Disease | active | 2022-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1068 | Chronic Malnutrition | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1070 | Chronic Malnutrition | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1100 | Malabsorption Syndromes | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1102 | Malabsorption Syndromes | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1105 | Intussusception | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1106 | Intussusception | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1107 | Influenza Virus LAIV Vaccine | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.11.1108 | Influenza Virus LAIV Vaccine Administered | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.12.1031 | Anaphylactic Reaction to DTaP Vaccine | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.12.1035 | Chronic Liver Disease | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.12.1036 | Chronic Malnutrition | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.12.1050 | Malabsorption Syndromes | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.199.12.1056 | Intussusception | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2446 | Lower Extremity Visual Inspection Test | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2447 | Pedal Pulse Result or Finding | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2448 | Monofilament Test Result or Finding | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2449 | Monofilament Tests | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2450 | Lower Extremity Neurological Assessment Result or Finding | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2451 | Lower Extremity Neurological Tests | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2452 | Lower Extremity Visual Inspection Result or Finding | active | 2023-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1004.2616 | Autonomous Eye Exam Result or Finding | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.1577 | Pharmacologic Therapy for Hypertension | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1036 | Chronic Kidney Disease, Stage 5 | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1037 | Chronic Kidney Disease, Stage 5 | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1049 | Patient Provider Interaction | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1058 | Psych Visit for Family Psychotherapy | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1062 | Physical Therapy Evaluation | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1063 | Occupational Therapy Evaluation | active | 2017-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1064 | Neurobehavioral Status Exam (CPT) | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1067 | Dementia and Mental Degenerations | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1068 | Dementia and Mental Degenerations | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1069 | Standardized Tools for Assessment of Cognition | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1071 | Radiation Treatment Management | active | 2017-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1072 | Radiation Treatment Management | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1073 | Standardized Pain Assessment Tool | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1078 | Cancer | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1079 | Cancer | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1080 | Chemotherapy Administration | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1081 | Chemotherapy Administration | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.111 | Ophthalmological Services | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.113 | Prostate Cancer Treatment | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.118 | Initial Myocardial Infarction | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.119 | Initial Myocardial Infarction | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.120 | Coronary Artery Disease No MI | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1238 | Ejection Fraction | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1243 | Psychoanalysis | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1244 | Renal Failure Due to ACE Inhibitor | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1251 | Group Psychotherapy | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1256 | Allergy to ACE Inhibitor or ARB | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1257 | Intolerance to ACE Inhibitor or ARB | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.133 | Beta Blocker Therapy | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1333 | Allergy to Beta Blocker Therapy | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1334 | Intolerance to Beta Blocker Therapy | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1341 | Heart Rate | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1342 | Beta Blocker Therapy for LVSD | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1344 | Acute and Subacute Iridocyclitis | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1353 | Limited Life Expectancy | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1363 | Annual Wellness Visit | active | 2023-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1364 | Macular Exam | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1372 | Tobacco Use Screening | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1374 | Bone Scan | active | 2018-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1377 | Level of Severity of Retinopathy Findings | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1381 | Macular Edema Findings Present | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1401 | Cognitive Assessment | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1402 | Cup to Disc Ratio | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1403 | Optic Disc Exam for Structural Abnormalities | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1509 | Acute and Subacute Iridocyclitis | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1521 | Burn Confined to Eye and Adnexa | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1523 | Burn Confined to Eye and Adnexa | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1524 | Cataract Secondary to Ocular Disorders | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1526 | Cataract Secondary to Ocular Disorders | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1527 | Cataract Surgery | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1528 | Cataract Surgery | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1529 | Cataract Congenital | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1530 | Cataract Congenital | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1532 | Cataract Mature or Hypermature | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1534 | Cataract Mature or Hypermature | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1535 | Cataract Posterior Polar | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1537 | Cataract Posterior Polar | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1538 | Certain Types of Iridocyclitis | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1540 | Certain Types of Iridocyclitis | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1542 | Chronic Iridocyclitis | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1543 | Chronic Iridocyclitis | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1544 | Cloudy Cornea | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1546 | Cloudy Cornea | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1548 | Corneal Edema | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1549 | Corneal Edema | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1550 | Disorders of Cornea Including Corneal Opacity | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1552 | Disorders of Cornea Including Corneal Opacity | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1561 | Glaucoma | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1562 | Glaucoma | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1564 | Hereditary Corneal Dystrophies | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1566 | Hereditary Corneal Dystrophies | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1571 | Hypotony of Eye | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1572 | Hypotony of Eye | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1574 | Injury to Optic Nerve and Pathways | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1575 | Injury to Optic Nerve and Pathways | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1577 | Central Corneal Ulcer | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1578 | Central Corneal Ulcer | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1582 | Open Wound of Eyeball | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1583 | Open Wound of Eyeball | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1587 | Pathologic Myopia | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1588 | Pathologic Myopia | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1590 | Posterior Lenticonus | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1591 | Posterior Lenticonus | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1601 | Retrolental Fibroplasias | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1603 | Retrolental Fibroplasias | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1612 | Traumatic Cataract | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1613 | Traumatic Cataract | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1615 | Uveitis | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1617 | Uveitis | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1618 | Vascular Disorders of Iris and Ciliary Body | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1620 | Vascular Disorders of Iris and Ciliary Body | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1621 | Visual Field Defects | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1623 | Visual Field Defects | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1626 | Amblyopia | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1628 | Amblyopia | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1632 | Choroidal Degenerations | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1634 | Choroidal Degenerations | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1635 | Choroidal Detachment | active | 2024-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1637 | Choroidal Detachment | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1638 | Choroidal Hemorrhage and Rupture | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1640 | Choroidal Hemorrhage and Rupture | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1641 | Degeneration of Macula and Posterior Pole | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1643 | Degeneration of Macula and Posterior Pole | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1644 | Degenerative Disorders of Globe | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1646 | Degenerative Disorders of Globe | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1647 | Diabetic Macular Edema | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1649 | Diabetic Macular Edema | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1653 | Disorders of Optic Chiasm | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1655 | Disorders of Optic Chiasm | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1656 | Disorders of Visual Cortex | active | 2021-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1658 | Disorders of Visual Cortex | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1659 | Disseminated Chorioretinitis and Disseminated Retinochoroiditis | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1661 | Disseminated Chorioretinitis and Disseminated Retinochoroiditis | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1662 | Focal Chorioretinitis and Focal Retinochoroiditis | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1664 | Focal Chorioretinitis and Focal Retinochoroiditis | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1665 | Glaucoma Associated with Congenital Anomalies and Dystrophies and Systemic Syndromes | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1667 | Glaucoma Associated with Congenital Anomalies and Dystrophies and Systemic Syndromes | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1668 | Hereditary Choroidal Dystrophies | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1670 | Hereditary Choroidal Dystrophies | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1671 | Hereditary Retinal Dystrophies | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1673 | Hereditary Retinal Dystrophies | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1677 | Nystagmus and Other Irregular Eye Movements | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1679 | Nystagmus and Other Irregular Eye Movements | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.168 | Cardiac Surgery | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1680 | Optic Atrophy | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1682 | Optic Atrophy | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1683 | Optic Neuritis | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1685 | Optic Neuritis | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1686 | Other and Unspecified Forms of Chorioretinitis and Retinochoroiditis | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1688 | Other and Unspecified Forms of Chorioretinitis and Retinochoroiditis | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1689 | Other Background Retinopathy and Retinal Vascular Changes | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.169 | Cardiac Surgery | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1691 | Other Background Retinopathy and Retinal Vascular Changes | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1695 | Other Disorders of Optic Nerve | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1697 | Other Disorders of Optic Nerve | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1701 | Other Endophthalmitis | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1703 | Other Endophthalmitis | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1707 | Prior Penetrating Keratoplasty | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1709 | Prior Penetrating Keratoplasty | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1713 | Purulent Endophthalmitis | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1715 | Purulent Endophthalmitis | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1716 | Retinal Detachment with Retinal Defect | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1718 | Retinal Detachment with Retinal Defect | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1719 | Retinal Vascular Occlusion | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1721 | Retinal Vascular Occlusion | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1722 | Other Proliferative Retinopathy | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1724 | Other Proliferative Retinopathy | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1728 | Separation of Retinal Layers | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1730 | Separation of Retinal Layers | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1731 | Visual Acuity 20/40 or Better | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.175 | Hypotension | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1752 | Speech and Hearing Evaluation | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.176 | Arrhythmia | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1766 | Morgagnian Cataract | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1767 | Morgagnian Cataract | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1769 | Macular Scar of Posterior Polar | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.177 | Atrioventricular Block | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1770 | Macular Scar of Posterior Polar | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1771 | Ophthalmological Services | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1772 | Annual Wellness Visit | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1773 | Speech and Hearing Evaluation | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1774 | Occupational Therapy Evaluation | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1775 | Behavioral Neuropsych Assessment | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1776 | Psych Visit Diagnostic Evaluation | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1777 | Psych Visit Psychotherapy | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1778 | Psychoanalysis | active | 2019-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1779 | Group Psychotherapy | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.178 | Cardiac Pacer in Situ | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1780 | Psych Visit for Family Psychotherapy | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1781 | Best Corrected Visual Acuity Exam Using Snellen Chart | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1782 | Physical Therapy Evaluation | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.180 | Hypotension | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.181 | Arrhythmia | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.183 | Cardiac Pacer in Situ | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.185 | Hypotension | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.186 | Arrhythmia | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.187 | Atrioventricular Block | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1912 | Major Depressive Disorder Active | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1918 | Major Depressive Disorder Active | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1921 | Beta Blocker Therapy Ingredient | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1923 | Psych Visit Diagnostic Evaluation | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.1924 | Cardiac Pacer in Situ | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.408 | Bradycardia | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.410 | Bradycardia | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.411 | Bradycardia | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.422 | Tobacco User | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.423 | Tobacco Use Cessation Pharmacotherapy | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.424 | Tobacco Use Cessation Counseling | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.425 | Tobacco Use Cessation Counseling | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.450 | Pain Warranting Further Investigation for Prostate Cancer | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.469 | Bilateral Oophorectomy | active | 2017-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.470 | Bilateral Oophorectomy | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.483 | Chemotherapy | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.484 | Chemotherapy | active | 2021-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.511 | Tobacco Non User | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.532 | Pregnancy | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.56 | Coronary Artery Disease No MI | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.57 | Coronary Artery Disease No MI | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.58 | Initial Myocardial Infarction | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.589 | End Stage Renal Disease | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.59 | Asthma | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.590 | End Stage Renal Disease | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.60 | Asthma | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.61 | Asthma | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.73 | Primary Open Angle Glaucoma | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.74 | Primary Open Angle Glaucoma | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.76 | Diabetic Retinopathy | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.80 | Diabetic Retinopathy | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.859 | Left Ventricular Systolic Dysfunction | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.860 | Moderate or Severe | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.861 | Moderate or Severe LVSD | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.91 | Prostate Cancer | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.2.92 | Prostate Cancer | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1002 | Chronic Kidney Disease, Stage 5 | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1005 | Dementia and Mental Degenerations | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1006 | Standardized Tools Score for Assessment of Cognition | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1007 | Medical Reason | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1008 | Patient Reason | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1010 | Cancer | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1011 | Occupational Therapy Evaluation | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1012 | Patient Provider Interaction | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1018 | Psych Visit for Family Psychotherapy | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1022 | Physical Therapy Evaluation | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1023 | Behavioral or Neuropsych Assessment | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1026 | Radiation Treatment Management | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1027 | Chemotherapy Administration | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1028 | Standardized Pain Assessment Tool | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1090 | Moderate or Severe LVSD | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1091 | Left Ventricular Systolic Dysfunction | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1092 | Moderate or Severe | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1134 | Ejection Fraction | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1139 | ACE Inhibitor or ARB or ARNI | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1140 | Patient Reason for ACE Inhibitor or ARB Decline | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1141 | Psychoanalysis | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1151 | Renal Failure Due to ACE Inhibitor | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1170 | Tobacco User | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1174 | Beta Blocker Therapy | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1176 | Heart Rate | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1177 | Allergy to Beta Blocker Therapy | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1178 | Intolerance to Beta Blocker Therapy | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1184 | Beta Blocker Therapy for LVSD | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1187 | Group Psychotherapy | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1189 | Tobacco Non User | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1190 | Tobacco Use Cessation Pharmacotherapy | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1193 | Cardiac Pacer | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1211 | Allergy to ACE Inhibitor or ARB | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1212 | Intolerance to ACE Inhibitor or ARB | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1240 | Annual Wellness Visit | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1241 | Acute and Subacute Iridocyclitis | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1251 | Macular Exam | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1259 | Limited Life Expectancy | active | 2025-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1278 | Tobacco Use Screening | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1283 | Level of Severity of Retinopathy Findings | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1285 | Ophthalmological Services | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1320 | Macular Edema Findings Present | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1332 | Cognitive Assessment | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1333 | Cup to Disc Ratio | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1334 | Optic Disc Exam for Structural Abnormalities | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1409 | Burn Confined to Eye and Adnexa | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1410 | Cataract Secondary to Ocular Disorders | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1411 | Cataract Surgery | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1412 | Cataract Congenital | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1413 | Cataract Mature or Hypermature | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1414 | Cataract Posterior Polar | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1415 | Certain Types of Iridocyclitis | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1416 | Chronic Iridocyclitis | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1417 | Cloudy Cornea | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1418 | Corneal Edema | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1419 | Disorders of Cornea Including Corneal Opacity | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1423 | Glaucoma | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1424 | Hereditary Corneal Dystrophies | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1426 | Hypotony of Eye | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1427 | Injury to Optic Nerve and Pathways | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1428 | Central Corneal Ulcer | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1430 | Open Wound of Eyeball | active | 2021-04 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1432 | Pathologic Myopia | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1433 | Posterior Lenticonus | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1438 | Retrolental Fibroplasias | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1443 | Traumatic Cataract | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1444 | Uveitis | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1445 | Vascular Disorders of Iris and Ciliary Body | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1446 | Visual Field Defects | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1448 | Amblyopia | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1450 | Choroidal Degenerations | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1451 | Choroidal Detachment | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1452 | Choroidal Hemorrhage and Rupture | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1453 | Degeneration of Macula and Posterior Pole | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1454 | Degenerative Disorders of Globe | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1455 | Diabetic Macular Edema | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1457 | Disorders of Optic Chiasm | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1458 | Disorders of Visual Cortex | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1459 | Disseminated Chorioretinitis and Disseminated Retinochoroiditis | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1460 | Focal Chorioretinitis and Focal Retinochoroiditis | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1461 | Glaucoma Associated with Congenital Anomalies and Dystrophies and Systemic Syndromes | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1462 | Hereditary Choroidal Dystrophies | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1463 | Hereditary Retinal Dystrophies | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1465 | Nystagmus and Other Irregular Eye Movements | active | 2021-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1466 | Optic Atrophy | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1467 | Optic Neuritis | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1468 | Other and Unspecified Forms of Chorioretinitis and Retinochoroiditis | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1469 | Other Background Retinopathy and Retinal Vascular Changes | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1471 | Other Disorders of Optic Nerve | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1473 | Other Endophthalmitis | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1475 | Prior Penetrating Keratoplasty | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1477 | Purulent Endophthalmitis | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1478 | Retinal Detachment with Retinal Defect | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1479 | Retinal Vascular Occlusion | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1480 | Other Proliferative Retinopathy | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1482 | Separation of Retinal Layers | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1483 | Visual Acuity 20/40 or Better | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1489 | ACE Inhibitor or ARB or ARNI Ingredient | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1491 | Major Depressive Disorder Active | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1492 | Psych Visit Diagnostic Evaluation | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1493 | Beta Blocker Therapy Ingredient | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1496 | Psych Visit Psychotherapy | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1530 | Speech and Hearing Evaluation | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1558 | Morgagnian Cataract | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1559 | Macular Scar of Posterior Polar | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1560 | Best Corrected Visual Acuity Exam Using Snellen Chart | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1561 | Medications for Above Normal BMI | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1562 | Medications for Below Normal BMI | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1563 | Underweight | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1566 | Adult Depression Medications | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1567 | Adolescent Depression Medications | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1568 | Follow Up for Adult Depression | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1569 | Follow Up for Adolescent Depression | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1570 | Referral for Adolescent Depression | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1571 | Referral for Adult Depression | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1572 | High Intensity Statin Therapy | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1573 | LDL Cholesterol | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1574 | Low Intensity Statin Therapy | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1575 | Moderate Intensity Statin Therapy | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1576 | Outpatient Encounters for Preventive Care | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1578 | Follow Up Within 4 Weeks | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1580 | Referral to Primary Care or Alternate Provider | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1581 | Lifestyle Recommendation | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1582 | Patient Declined | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1583 | Referral or Counseling for Alcohol Consumption | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.1584 | Hospice Care Ambulatory | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.3000 | Metformin | active | 2019-12 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.319 | Prostate Cancer | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.320 | Bone Scan | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.326 | Primary Open Angle Glaucoma | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.327 | Diabetic Retinopathy | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.353 | End Stage Renal Disease | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.362 | Asthma | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.366 | Arrhythmia | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.367 | Atrioventricular Block | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.368 | Cardiac Pacer in Situ | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.369 | Coronary Artery Disease No MI | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.370 | Hypotension | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.371 | Cardiac Surgery | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.376 | Heart Failure | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.378 | Pregnancy | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.398 | Prostate Cancer Treatment | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.399 | Salvage Therapy | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.401 | Prostate Specific Antigen Test | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.403 | Initial Myocardial Infarction | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.412 | Bradycardia | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.451 | Pain Warranting Further Investigation for Prostate Cancer | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.471 | Bilateral Oophorectomy | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.485 | Chemotherapy | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.526.3.509 | Tobacco Use Cessation Counseling | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1498 | Medications for Above Normal BMI | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1499 | Medications for Below Normal BMI | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1519 | Follow Up for Above Normal BMI | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1523 | Follow Up for Above Normal BMI | active | 2017-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1524 | Follow Up for BMI Outside Normal Parameters | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1525 | Follow Up for Above Normal BMI | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1526 | Follow Up for Above Normal BMI | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1527 | Referrals Where Weight Assessment May Occur | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1528 | Follow Up for Below Normal BMI | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1549 | Follow Up for Below Normal BMI | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1550 | Follow Up for Below Normal BMI | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1551 | Follow Up for Below Normal BMI | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1578 | Palliative Care | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1579 | Palliative or Hospice Care | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1608 | Encounter to Document Medications | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1609 | Encounter to Document Medications | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1610 | Referrals Where Weight Assessment May Occur | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1751 | Encounter to Evaluate BMI | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1834 | Encounter to Document Medications | active | 2024-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.1917 | Encounter to Document Medications | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.695 | Encounter to Evaluate BMI | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.885 | Encounter to Evaluate BMI | active | 2018-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1.886 | Encounter to Evaluate BMI | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1475 | Referral to Primary Care or Alternate Provider | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1476 | Pharmacologic Therapy for Hypertension | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1482 | Laboratory Tests for Hypertension | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1497 | Encounter to Screen for Blood Pressure | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1508 | Lifestyle Recommendation | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1509 | Weight Reduction Recommended | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1510 | Weight Reduction Recommended | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1511 | Dietary Recommendations | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1512 | Dietary Recommendations | active | 2025-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1514 | Dietary Recommendations | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1515 | Dietary Recommendations | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1516 | Exercise Class | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1518 | Recommendation to Increase Physical Activity | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1537 | Follow Up Within 4 Weeks | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1538 | Encounter to Screen for Depression | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1914 | Encounter to Screen for Depression | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1915 | Encounter to Screen for Depression | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1916 | Encounter to Screen for Depression | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1918 | Encounter to Screen for Blood Pressure | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.192 | Encounter to Screen for Blood Pressure | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.1920 | Encounter to Screen for Blood Pressure | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.2387 | Overweight or Obese | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.2388 | Underweight | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.2395 | Finding of Hypertension | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.2462 | Laboratory Tests for Hypertension | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.2466 | Dental Tooth Extraction | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.259 | Diagnosis of Hypertension | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.261 | Diagnosis of Hypertension | active | 2021-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.263 | Diagnosis of Hypertension | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.467 | Follow Up for Adolescent Depression | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.468 | Follow Up for Adult Depression | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.469 | Adolescent Depression Medications | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.470 | Adult Depression Medications | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.537 | Referral for Adolescent Depression | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.538 | Referral for Adult Depression | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.791 | Patient Declined | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.805 | Weight Reduction Recommended | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.810 | Recommendation to Increase Physical Activity | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.600.823 | Referral or Counseling for Alcohol Consumption | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.6366.117 | Absence of Cervix | active | 2024-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.1250 | Major Surgical Procedure | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.1668 | CABG Surgeries | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.1743 | General or Neuraxial Anesthesia | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.1940 | Immunocompromised Conditions | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2262 | CABG Surgeries | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2328 | Immunocompromised Conditions I10 | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2343 | Immunocompromised Conditions | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2363 | Creatinine Lab Test | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.3011 | Acute Myocardial Infarction | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.3024 | Acute Myocardial Infarction | active | 2016-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.307 | Encounter Inpatient | active | 2020-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.335 | Bone Marrow Transplant | active | 2021-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.336 | Bone Marrow Transplant | active | 2024-01 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.404 | Bone Marrow Transplant | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.623 | Acute Myocardial Infarction | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.694 | CABG Surgeries | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.737 | PCI | active | 2018-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.747 | Endotracheal Intubation | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.128 | Bipolar Disorder | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.2433 | Delivery | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.2435 | HBsAg | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.246 | Personality Disorder Emotionally Labile | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.247 | Personality Disorder Emotionally Labile | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.248 | Personality Disorder Emotionally Labile | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.249 | Personality Disorder Emotionally Labile | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.254 | Dysthymia | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.256 | Dysthymia | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.257 | Dysthymia | active | 2023-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.262 | Deceased | active | 2014-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.263 | PHQ 9 and PHQ 9M Tools | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.269 | Hepatitis B | active | 2017-08 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.271 | Hepatitis B | active | 2017-05 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.272 | Hepatitis B | active | 2023-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.273 | Live Birth or Delivery | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.274 | Live Birth or Delivery I10 | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.275 | Live Birth or Delivery | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.277 | Delivery | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.278 | Delivery - Diagnosis | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.279 | HBsAg | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.281 | HBsAg | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.43 | Bipolar Disorder | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.44 | Bipolar Disorder | active | 2025-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.45 | Bipolar Disorder | active | 2022-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.1.82 | Delivery | active | 2024-07 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.11.721 | Deceased | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.67.1.101.11.723 | PHQ-9 Tool | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.6929.2.1000 | Estimated Glomerular Filtration Rate | active | 2024-02 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.6929.2.1002 | Urine Albumin Creatinine Ratio | active | 2025-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.6929.3.1000 | Estimated Glomerular Filtration Rate | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.6929.3.1007 | Urine Albumin Creatinine Ratio | active | 2022-03 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1000 | Strabismic Amblyopia | active | 2019-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1001 | Strabismic Amblyopia | active | 2019-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1002 | Refractive Amblyopia | active | 2019-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1003 | Refractive Amblyopia | active | 2019-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1004 | Routine Ophthalmological Examination | active | 2019-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1005 | Pediatric Best Corrected Visual Acuity Exam | active | 2019-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1006 | LogMAR Visual Acuity Exam | active | 2019-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1007 | Aphakia | active | 2019-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1008 | Aphakia | active | 2019-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1009 | Infantile and Juvenile Cataract | active | 2019-09 | hl7 |
| us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.8420.2.1010 | Infantile and Juvenile Cataract | active | 2019-09 | hl7 |
XIG built as of 22 Jun 2025. Found 77205 resources in 1238 packages.
FHIR